

Compound having ERK kinase inhibitory activity and use thereof

Field of the Invention


The invention belongs to the field of pharmaceutical chemistry. Specifically, the invention relates to novel compounds or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising said compounds or pharmaceutically acceptable salts thereof, which are useful as modulators of the extracellular signal-regulated kinase (ERK) pathway, in particular as inhibitors of ERK kinases such as ERK1 and/or ERK2 kinase.


Background of the Invention


The Ras-Raf-MEK-ERK pathway is a mitogen activated protein kinase (MAPK) signaling pathway and regulates multiple functions such as proliferation, differentiation, and apoptosis of cells. Mutations of this pathway are present in more than one third of all human cancers. Therefore, the nodal proteins on this pathway have become a hotspot for the development of targeting anti-cancer drugs in recent years. Specific B-Raf inhibitors vemurafenib and dabrafenib were approved by the U.S. FDA for the treatment of melanoma in 2011 and 2013, respectively. The MEK1/2 inhibitor trametinib was approved by the U.S. FDA for the treatment of melanoma in 2013. The combination of vemurafenib and the MEK inhibitor cobimetinib was approved by the U.S. FDA for the treatment of B-Raf V600E or V600K mutant melanoma in 2015. The U.S. FDA also approved the combination of dabrafenib and trametinib for the treatment of B-Raf V600E mutant non-small cell lung cancer in 2017. However, there are limitations for the inhibition of these upstream pathway nodes. Tumors can rapidly become resistant to B-Raf and MEK inhibitors, and the mechanisms of the resistance include a variety of ways such as point mutation, change of multimeric form of proteins, and change of peptide chain length of proteins. This is a great challenge for the development of next generation of drugs against Raf and MEK. Meanwhile, as a terminal key node of MAPK, the activated ERK can transmit extracellular signals to cell nucleus, promote the phosphorylation of cytoplasmic target proteins or regulate the activity of other protein kinases, thereby regulating gene expression. It is undoubtedly important in the development of anti-tumor drugs. Especially when the majority of the current MAPK upstream targeting therapies eventually show drug resistance, the ERK inhibitors will probably become a more effective therapeutic means because of being less prone to generate acquired drug resistance. Since ERK was discovered in the 1990s, there has been much extensive and intensive research on it, but to date no ERK inhibitors have been approved for marketing as pharmaceuticals. Currently the highly selective ERK inhibitor BVD-523 (Ulixertinib) in Phase 2 clinic trial is at the leading level worldwide. In early 2017, it is reported that BVD-523 at the dose of 600mg twice a day showed acceptable safety in patients and produced a lasting efficacy in patients having melanoma with NRAS mutation and solid tumors with BRAF V600 and non-V600 mutants (including melanoma, glioblastoma multiforme, brain metastatic cancer, gallbladder adenocarcinoma, and head and neck tumor). These data further support the clinical development of ERK inhibitors.

In conclusion, the ERK inhibitors alone or in combination can be expected to have wide

prospects in the anti-tumor field, and the development of a novel ERK inhibitor is urgently needed in this field. Patent application WO2017/114510A1 discloses a series of ERK inhibitors, but the inventors of the present application found that in said patent application, some compounds,




especially those having the structure of , had a poor chemical stability, and easily generate impurities, especially under alkaline conditions, which properties of these compounds bring certain difficulties to drug development; and some compounds having the structure of




, wherein R is amino, carboxyl or amido etc., although active in preliminary in vitro tests, had unsatisfactory pharmacokinetic parameters, which brings certain difficulties to drug development. In short, comprehensive evaluation (for example, in terms of chemical stability and/or pharmacokinetic properties, etc.) revealed that some compounds disclosed in the patent application WO2017/114510A1 showed difficulties in drug development. Therefore, there is a need to look for highly selective compounds with ERK kinase inhibitory activity, which are more suitable for drug development, through comprehensive evaluation.

Description of the Invention

Through many experimental research, the inventors finally found that the compounds having




the core structure  and wherein R₃ is halogen, unsubstituted alkyl, haloalkyl, deuterated alkyl or the like had a good chemical stability as well as better solubility and permeability, all showed ERK kinase inhibitory activity in the enzyme and cell assays, and had good pharmacokinetic parameters, so they were particularly suitable for drug development.

Embodiments

In one aspect, the invention provides novel ERK kinase inhibitors. Specifically, the invention provides the following embodiments:

Embodiment 1. A compound of formula (I), or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof,



(I)

Wherein

X₁ is selected from the group consisting of CR_{9a} and N;

X₂ is selected from the group consisting of CR_{9b} and N;

X₃ is selected from the group consisting of CR_{9c} and N; and at most one of X₁, X₂ and X₃ is N;

Y₁ and Y₂ are each independently selected from the group consisting of CR_{9'} and N;

R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylcarbonyl, optionally substituted alkoxy carbonyl, optionally substituted cycloalkyl, amino, optionally substituted mono- or di-(alkyl) amino and -CONR_aR_b;

R_{9'} is selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylcarbonyl, optionally substituted alkoxy carbonyl, optionally substituted cycloalkyl, amino, optionally substituted mono- or di-(alkyl) amino and CONR_aR_b;

R₁ is selected from the group consisting of H and D;

R₂ is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or R₂ together with X₁ forms optionally substituted heterocyclyl;

R₃ is selected from the group consisting of halo and optionally substituted alkyl;

R₄ is selected from the group consisting of H, D, optionally substituted alkyl, optionally substituted alkoxy, -CO(CR₁₀R₁₁)_mR₁₂, -SO₂(CR₁₀R₁₁)_mR₁₂, -CONR₁₃(CR₁₀R₁₁)_mR₁₂, -COO(CR₁₀R₁₁)_mR₁₂, -CR₁₃R_{13'}(CR₁₀R₁₁)_mR₁₂ and C₁₋₈ alkylcarbonyl-; wherein m is 0, 1, 2 or 3, and wherein

R₁₀ and R₁₁ are each independently selected from the group consisting of H, D, halo, optionally substituted alkyl, and optionally substituted alkoxy; or R₁₀ and R₁₁ are joined together to form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and

R₁₂ is each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; and

R₁₃ and R_{13'} are each independently selected from the group containing of H and optionally substituted alkyl; or R₁₃ and R_{13'} together with the adjacent carbon form optionally substituted cycloalkyl, cycloalkenyl and heterocyclyl;

R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of -H, -D, halo, -OH, amino, cyano, optionally substituted alkyl, optionally substituted alkoxy, -(CH₂)₀₋₃CONR_aR_b, -(CH₂)₀₋₃COOH, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; or any two of R₅, R₆, R₇ and R₈ together with the adjacent carbon form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and

R_a and R_b are each independently selected from the group consisting of H, D and optionally substituted alkyl;

Wherein the optional substituents are independently selected from the group consisting of deuterium (D), halo, -OH, mercapto, cyano, -CD₃, -C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, 3-8 membered cycloalkyl, aryl, 3-8 membered heterocyclyl, heteroaryl, aryl-C₁-C₆alkyl, heteroaryl-C₁-C₆alkyl-, C₁-C₆haloalkyl-, -OC₁-C₆alkyl, -OC₂-C₆alkenyl, -OC₁-C₆alkylphenyl, -C₁-C₆ alkyl-OH, -C₁-C₆alkyl-SH, -C₁-C₆alkyl-O-C₁-C₆alkyl, -OC₁-C₆haloalkyl, -NH₂,

-C₁-C₆alkyl-NH₂, -N(C₁-C₆alkyl)₂, -NH(C₁-C₆alkyl), -N(C₁-C₆alkyl)(C₁-C₆alkylphenyl), -NH(C₁-C₆alkylphenyl), nitro, -C(O)-OH, -C(O)OC₁-C₆alkyl, -CONR_iR_{ii} (wherein R_i and R_{ii} are each independently selected from the group consisting of H, D and C₁₋₆alkyl), -NHC(O)(C₁-C₆alkyl), -NHC(O)(phenyl), -N(C₁-C₆alkyl)C(O)(C₁-C₆alkyl), -N(C₁-C₆alkyl)C(O)(phenyl), -C(O)C₁-C₆alkyl, -C(O)-5-7 membered heteroaryl, -C(O)C₁-C₆alkylphenyl, -C(O)C₁-C₆haloalkyl, -OC(O)C₁-C₆alkyl, -S(O)₂-C₁-C₆alkyl, -S(O)-C₁-C₆alkyl, -S(O)₂-phenyl, -S(O)₂-C₁-C₆haloalkyl, -S(O)₂NH₂, -S(O)₂NH(C₁-C₆alkyl), -S(O)₂NH(phenyl), -NHS(O)₂(C₁-C₆alkyl), -NHS(O)₂(phenyl), and -NHS(O)₂(C₁-C₆haloalkyl), wherein each of said alkyl, cycloalkyl, phenyl, aryl, heterocyclyl and heteroaryl is optionally further substituted with one or more substituents selected from the group consisting of halo, -OH, -NH₂, cycloalkyl, 3-8 membered heterocyclyl, C₁-C₄alkyl, C₁-C₄haloalkyl-, -OC₁-C₄alkyl, -C₁-C₄alkyl-OH, -C₁-C₄alkyl-O-C₁-C₄alkyl, -OC₁-C₄haloalkyl, cyano, nitro, -C(O)-OH, -C(O)OC₁-C₆alkyl, -CON(C₁-C₆alkyl)₂, -CONH(C₁-C₆alkyl), -CONH₂, -NHC(O)(C₁-C₆alkyl), -NH(C₁-C₆alkyl)C(O)(C₁-C₆alkyl), -SO₂(C₁-C₆alkyl), -SO₂(phenyl), -SO₂(C₁-C₆haloalkyl), -SO₂NH₂, -SO₂NH(C₁-C₆alkyl), -SO₂NH(phenyl), -NHSO₂(C₁-C₆alkyl), -NHSO₂(phenyl) and -NHSO₂(C₁-C₆haloalkyl), provided that the compound is not 2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-(hydroxymethyl)-5-(2-(isopropylamino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one.

Embodiment 2. The compound according to Embodiment 1, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

X₁ is selected from the group consisting of CR_{9a} and N;

X₂ is selected from the group consisting of CR_{9b} and N;

X₃ is selected from the group consisting of CR_{9c} and N; and at most one of X₁, X₂ and X₃ is N;

Y₁ and Y₂ are each independently selected from the group consisting of CR_{9'} and N;

R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted C₁₋₃alkyl, optionally substituted C₁₋₃alkoxyl, optionally substituted C₁₋₃alkylcarbonyl, optionally substituted C₁₋₃alkoxylcarbonyl, optionally substituted C₃₋₈cycloalkyl, amino, optionally substituted mono- or di-(C₁₋₃alkyl)amino, and -CONR_aR_b;

R_{9'} is selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted C₁₋₃alkyl, optionally substituted C₁₋₃alkoxyl, optionally substituted C₁₋₃alkylcarbonyl, optionally substituted C₁₋₃alkoxylcarbonyl, optionally substituted C₃₋₈cycloalkyl, amino, optionally substituted mono- or di-(C₁₋₃alkyl)amino, and CONR_aR_b;

R₁ is selected from the group consisting of H and D;

R₂ is selected from the group consisting of optionally substituted C₁₋₈alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl, or R₂ together with X₁ forms optionally substituted 3-8 membered heterocyclyl;

R₃ is selected from the group consisting of halo and C₁₋₈alkyl optionally substituted with one or more substituents independently selected from the group consisting of D and halo;

R₄ is selected from the group consisting of H, D, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxyl, -CO(CR₁₀R₁₁)_mR₁₂, -SO₂(CR₁₀R₁₁)_mR₁₂, -CONR₁₃(CR₁₀R₁₁)_mR₁₂,

-COO(CR₁₀R₁₁)_mR₁₂, -CR₁₃R_{13'}(CR₁₀R₁₁)_mR₁₂ and C₁₋₈alkylcarbonyl-; wherein m is 0, 1, 2 or 3, and wherein

R₁₀ and R₁₁ are each independently selected from the group consisting of H, D, halo, optionally substituted C₁₋₈alkyl, and optionally substituted C₁₋₈alkoxyl, or R₁₀ and R₁₁ are joined together to form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and


R₁₂ are each independently selected from the group consisting of H, optionally substituted C₁₋₃alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl; and

R₁₃ and R_{13'} are each independently selected from the group consisting of H and optionally substituted C₁₋₃alkyl; or R₁₃ and R_{13'} together with the adjacent carbon form optionally substituted C₃₋₈cycloalkyl, C₄₋₈cycloalkenyl and C₅₋₈heterocyclyl;

R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of -H, -D, halo, -OH, amino, cyano, optionally substituted C₁₋₃alkyl, optionally substituted C₁₋₃alkoxyl, -(CH₂)₀₋₃CONR_aR_b, -(CH₂)₀₋₃COOH, optionally substituted C₃₋₈cycloalkyl, and optionally substituted 3-8 membered heterocyclyl; or any two of R₅, R₆, R₇ and R₈ together with the adjacent carbon form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and

R_a and R_b are each independently selected from the group consisting of H, D and optionally substituted C₁₋₃alkyl.

Embodiment 3. The compound according to any one of Embodiments 1 to 2, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: the compound is represented by formula Ia, Ib, Ic or Id:



R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D, C₁₋₃alkyl, C₁₋₃haloalkyl, C₁₋₃alkoxyl, -OH, cyano, halo, amino, mono- or di-(C₁₋₃alkyl)amino, C₁₋₃alkylcarbonyl, C₁₋₃alkoxylcarbonyl and C₃₋₈cycloalkyl; preferably, R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D and C₁₋₃alkyl; more preferably, R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H and D; and Other variables are as defined in Embodiment 1 or 2.

Embodiment 4. The compound according to any one of Embodiments 1 to 3, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

Y₁ is CR_{9'}, Y₂ is CR_{9'}, and wherein R_{9'} is selected from the group consisting of H, D, halo

and C₁₋₃alkyl; more preferably, Y₁ is CR₉', Y₂ is CR₉', and wherein R₉' is H, D, F or methyl;

or

Y₁ is CR₉', Y₂ is N, and wherein R₉' is selected from the group consisting of H, D, halo and C₁₋₃alkyl; more preferably, Y₁ is CR₉', Y₂ is N, and wherein R₉' is H, D, F or methyl;


or

Y₁ is N, Y₂ is CR₉', and wherein R₉' is selected from the group consisting of H, D, halo and C₁₋₃alkyl; more preferably, Y₁ is N, Y₂ is CR₉', and wherein R₉' is H, D, F or methyl;

or

Y₁ is N, and Y₂ is N.

Embodiment 5. The compound according to Embodiment 1, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: the compound is represented by formula Ie:



Ie

Wherein the variables are as defined in claim 1.

Embodiment 6. The compound according to any one of Embodiments 1, 2 and 5, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: X₁ is selected from the group consisting of CR_{9a} and N, wherein R_{9a} is selected from the group consisting of H, D, halo, -OH, cyano, C₁₋₃alkyl, C₁₋₃haloalkyl, C₁₋₃alkoxyl, C₁₋₃alkylcarbonyl, C₁₋₃alkoxycarbonyl, C₃₋₈cycloalkyl, amino, and mono- or di-(C₁₋₃alkyl)amino; preferably, X₁ is selected from the group consisting of CR_{9a} and N, wherein R_{9a} is selected from the group consisting of H, D and C₁₋₃alkyl; more preferably, X₁ is selected from the group consisting of CH, CD and N.

Embodiment 7. The compound according to any one of Embodiments 1 and 5, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:


R₂ is selected from the group consisting of optionally substituted C₁₋₆alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted 3-8 membered heterocyclyl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, hydroxyl, -CD₃, C₁₋₆alkyl and hydroxylC₁₋₆alkyl, preferably is one or more substituents independently selected from the group consisting of D, halo, hydroxyl, -CD₃, -CH₃ and -CH₂OH;

or


R₂ is selected from the group consisting of C₁₋₆alkyl optionally substituted with one or more hydroxyl, C₃₋₈cycloalkyl optionally substituted with one or more hydroxyl, 3-8 membered

heterocyclyl, and 5-12 membered heteroaryl such as 5-7 membered heteroaryl optionally substituted with one or more substituents selected from -CD₃, C₁₋₆alkyl and hydroxylC₁₋₆alkyl;


or




or



or



or



Embodiment 8. The compound according to any one of Embodiments 1 to 7, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R₃ is selected from the group consisting of halo and C₁₋₆alkyl optionally substituted with one or more substituents independently selected from the group consisting of D and halo; or R₃ is selected from the group consisting of halo and C₁₋₃alkyl optionally substituted with one or more substituents independently selected from the group consisting of D and halo; or R₃ is selected from the group consisting of halo and C₁₋₆alkyl; or R₃ is selected from the group consisting of fluoro, chloro, bromo, iodo, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₃, -CF₃, -CHF₂, CF₃CH₂-, and CD₃-; or R₃ is selected from the group consisting of fluoro, chloro, and -CH₃; or R₃ is fluoro.

Embodiment 9. The compound according to any one of Embodiments 1 to 8, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

R_4 is selected from the group consisting of $-\text{CO}(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$ and $-\text{CR}_{13}\text{R}_{13}'(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$; wherein m is 0, 1, 2 or 3, and wherein

R_{10} and R_{11} are each independently selected from the group consisting of H, D and C_{1-4} alkyl optionally substituted with hydroxyl;


R_{12} is each independently selected from the group consisting of optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl;

R_{13} and R_{13}' are each independently selected from the group consisting of H, C_{1-3} alkyl and C_{1-3} haloalkyl.





Embodiment 10. The compound according to Embodiment 9, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R_{12} is each independently selected from the group consisting of optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, C_{1-4} alkyl, cyano, and C_{3-8} heterocyclyl- $(\text{CH}_2)_{0-4}$ - (for example, morpholinyl such as morpholino, piperazinyl, tetrahydropyranyl such as tetrahydropyran-4-yl, morpholinylmethyl such as morpholinomethyl, or piperazinylmethyl);


or R_{12} is selected from the group consisting of optionally substituted phenyl and optionally substituted pyridinyl such as pyridin-3-yl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, C_{1-4} alkyl (for example, methyl or ethyl), cyano, and C_{3-8} heterocyclyl- $(\text{CH}_2)_{0-4}$ - (for example, morpholinyl such as morpholino, piperazinyl, tetrahydropyranyl such as tetrahydropyran-4-yl, morpholinylmethyl such as morpholinomethyl, or piperazinylmethyl);

or R_{12} is selected from the group consisting of





, wherein R_c is selected from the group consisting of halo such as fluoro or chloro,

C_{1-4} alkyl such as methyl, , , , and  ;




, wherein R_d is selected from the group consisting of H, C_{1-4} alkyl such as methyl or

ethyl, and  ;




, wherein R_e is selected from the group consisting of halo such as fluoro and chloro, and p is 1 or 2; and



Embodiment 11. The compound according to any one of Embodiments 1 to 8, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R_4 is selected from the group consisting of $-\text{CO}(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$, wherein m is 0, 1, 2 or 3, and wherein

R_{10} and R_{11} are each independently selected from the group consisting of H; and

R_{12} is selected from the group consisting of



Embodiment 12. The compound according to any one of Embodiments 1 to 8, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R_4 is selected from the group consisting of $-\text{CO}(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$, wherein m is 0, 1, 2 or 3, and wherein R_{10} and R_{11} are each independently selected from the group consisting of H; R_{12} is selected from the group consisting of 2-cyanophenyl, 5-chloro-2-fluorophenyl, 2-chloro-3-fluorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-5-fluorophenyl, 2,5-difluorophenyl, 3-chloropyridin-2-yl, 6-chloropyridin-2-yl, 3-chloropyridin-4-yl, or 4-chloropyridin-3-yl.

Embodiment 13. The compound according to any one of Embodiments 1 to 12, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

R_5 , R_6 , R_7 and R_8 are each independently selected from the group consisting of -H, -D, halo, -OH, amino, cyano, optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkoxyl, $-(\text{CH}_2)_{0-3}\text{CONR}_a\text{R}_b$, $-(\text{CH}_2)_{0-3}\text{COOH}$, optionally substituted C_{3-8} cycloalkyl, and optionally substituted 3-8 membered heterocyclyl, wherein the optional substituent is one or more substituents

independently selected from the group consisting of D, -OH, -OC₁₋₆alkyl and NH₂, and wherein R_a and R_b are each independently selected from the group consisting of H, D and C₁₋₃alkyl;





or R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of H and C₁₋₆alkyl optionally substituted with hydroxyl or -OC₁₋₆alkyl;







or R₅ and R₆ are each independently selected from the group consisting of H and C₁₋₆alkyl; and R₇ and R₈ are each independently selected from the group consisting of H and C₁₋₆alkyl optionally substituted with hydroxyl or -OC₁₋₆alkyl;







or R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of -H, -CH₃ and -CH₂OH;








or R₅, R₆ and R₇ are H, and R₈ is H, -CH₃ or -CH₂OH.








Embodiment 14. A compound selected from the group consisting of Examples P1-P20, P23-P25, P28-51, P53-P64:







P1	 P1
P2	 P2
P3	 P3
P4	 P4

P5	 P5
P6	 P6
P7	 P7
P8	 P8
P9	 P9
P10	 P10








P11	 P11
P12	 P12
P13	 P13
P14	 P14
P15	
P16	

P17	 P17
P18	 P18
P19	 P19
P20	
P23	
P24	
P25	


P28	
P29	
P30	
P31	
P32	
P33	
P34	

P35	 P35
P36	
P37	
P38	
P39	
P40 and P41	

P42 and P43	
P44	
P45	
P46	
P47	
P48	

P49	
P50	
P51	
P53	 (racemate)
P54	
P55	
P56	

P57	
P58	
P59	
P60	
P61	
P62 and P63	



or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides a pharmaceutical composition comprising the novel compounds above, uses of the novel compounds above, and methods for treatment using the novel compounds above:

Embodiment 15. The compound according to any one of Embodiments 1 to 14, or a pharmaceutically acceptable salt thereof, for use as a medicament.


Embodiment 16. A pharmaceutical composition, comprising the compound according to any one of Embodiments 1 to 14, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.

Embodiment 17. Use of the compound according to any one of Embodiments 1 to 14, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for prevention and/or treatment of a disease related to an ERK kinase, or use of the compound according to any one of Embodiments 1 to 14, or a pharmaceutically acceptable salt thereof, for use as a product as an ERK kinase inhibitor.

Embodiment 18. A non-therapeutic method of inhibiting an ERK kinase activity, comprising contacting an effective amount of the compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, with an ERK kinase, thereby inhibiting the ERK kinase.


In another aspect, the invention provides intermediates (for example, intermediates 1-82, particularly intermediate 25, disclosed herein) and methods (for example, the methods shown in Figures 1-4, particularly the method shown in Figure 3) for preparing the novel compounds above:

Embodiment 19. The compound t-butyl (4-(7-fluoroindolin-5-yl)pyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate represented by the formula:



or a stereoisomer, racemate, geometric isomer, tautomer, hydrate, solvate, or pharmaceutically acceptable salt thereof.


Embodiment 20. A method for preparing the compound of formula (I) according to Embodiment 1, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate or pharmaceutically acceptable salt thereof, said compound of formula (I) is the compound of formula C3:



C3


wherein X_1 , R_2 , R_3 , R_{10} , R_{11} , R_{12} and m are as defined in Embodiment 1, comprising the steps of:

(a) subjecting the compound of formula C1



C1


and the compound $\text{HO}-\text{C}(=\text{O})-(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$ to amide coupling reaction, to give the compound of formula C2,



C2

; and

(b) when the compound of formula C2 is Boc-protected, deprotecting it, to give the compound of formula C3,



C3

Embodiment 21. The method according to Embodiment 20, wherein the amide coupling

reaction is carried out in the presence of a condensing agent and a base in an inert solvent.

Embodiment 22. The method according to Embodiment 20, wherein the deprotection is carried out in the presence of an acid in an inert solvent.

Embodiment 23. The method according to Embodiment 21 or 22, wherein the inert solvent is selected from the group consisting of ethyl acetate, tetrahydrofuran, methyltetrahydrofuran, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, dichloromethane, 1,2-dichloroethane, N-methyl-2-pyrrolidone, or a combination thereof.

Embodiment 24. The method according to Embodiment 21, wherein the condensing agent is one or more selected from the group consisting of 1-hydroxybenzotriazole (HOBT), 1-hydroxy-7-azobenzotriazole (HOAT), benzotriazol-1-yl-oxytripyrrolidino-phosphonium hexafluorophosphate (PyBOP), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), 1,1-carbonyldiimidazole (CDI), 1-propylphosphonic anhydride (T₃P), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl), N,N-dicyclohexylcarbodiimide (DCC), acetic anhydride, acetyl chloride, oxalyl chloride, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU).

Embodiment 25. The method according to Embodiment 21, wherein the base is one or more selected from the group consisting of triethylamine, DIPEA, pyridine, 2,4-dimethylpyridine, NaOH, KOH, LiOH, Na₂CO₃, K₂CO₃, NaHCO₃, Cs₂CO₃, Na₃PO₄, or K₃PO₄.

Embodiment 26. The method according to Embodiment 20, wherein the amide coupling reaction is carried out at a temperature from room temperature to reflux for 0.5 -24 h.

Embodiment 27. The method according to Embodiment 22, wherein the acid is one or more selected from the group consisting of hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, formic acid, and phosphoric acid.

Embodiment 28. The method according to Embodiment 20, wherein the deprotection is carried out at a temperature from -10°C to 80°C for 0.5 – 24 h.

Definitions

The following terms and symbols used in the present application have the meanings as described below, unless otherwise specified in the context.

A dash (“-”) that is not between two letters or symbols indicates a point of attachment of a substituent. For example, -O(C₁₋₃alkyl) refers to C₁₋₃alkyl which is attached to the rest of the molecule through an oxygen atom. However, when the attachment point of a substituent is apparent to those skilled in the art, for example, for a halogen substituent, the dash “-” may be omitted.

When a group carries a wavy line “”, the wavy line indicates the point of attachment of the group to the rest of the molecule.

As used herein, the term “alkyl” refers to a straight or branched chain saturated monovalent hydrocarbon radical having from 1 to 8 carbon atoms, such as from 1 to 6 carbon atoms, such as from 1 to 4 carbon atoms, such as 1, 2 or 3 carbon atoms. For example, “C₁₋₈ alkyl” refers to alkyl having from 1 to 8 carbon atoms. Similarly, “C₁₋₄ alkyl” refers to alkyl having from 1 to 4 carbon atoms, and “C₁₋₃ alkyl” refers to alkyl having from 1 to 3 carbon atoms. Examples of alkyl include, but are not limited to, methyl (“Me”), ethyl (“Et”), n-propyl (“n-Pr”), isopropyl (“i-Pr”), n-butyl (“n-Bu”), isobutyl (“i-Bu”), sec-butyl (“s-Bu”), t-butyl (“t-Bu”), etc. Whether the term “alkyl” is used alone or as part of another group such as haloalkyl, alkoxy, etc., this definition applies.

As used herein, the term “alkenyl” refers to a straight or branched chain monovalent hydrocarbon radical having from 2 to 8 carbon atoms, such as 2 to 6 carbon atoms, for example 2, 3 or 4 carbon atoms, and containing one or more, for example 1, 2 or 3, carbon-carbon double bonds (C=C). For example, “C₂₋₆ alkenyl” denotes alkenyl having from 2 to 6 carbon atoms and containing 1 or 2, preferably 1, carbon-carbon double bonds. Similarly, “C₂₋₃ alkenyl” denotes alkenyl having from 2 to 3 carbon atoms and containing 1 carbon-carbon double bond. Examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, and 2-butenyl.

As used herein, the term “alkynyl” refers to a straight or branched chain monovalent hydrocarbon radical having from 2 to 8 carbon atoms, such as from 2 to 6 carbon atoms, such as from 2 to 4 carbon atoms, and containing one or more, for example 1, 2 or 3, carbon-carbon triple bonds (C≡C). For example, “C₂₋₆ alkynyl” refers to alkynyl having from 2 to 6 carbon atoms and containing 1 or 2, preferably 1, carbon-carbon triple bonds. Similarly, “C₂₋₃ alkynyl” refers to alkynyl having from 2 to 3 carbon atoms and containing 1 carbon-carbon triple bond. Examples of alkynyl include, but are not limited to, ethynyl, 2-propynyl and 2-butyne.

As used herein, the term “alkoxy” refers to the group -O-alkyl, wherein alkyl is as defined above. For example, “C₁₋₈alkoxy” refers to -O-C₁₋₈alkyl, i.e., alkoxy having from 1 to 8 carbon atoms. Similarly, “C₁₋₃alkoxy” refers to -O-C₁₋₃alkyl, i.e., alkoxy having from 1 to 3 carbon atoms. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, pentoxy and hexoxy etc. Whether the term “alkoxy” is used alone or as part of another group, this definition applies.

As used herein, the term “halo” or “halogen” refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I), preferably fluoro and chloro, most preferably fluoro.

As used herein, the term “haloalkyl” refers to alkyl as defined herein wherein one or more hydrogen atoms, for example 1, 2, 3, 4 or 5 hydrogen atoms, are replaced by halogen, and when more than one hydrogen atom is replaced by a halogen atom, said halogen atoms may be the same or different from one another. Examples of haloalkyl include, but are not limited to, -CF₃, -CHF₂

and $-\text{CH}_2\text{CF}_3$ etc.

As used herein, the term “hydroxyl” refers to the group $-\text{OH}$.

As used herein, the term “mercapto” refers to the group $-\text{SH}$.

As used herein, the term “cyano” refers to the group $-\text{CN}$.

As used herein, the term “carboxyl” refers to the group $-\text{C}(\text{O})-\text{OH}$, and may also be represented by $-\text{COOH}$.

As used herein, the term “carbonyl” refers to the group $-\text{C}(\text{O})-$, and may also be represented by $-\text{CO}-$.

As used herein, the term “hydrogen” refers to the group $-\text{H}$.

As used herein, the symbol “D” refers to deuterium.

As used herein, the term “amino” refers to the group $-\text{NH}_2$.

As used herein, the term “alkylamino” or “mono-alkylamino” refers to the group $\text{alkyl}-\text{NH}-$, wherein alkyl is as defined herein.

As used herein, the term “di-alkylamino” refers to the group $(\text{alkyl})_2\text{-N}-$, wherein alkyl is as defined herein.

As used herein, the term “alkylcarbonyl” refers to alkyl attached to another group through carbonyl, i.e., $\text{alkyl}-\text{C}(\text{O})-$, wherein alkyl is as defined herein.

As used herein, the term “alkoxycarbonyl” refers to alkoxyl attached to another group through carbonyl, i.e., $\text{alkoxyl}-\text{C}(\text{O})-$, wherein alkoxyl is as defined herein.

As used herein, the term “oxo” refers to the group $=\text{O}$.

As used herein, the term “nitro” refers to the group $-\text{NO}_2$.

As used herein, the term “cycloalkyl” refers to a saturated, monovalent monocyclic or bicyclic hydrocarbon radical having from 3 to 12 ring carbon atoms, such as from 3 to 8 ring carbon atoms, such as from 3 to 6 ring carbon atoms. For example, “ C_{3-8} cycloalkyl” refers to cycloalkyl having from 3 to 8 ring carbon atoms. Similarly, “ C_{3-6} cycloalkyl” refers to cycloalkyl having from 3 to 6 ring carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

As used herein, the term “cycloalkenyl” refers to cycloalkyl as defined herein containing one or more double bonds, such as 1, 2, 3 or 4 double bonds, the ring of which is non-aromatic. For example, “C₃₋₈cycloalkenyl” refers to cycloalkenyl having from 3 to 8 ring carbon atoms. Similarly, “C₃₋₆cycloalkenyl” refers to cycloalkenyl having from 3 to 6 ring carbon atoms. Examples of cycloalkenyl include, but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

As used herein, the term “heterocyclyl” or “heterocyclic” or “heterocycle” refers to monocyclic, bicyclic or tricyclic, saturated and partially unsaturated non-aromatic rings having from 3 to 20 ring atoms, such as from 3 to 12 ring atoms, such as from 3 to 8 ring atoms, such as from 3 to 6 ring atoms, which contain at least one carbon atom in addition to from 1 to 4, such as from 1 to 3, such as 1 or 2, such as 1, heteroatoms selected from the group consisting of O, S and N. In one example, said “heterocyclyl” or “heterocyclic” or “heterocycle” is monocyclic and has from 3 to 8 ring atoms, such as 3, 4, 5 or 6 ring atoms, which contain at least one carbon atom in addition to from 1 to 4, such as from 1 to 3, such as 1 or 2, such as 1, heteroatoms selected from the group consisting of O, S and N. In one example, said “heterocyclyl” or “heterocyclic” or “heterocycle” contains 0, 1, 2 or 3 double bonds. Any nitrogen or sulfur heteroatom may be optionally oxidized (e.g., NO, SO, SO₂), and any nitrogen heteroatom may be optionally quaternized (e.g., [NR₄]⁺Cl⁻, [NR₄]⁺OH⁻). Heterocyclyl having from 3 to 8 ring atoms is also referred to simply as 3-8 membered heterocyclyl, and heterocyclyl having other numbers of carbon atoms can be similarly abbreviated. Examples of heterocyclyl include, but are not limited to, oxiranyl, aziridinyl, thiiranyl, azetidiny, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, pyrrolidinyl (pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), dihydro-1H-pyrrolyl, dihydrofuranyl, tetrahydrofuranyl (e.g., tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl), dihydrothienyl, tetrahydrothienyl, imidazolidinyl, piperidinyl, piperazinyl (e.g., piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, piperazin-4-yl), isoquinolinyl, tetrahydroisoquinolinyl, morpholinyl (e.g., morpholino (i.e., morpholin-1-yl), morpholin-2-yl, morpholin-3-yl), thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, dihydropyranyl, tetrahydropyranyl (e.g., tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl), hexahydrothiopyranyl, hexahydropyrimidyl, oxazitanyl, thiazinanyl, thioxanthyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl, thiepanyl, azepinyl, oxazepanyl, diazepanyl, 1,4-diazepanyl, diazepinyl, thiazepinyl, thiazepanyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,1-dioxoisothiazolidonyl, oxazolidinonyl, imidazolidinonyl, 4,5,6,7-tetrahydro[2H]indazolyl, tetrahydrobenzimidazolyl, 4,5,6,7-tetrahydrobenzo[d]imidazolyl, 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridinyl, thiazinyl, oxazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl, oxathiazinyl, thiatiazinyl, oxatrazinyl, dithiadiazinyl, imidazolinyl, dihydropyrimidyl, tetrahydropyrimidinyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, thiopyranyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrimidinonyl, pyrimidindionyl, pyrimidin-2,4-dionyl, piperazinonyl, piperazindionyl, pyrazolidinyl, imidazolinyl, 3-azabicyclo[3.1.0]hexanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 2-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl, 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[2.2.2]octanyl, 7-oxabicyclo[2.2.1]heptanyl, azaspiro[3.5]nonanyl, azaspiro[2.5]octanyl, azaspiro[4.5]decanyl, 1-azaspiro[4.5]decan-2-onyl,

azaspiro[5.5]undecanyl, tetrahydroindolyl, octahydroindolyl, tetrahydroisoindolyl, tetrahydroindazolyl, 1,1-dioxohexahydrothiopyranyl. Examples of 5 membered heterocyclyl containing sulfur or oxygen atom and from 1 to 3 nitrogen atoms are: thiazolyl, including thiazol-2-yl and thiazol-2-yl N-oxide; thiadiazolyl, including 1,3,4-thiadiazol-5-yl and 1,2,4-thiadiazol-5-yl; oxazolyl, such as oxazol-2-yl; and oxadiazolyl, such as 1,3,4-oxadiazol-5-yl and 1,2,4-oxadiazol-5-yl. Examples of 5-membered heterocyclyl containing from 2 to 4 nitrogen atoms include: imidazolyl, such as imidazol-2-yl; triazolyl, such as 1,3,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-5-yl; and tetrazolyl, such as 1H-tetrazol-5-yl. Examples of benzo-fused 5-membered heterocyclyl are: benzoxazol-2-yl, benzothiazol-2-yl and benzimidazol-2-yl. Exemplary 6-membered heterocyclyl containing from 1 to 3 nitrogen atoms and optionally sulfur or oxygen atoms are: pyridinyl, such as pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; pyrimidinyl, such as pyrimidin-2-yl and pyrimidin-4-yl; triazinyl, such as 1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, especially pyridazin-3-yl; and pyrazinyl. Further examples of heterocyclyl are pyridine N-oxide and pyridazine N-oxide as well as pyridinyl, pyrimidin-2-yl, pyrimidin-4-yl, pyridazinyl and 1,3,4-triazin-2-yl.

As used herein, the term “hydroxylalkyl” refers to alkyl substituted with hydroxyl, i.e., -alkyl-OH, wherein alkyl is as defined herein. Examples of said group include, but not limited to hydroxymethyl, hydroxylethyl (such as 2-hydroxylethyl, 1-hydroxylethyl), hydroxylpropyl (such as 1-hydroxylprop-2-yl, 1-hydroxylprop-3-yl, 1-hydroxylprop-1-yl etc.), hydroxylbutyl (such as 4-hydroxylbut-2-yl etc.).

As used herein, the term “aryl” refers to a carbocyclic hydrocarbon radical consisting of one ring or fused rings, wherein at least one ring is aromatic, and having from 6 to 14 ring carbon atoms, such as from 6 to 12 ring carbon atoms, such as from 6 to 10 ring carbon atoms. Example of aryl include, but not limited to phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indenyl, preferably phenyl and naphthyl.

As used herein, the term “heteroaryl” refers to:

A monocyclic aromatic hydrocarbon radical having 5, 6 or 7 ring atoms, such as having 6 ring atoms, and containing one or more, such as 1, 2 or 3, such as 1 or 2, ring heteroatoms independently selected from the group consisting of N, O and S (e.g. N) in the ring, with the remaining ring atoms being carbon atoms; and

A bicyclic aromatic hydrocarbon radical having from 8 to 12 ring atoms, such as having 9 or 10 ring atoms, and containing one or more, such as 1, 2, 3 or 4, such as 1 or 2, ring heteroatoms independently from the group connecting of N, O and S (e.g. N) in the rings, with the remaining ring atoms being carbon atoms, wherein at least one of the rings is aromatic.

When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another.

The heteroaryl group also includes those wherein the N heteroatom occurs as N-oxide, such as pyrimidinyl N-oxides.

In some embodiments, the heteroaryl above in which the heteroatom(s) in the ring(s) is N

atom(s) is defined herein as “nitrogen-containing heteroaryl”. The nitrogen-containing heteroaryl also includes those wherein the N heteroatom occurs as N-oxide, such as pyridyl N-oxides. For example, the nitrogen-containing heteroaryl is a monocyclic heteroaryl having 5 ring atoms and containing 1 or 2 N heteroatoms in the ring, with the remaining ring atoms being carbon atoms; and as another example, the nitrogen-containing heteroaryl is a monocyclic heteroaryl having 6 ring atoms, and containing 1, 2 or 3 heteroatoms in the ring, with the remaining ring atoms being carbon atoms.

Examples of heteroaryl include, but are not limited to, pyridyl (such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-5-yl, pyridin-6-yl), pyridyl N-oxide; pyrazinyl; pyrimidinyl; pyrazolyl (such as pyrazol-5-yl, pyrazol-1-yl, pyrazol-2-yl, pyrazol-3-yl, pyrazol-4-yl); imidazolyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; thiadiazolyl; tetrazolyl; triazolyl; thienyl; furyl; pyranyl; pyrrolyl; pyridazinyl; benzo[d]thiazolyl; bezodioxolyl, such as benzo[d][1,3]dioxolyl; benzoxazolyl, such as benzo[d]oxazolyl; imidazopyridyl, such as imidazo[1,2-a]pyridyl; triazolopyridyl, such as [1,2,4]triazolo[4,3-a]pyridyl and [1,2,4]triazolo[1,5-a]pyridyl; indazolyl, 2H-indazolyl; pyrrolopyrimidinyl, such as pyrrolo[3,4-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl; pyrazolopyrimidinyl, such as pyrazolo[1,5-a]pyrimidinyl; tetrazolopyridyl, such as tetrazolo[1,5-a]pyridyl; benzothienyl; benzofuryl; benzoimidazolyl; indolyl; indolyl; purinyl, such as 9H-purinyl and 7H-purinyl; quinolyl; isoquinolyl; 1,2,3,4-tetrahydroquinolyl; and 5,6,7,8-tetrahydroisoquinolyl.

Examples of the nitrogen-containing heteroaryl include, but are not limited to, pyrrolyl; pyrazolyl; imidazolyl; pyridyl; pyrazinyl; pyrimidinyl, pyrimidinyl N-oxide; pyridazinyl; pyrrolopyrimidinyl, such as pyrrolo[3,4-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl; purinyl, such as 9H-purinyl and 7H-purinyl; quinolyl; indolyl; and indazolyl.

As used herein, “aryl” or “aromatic” follows Hückel's rule wherein the number of π -electrons equals $4n+2$ where n is zero or any positive integer up to 6.

As used herein, the term “optional” or “optionally” means that the subsequently described substitution pattern, event, or circumstance may or may not occur, and that the description includes instances where the substitution pattern occurs and instances where it does not. For example, “optionally substituted alkyl” encompasses both “unsubstituted alkyl” and “substituted alkyl” as defined herein. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, chemically incorrect, synthetically non-feasible and/or inherently unstable.

As used herein, the term “substituted” or “substituted with.....” means that one or more hydrogen atoms on the designated atom or group are replaced with one or more substituents selected from the indicated group of substituents, provided that the designated atom's normal valence is not exceeded. When a substituent is oxo (i.e., =O), then two hydrogens on a single atom are replaced by the oxo. Combinations of substituents and/or variables are permissible only if such

combinations result in a chemically correct and stable compound. A chemically correct and stable compound means a compound that is sufficiently robust to survive isolation from a reaction mixture for the identification of the chemical structure of the compound, and subsequently to be prepared into a formulation having at least one practical utility. For example, under the circumstances that the substituents are not specifically indicated, the term “substituted” or “substituted with.....” as used herein means that one or more hydrogen atoms on a given atom or group are independently replaced by one or more, for example 1, 2, 3 or 4 substituents independently selected from the group consisting of deuterium (D), halo, -OH, mercapto, cyano, -CD₃, -C₁-C₆alkyl (preferably -C₁₋₃alkyl), C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl (preferably 3-8 membered cycloalkyl), aryl, heterocyclyl (preferably 3-8 membered heterocyclyl), heteroaryl, aryl-C₁-C₆alkyl-, heteroaryl-C₁-C₆alkyl-, C₁-C₆haloalkyl-, -OC₁-C₆alkyl (preferably -OC₁-C₃alkyl), -OC₂-C₆alkenyl, -OC₁-C₆alkylphenyl, -C₁-C₆alkyl-OH (preferably -C₁-C₄alkyl-OH), -C₁-C₆alkyl-SH, -C₁-C₆alkyl-O-C₁-C₆alkyl, -OC₁-C₆haloalkyl, -NH₂, -C₁-C₆alkyl-NH₂ (preferably -C₁-C₃alkyl-NH₂), -N(C₁-C₆alkyl)₂ (preferably -N(C₁-C₃alkyl)₂), -NH(C₁-C₆alkyl) (preferably -NH(C₁-C₃alkyl)), -N(C₁-C₆alkyl)(C₁-C₆alkylphenyl), -NH(C₁-C₆alkylphenyl), nitro, -C(O)-OH, -C(O)OC₁-C₆alkyl (preferably -C(O)OC₁-C₃alkyl), -CONR_iR_{ii} (wherein R_i and R_{ii} are selected from the group consisting of H, D and C₁₋₆alkyl, preferably C₁₋₃alkyl), -NHC(O)(C₁-C₆alkyl), -NHC(O)(phenyl), -N(C₁-C₆alkyl)C(O)(C₁-C₆alkyl), -N(C₁-C₆alkyl)C(O)(phenyl), -C(O)C₁-C₆alkyl, -C(O)heteroaryl (preferably -C(O)-5-7 membered heteroaryl), -C(O)C₁-C₆alkylphenyl, -C(O)C₁-C₆haloalkyl, -OC(O)C₁-C₆alkyl (preferably -OC(O)C₁-C₃alkyl), -S(O)₂-C₁-C₆alkyl, -S(O)-C₁-C₆alkyl, -S(O)₂-phenyl, -S(O)₂-C₁-C₆haloalkyl, -S(O)₂NH₂, -S(O)₂NH(C₁-C₆alkyl), -S(O)₂NH(phenyl), -NHS(O)₂(C₁-C₆alkyl), -NHS(O)₂(phenyl), and -NHS(O)₂(C₁-C₆haloalkyl), wherein said alkyl, cycloalkyl, phenyl, aryl, heterocyclyl and heteroaryl are each optionally further substituted with one or more substituents selected from the group consisting of halo, -OH, -NH₂, cycloalkyl, 3-8 membered heterocyclyl, C₁-C₄alkyl, C₁-C₄haloalkyl-, -OC₁-C₄alkyl, -C₁-C₄alkyl-OH, -C₁-C₄alkyl-O-C₁-C₄alkyl, -OC₁-C₄haloalkyl, cyano, nitro, -C(O)-OH, -C(O)OC₁-C₆alkyl, -CON(C₁-C₆alkyl)₂, -CONH(C₁-C₆alkyl), -CONH₂, -NHC(O)(C₁-C₆alkyl), -NH(C₁-C₆alkyl)C(O)(C₁-C₆alkyl), -SO₂(C₁-C₆alkyl), -SO₂(phenyl), -SO₂(C₁-C₆haloalkyl), -SO₂NH₂, -SO₂NH(C₁-C₆alkyl), -SO₂NH(phenyl), -NHSO₂(C₁-C₆alkyl), -NHSO₂(phenyl), and -NHSO₂(C₁-C₆haloalkyl). When an atom or group is substituted with more than one substituents, the substituents may be same or different.

As used herein, the term “pharmaceutically acceptable” means non-toxic, biologically tolerable and suitable for administration to a subject.

As used herein, the term “pharmaceutically acceptable salt” refers to a base or acid addition salt of the compound of formula (I) that is non-toxic, biologically tolerable and suitable for administration to a subject. The “Pharmaceutically acceptable salt” includes, but are not limited to, acid addition salts formed by the compound of formula (I) with an inorganic acid, such as hydrochloride, hydrobromide, carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate, and the like, as well as with an organic acid, such as formate, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethanesulfonate, benzoate, salicylate, stearate, and salts with alkane-dicarboxylic acid of formula

HOOC-(CH₂)_n-COOH (wherein n is 0-4), etc. Also, “pharmaceutically acceptable salt” includes base addition salts formed by the compound of formula (I) carrying an acidic moiety with a pharmaceutically acceptable cations such as sodium, potassium, calcium, aluminum, lithium and ammonium.

In addition, if a compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product is a free base, an acid addition salt, particularly a pharmaceutically acceptable acid addition salt, may be produced by dissolving the free base in a suitable solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will be able to determine, without undue experimentation, a variety of synthetic methods, which are used to prepare non-toxic pharmaceutically acceptable acid addition salts.

The compounds of the invention may exist in the form of solvates. The term “solvates” means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. If the solvent is water, the solvate formed is a hydrate, and when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H₂O. Such combination may form one or more kinds of hydrates, for example, hemihydrates, monohydrate, and dihydrate.

As used herein, the term “prodrug” refers to an active or inactive compound that will be chemically modified to form the compounds of the invention by physiological effects in vivo, such as hydrolysis, metabolism, and the like, upon administration to a subject. The suitability and techniques involved in preparing and using a prodrug are well known to those skilled in the art. Exemplary prodrugs are, for example, esters of free carboxylic acids, S-acyl derivatives of thiols and O-acyl derivatives of alcohols or phenols. Suitable prodrugs are generally pharmaceutically acceptable ester derivatives which are convertible under physiological conditions by solvolysis to the parent carboxylic acid, for example, lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di-substituted lower alkyl esters, such as ω-(amino, mono- or di-lower alkyl amino, carboxyl, lower alkoxy carbonyl)-lower alkyl esters, α-(lower alkanoyloxy, lower alkoxy carbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, for example, pivaloyloxymethyl ester and the like, which are conventional in the art.

It will be appreciated by those skilled in the art that some of the compounds of formula (I) may contain one or more chiral centers and therefore exist in two or more stereoisomeric forms. Thus, the compounds of the invention may exist as individual stereoisomers (for example, enantiomers, diastereomers) and mixtures thereof in any proportion, such as racemate, and, where appropriate, as tautomers and geometric isomers.

As used herein, the term “stereoisomer” refers to compounds that have the same chemical constitution but are different in the spatial arrangement of the atoms or groups. Stereoisomers

include enantiomers, diastereomers, conformers, and the like.

As used herein, the term “enantiomer” refers to two stereoisomers of a compound that are nonsuperimposable mirror images of each other.

As used herein, the term “diastereomer” refers to stereoisomers which have two or more chiral centers and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, or biological activities. Mixtures of diastereomers may be separated under high resolution analytical procedures such as electrophoresis and chromatography such as HPLC.

Stereochemical definitions and conventions used herein follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes *d* and *l* or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or *l* meaning that the compound is levorotatory. A compound prefixed with (+) or *d* is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

The racemates can be used as such or can be resolved into their individual isomers. The resolution can afford stereochemically pure compounds or mixtures enriched in one or more isomers. Methods for separation of isomers are well known (*cf.* Allinger N. L. and Eliel E. L. in “*Topics in Stereochemistry*”, Vol. 6, Wiley Interscience, 1971) and include physical methods such as chromatography using a chiral adsorbent. Individual isomers can be prepared in chiral form from chiral precursors. Alternatively individual isomers can be separated chemically from a mixture by forming diastereomeric salts with a chiral acid (such as the individual enantiomers of 10-camphorsulfonic acid, camphoric acid, alpha-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like), fractionally crystallizing the salts, and then freeing one or both of the resolved bases, optionally repeating the process, so as obtain either or both substantially free of the other, i.e., in a form having an optical purity of, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% by weight of the desired stereoisomer. Alternatively the racemates can be covalently linked to a chiral compound (auxiliary) to produce diastereomers which can be separated by chromatography or by fractional crystallization after which time the chiral auxiliary is chemically removed to afford the pure enantiomers, as is known to those skilled in the art.

As used herein, the term “conformer” refers to an isomer formed due to the different spatial position of an atom or group around a single bond in a covalent compound molecule, such as the half-chair conformer and envelope conformer of cyclopentane.

As used herein, the term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of some of the bonding electrons.

As used herein, the term “geometric isomer” is an isomer caused by the inability of a double bond or a single bond of ring carbon atoms to rotate freely, and is also known as *cis*- and *trans*-isomers. The *cis*-isomer occurs when substituents are located on the same side of a plane, and the *trans*-isomer occurs when substituents are located on the opposite side of a plane.

As used herein, the terms “treating”, “treat,” or “treatment” of a disease refer to administering one or more pharmaceutical substances, especially a compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein to a subject that has the disease, or has a symptom of the disease, with the purpose to heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease or the symptoms of the disease. In some embodiments, the disease is cancer.

As used herein, the terms “preventing”, “prevent” or “prevention” of a disease refer to administering one or more pharmaceutical substances, especially a compound of formula (I) and/or a pharmaceutically acceptable salt thereof described herein to a subject that has a predisposition toward the disease, with the purpose to prevent the development of the disease in the subject. In some embodiments, the disease is a disease associated with an ERK kinase such as ERK1 and/or ERK2 kinase. In further embodiments, the disease is a disease associated with high expression or high activity of an ERK kinase such as ERK1 and/or ERK2 kinase. In further embodiments, the disease is cancer or tumor.

As used herein, the terms “cancer”, “carcinoma” and “tumor” refer to a physiological condition typically characterized by dysregulated cell proliferation in mammals. Examples of the cancer include blastoma, glioma, sarcoma, seminoma, glioblastoma, melanoma, leukemia, and myeloid or lymphoid malignancies. More specific examples of the cancer include squamous cell cancer (e.g., epithelial squamous cell cancer) and lung cancer, including small-cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, and lung squamous cell cancer. Additional cancers include skin cancer, keratoacanthoma, follicular carcinoma, hairy cell leukemia, buccal cavity, pharynx cancer, lip cancer, tongue cancer, mouth cancer, salivary gland cancer, esophageal cancer, laryngeal cancer, hepatocellular cancer, gastric cancer, gastrointestinal cancer, small intestine cancer, large intestine cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer,

genitourinary system cancer, biliary tract cancer, gallbladder adenocarcinoma, thyroid cancer, papillary cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, testicular cancer, vulval cancer, peritoneal cancer, anal cancer, penile cancer, bone cancer, multiple myeloma, B cell lymphoma, central nervous system cancer, brain cancer, head and neck cancer, Hodgkin's lymphoma. Examples also include myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, myelofibrosis such as primary myelofibrosis, acute myeloid leukemia, and chronic myeloid leukemia (CML).

The terms “treating”, “contacting” and “reacting” in the context of a chemical reaction, mean adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately lead to the formation of the indicated and/or the desired product.

As used herein, the term “effective amount” refers to an amount sufficient to generally bring about a beneficial effect in a subject. The effective amount of the compounds of the invention may be ascertained by conventional methods (such as modeling, dose escalation studies or clinical trials), and by taking into consideration conventional influencing factors (such as the mode of administration, the pharmacokinetics of the compound, the severity and course of the disease, the subject's medical history, the subject's health status and response to drugs).

The term “inhibition”, “inhibitory” or “inhibiting” indicates a decrease in the baseline activity of a biological activity or process. The term “inhibition of ERK activity” or “inhibiting ERK activity” refers to a decrease in the activity of ERK as a direct or indirect response to the presence of the compound of formula (I) and/or the pharmaceutically acceptable salt thereof described herein, relative to the activity of ERK in the absence of the compound of formula (I) and/or the pharmaceutically acceptable salt thereof. The decrease in activity may be due to the direct interaction of the compound of formula (I) and/or the pharmaceutically acceptable salt thereof described herein with ERK, or due to the interaction of the compound of formula (I) and/or the pharmaceutically acceptable salt thereof described herein, with one or more other factors that in turn affect the ERK activity.

As used herein, the term “subject” refers to mammals and non-mammals. Mammals means any member of the mammalian class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term “subject” does not denote a particular age or sex. In some embodiments, the subject is a human.

In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20%.

Technical and scientific terms used herein and not specifically defined have the meaning commonly understood by those skilled in the art to which the invention pertains.

General Synthesis Methods

The compounds of formula (I) in accordance with the invention, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate or pharmaceutically acceptable salt thereof, may be prepared by a variety of methods, including those indicated below, those exemplified in the Examples, or methods analogous thereto. Suitable general synthetic schemes are depicted below. Suitable reaction conditions for each reaction step are known to those skilled in the art. Starting materials for the preparation are commercially available or may be prepared using methods indicated below or analogous thereto, or well known to those skilled in the art. Variables in general formulae have the same meaning as above unless otherwise indicated.

The general synthesis methods for preparation of the compounds of the invention are shown in Figures 1 to 4.

Figure 1 shows general synthetic scheme A for the synthesis of the compounds of the invention.

Figure 2 shows general synthetic scheme B for the synthesis of the compounds of the invention.

Figure 3 shows general synthetic scheme C for the synthesis of the compounds of the invention.

Figure 4 shows general synthetic scheme D for the synthesis of the compounds of the invention.

In these schemes, it is well understood that protecting groups for sensitive or reactive groups (e.g., amino, hydroxyl and carboxyl) are used, when necessary, according to common principles or chemistry to prevent undesired chemical reactions. The protecting groups are treated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 5th Edition, Wiley, New York 2014.). These groups are removed at a convenient stage of synthesis of a compound using methods well known to those skilled in the art. The selection of the process, the reaction conditions and the performance sequence should be in accordance with the preparation of the compounds of formula (I).

Examples of amino-protecting groups include carbamates, amides, alkyl and aryl groups, imines, as well as many N-heteroatom derivatives which can be removed to regenerate the desired amine group. Specific amino protecting groups are Pmb (p-methoxybenzyl), Boc (t-butyloxycarbonyl), Fmoc (9-fluorenylmethyloxycarbonyl) and Cbz (carbobenzyloxy). Further


examples of these groups are found in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 3rd Edition, John Wiley & Sons, Inc., 1999.

Examples of hydroxyl-protecting groups include tetrahydropyranyloxy, benzoyl, acetoxy, carbamoyloxy, benzyl, and silylethers (e.g. TBS, TBDPS) groups. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 3rd Edition, John Wiley & Sons, Inc., 1999.

Examples of carboxy protecting groups include, ester groups and heterocyclyl groups. Ester derivatives of the carboxylic acid group may be employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups of the compound. Examples of such ester groups include substituted arylalkyl, including substituted benzyls, such as 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl; alkyl or substituted alkyl esters such as methyl, ethyl, t-butylallyl or t-amyl, triphenylmethyl (trityl), 4-methoxytrityl, 4,4'-dimethoxytrityl, 4,4',4''-trimethoxytrityl, 2-phenylprop-2-yl; thioesters such as t-butyl thioester; silyl esters such as trimethylsilyl esters, t-butyl dimethylsilyl esters (TBSO), and the like. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 5th Edition, Wiley, New York, 2014.

Those skilled in the art will recognize whether a stereocentre is present in the compounds of formula (I). Accordingly, when a compound is desired as a single enantiomer or diastereomer, it can be obtained either by stereospecific synthesis or by resolution of the final product or any appropriate intermediate. The resolution of the final product, intermediates or starting materials may be carried out using any appropriate method known in the art. See, for example, E. L. Eliel, S. H. Wilen and L. N. Mander, "Stereochemistry of Organic Compounds" (Wiley-Interscience, 1994).

In the methods of Figure 3 and Embodiment 20, the preparation of Compound C2 is achieved by amide coupling reaction of Compound C1 with the carboxylic acid



Preferably, the amide coupling reaction is carried out in an inert solvent. More preferably, the amide coupling reaction is carried out in the presence of a condensing agent and a base in an inert solvent.

The inert solvent is preferably selected from the group consisting of ethyl acetate, tetrahydrofuran, methyltetrahydrofuran, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, dichloromethane, 1,2-dichloroethane, N-methyl-2-pyrrolidone, or a combination thereof.

The condensing agent is preferably one or more selected from the group consisting of 1-hydroxybenzotriazole (HOBT), 1-hydroxy-7-azobenzotriazole (HOAT), benzotriazol-1-yl-oxytripyrrolidino-phosphonium hexafluorophosphate (PyBOP),

benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), 1,1-carbonyldiimidazole (CDI), 1-propylphosphonic anhydride (T3P), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl), N,N-dicyclohexylcarbodiimide (DCC), acetic anhydride, acetyl chloride, oxalyl chloride, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), and is more preferably T₃P.

The base is preferably one or more selected from the group consisting of triethylamine, DIPEA, pyridine, 2,4-dimethylpyridine, NaOH, KOH, LiOH, Na₂CO₃, K₂CO₃, NaHCO₃, Cs₂CO₃, Na₃PO₄ or K₃PO₄; and is more preferably DIPEA.

Preferably, the amide coupling reaction is carried out at a temperature from room temperature to reflux.

Preferably, the amide coupling reaction is carried out for 0.5 – 24 h.

In the methods of Figure 3 and Embodiment 20, when Compound C2 is Boc-protected, Compound C2 may be subjected to deprotection to give Compound C3.

Preferably, the deprotection is carried out in an inert solvent. The inert solvent is preferably selected from the group consisting of ethyl acetate, tetrahydrofuran, methyltetrahydrofuran, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, dichloromethane, 1,2-dichloroethane, N-methyl-2-pyrrolidone, or a combination thereof.

Preferably, the deprotection is carried out in the presence of an acid. The acid is preferably one or more selected from the group consisting of hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, formic acid, and phosphoric acid.

Preferably, the deprotection is carried out at a temperature from -10°C to 80°C.

Preferably, the deprotection is carried out for 0.5 – 24 h.

Utility and Administration

The compounds of the invention are useful for the treatment of a disease associated with an ERK kinase such as ERK1 and/or ERK2 kinase, for example a disease associated with high expression or high activity of an ERK kinase such as ERK1 and/or ERK2 kinase, such as tumor and cancer. More specifically, the tumor and cancer are selected from the group consisting of, for example, blastoma, glioma, sarcoma, seminoma, glioblastoma, melanoma, leukemia, and myeloid or lymphoid malignancies. More specific examples of the cancer include squamous cell cancer (e.g., epithelial squamous cell cancer) and lung cancer, including small-cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, and lung squamous cell cancer. Additional cancers

include skin cancer, keratoacanthoma, follicular carcinoma, hairy cell leukemia, buccal cavity, pharynx cancer, lip cancer, tongue cancer, mouth cancer, salivary gland cancer, esophageal cancer, laryngeal cancer, hepatocellular cancer, gastric cancer, gastrointestinal cancer, small intestine cancer, large intestine cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, genitourinary system cancer, biliary tract cancer, gallbladder adenocarcinoma, thyroid cancer, papillary cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, testicular cancer, vulval cancer, peritoneal cancer, anal cancer, penile cancer, bone cancer, multiple myeloma, B cell lymphoma, central nervous system cancer, brain cancer, head and neck cancer, Hodgkin's lymphoma. Examples also include myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, myelofibrosis such as primary myelofibrosis, acute myeloid leukemia, and chronic myeloid leukemia (CML).

The compounds of the invention may be administered to a subject as a pharmaceutical composition, which may optionally comprise one or more pharmaceutically acceptable excipients.

The compounds of the invention can be administered by various known routes, including oral, rectal, intragastrical, intracranial and parenteral administration, e.g. intravenous, intramuscular, intranasal, intradermal, subcutaneous, and similar administration routes. Oral, intranasal and parenteral administration are particularly preferred. Depending on the route of administration, different pharmaceutical formulations are required and some of those may require that protective coatings are applied to the drug formulation to prevent degradation of a compound of the invention in, for example, the digestive tract.

The compounds of the invention may be formulated as a syrup, an infusion or injection solution, a spray, a tablet, a capsule, a lozenge, a liposome, a suppository, and the like.

Particular preferred pharmaceutical forms for the administration of the compounds of the invention are forms suitable for injectionable use and include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the final solution or dispersion form must be sterile and fluid. Typically, such a solution or dispersion will include a solvent or dispersion medium, containing, for example, water-buffered aqueous solutions, e.g. biocompatible buffers, ethanol, polyol such as glycerol, propylene glycol, polyethylene glycol, suitable mixtures thereof, surfactants or vegetable oils. The compounds of the invention can also be formulated into liposomes, in particular for parenteral administration. Liposomes provide the advantage of increased half life in the circulation, if compared to the free drug, and a prolonged more even release of the enclosed drug.

Sterilization of infusion or injection solutions can be accomplished by any techniques recognized in the art, including but not limited to addition of preservatives such as anti-bacterial or anti-fungal agents, e.g. parabens, chlorobutanol, phenol, sorbic acid or thimerosal. Further, isotonic agents, such as sugars or salts, in particular sodium chloride, may be incorporated in infusion or injection solutions.

Production of sterile injectable solutions containing one or more of the compounds of the invention is accomplished by incorporating the respective compound in the required amount in the appropriate solvent with various ingredients enumerated above as required followed by sterilization. To obtain a sterile powder the above solutions are vacuum-dried or freeze-dried as necessary. Preferred diluents of the present invention are water, physiological acceptable buffers, physiological acceptable buffer salt solutions or salt solutions. Preferred carriers are cocoa butter and vitebesole.

Excipients which can be used with the various pharmaceutical forms of the compounds of the invention can be selected from the following non-limiting list:

- a) binders such as lactose, mannitol, crystalline sorbitol, dibasic phosphates, sugars, microcrystalline cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, polyvinyl pyrrolidone and the like;
- b) lubricants such as magnesium stearate, talc, calcium stearate, zinc stearate, stearic acid, hydrogenated vegetable oil, leucine, glycerides and sodium stearyl fumarates,
- c) disintegrants such as starches, croscarmellose, sodium methyl cellulose, agar, bentonite, alginic acid, carboxymethyl cellulose, polyvinyl pyrrolidone and the like.

In one embodiment, the formulation is for oral administration and the formulation comprises one or more or all of the following ingredients: pregelatinized starch, talc, povidone K30, croscarmellose sodium, sodium stearyl fumarate, gelatin, titanium dioxide, sorbitol, monosodium citrate, xanthan gum, titanium dioxide, flavouring agent, sodium benzoate and saccharin sodium.

In one embodiment, the compounds of the invention are administered intranasally, it may be administered in the form of a dry powder inhaler or an aerosol spray from a pressurized container, pump, spray or nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoro-alkane such as 1,1,1,2-tetrafluoroethane (HFA 134A™) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA™), carbon dioxide, or another suitable gas. The pressurized container, pump, spray or nebulizer may contain a solution or suspension of the compounds of the invention, e.g., using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g., sorbitan trioleate.


The typical dosage of the compounds of the invention will be in the range of 0.001 - 1000 mg/kg body weight/day. The daily dosage may be administered in a single dose or in multiple divided doses. The appropriate dosage is determined by the attending physician, as appropriate, depending on the type and severity of the disease being treated, the health status and past medical history of the individual, the co-drug, the specific compound to be administered, and the route of administration. If desired, the dosage of the compounds of the invention may go beyond said dosage range.

It is understood that within the scope of the invention, a technical feature defined in the individual technical solutions above can be combined with a technical feature specifically described below (e.g., in the Examples) to form a new or preferred technical solution. Such technical solutions


are not reiterated one by one herein due to the length of the application.

The formula shall be relied on when there is discrepancy between the chemical name of any compound of the invention and its formula, unless the formula is obviously wrong.

As will be clearly understood by those skilled in the art, not all hydrogen atoms are explicitly depicted in the structural formulae of some compounds of the invention for the sake of simplicity. When a carbon atom or a nitrogen atom in a compound has a vacant valence, it means that hydrogen not explicitly depicted is present there. For example, the compound of Example P12 is



represented by the formula **P12** below, wherein one hydrogen atom is omitted on the nitrogen atom between the pyrimidine ring and the pyrazole ring. Those skilled in the art can understand that said formula represents the same compound as the formula



Brief Description of Figures

Figure 1 shows the general synthetic scheme A for the synthesis of the compounds of the invention, wherein individual variables are as defined herein.

Figure 2 shows the general synthetic scheme B for the synthesis of the compounds of the invention, wherein individual variables are as defined herein.

Figure 3 shows the general synthetic scheme C for the synthesis of the compounds of the invention, wherein individual variables are as defined herein.

Figure 4 shows the general synthetic scheme D for the synthesis of the compounds of the invention, wherein individual variables are as defined herein.

Examples

The following examples are merely provided for illustration of the invention and should not be construed to limit the scope of the invention.

The experimental procedures in the following examples, in which the specific conditions are

not indicated, can be carried out under the conventional conditions for such reactions or under the conditions recommended by the manufacturers. Unless otherwise specified, percentages and parts are indicated by weight.

The materials and reagents used in the following examples are commercially available, unless otherwise specified.

In the following examples, ^1H -NMR spectra were recorded using Bruker AVHD 400MHz or Bruker AVHD 500 MHz nuclear magnetic resonance spectrometer, ^{13}C -NMR spectra were recorded using Bruker AVHD 500MHz or Bruker AVHD 600MHz nuclear magnetic resonance spectrometer, with chemical shift shown in δ (ppm); Mass spectra were recorded using Waters UPLC H-Class+QDa (ESI) and Agilent 1260_6120 (ESI) mass spectrometer; and reverse phase preparative HPLC separation was carried out using Waters UV guided fully automatic purification system (Xbridge Prep C185 μm OBD column).

The abbreviations used in the examples have the following meanings:


<i>i</i> PrOH	isopropanol
EtOH	ethanol
DCM	dichloromethane
TFA or CF_3COOH	trifluoroacetic acid
MeOH	methanol
NaOH	sodium hydroxide
HCl	hydrogen chloride or hydrochloric acid
TEA	triethylamine
Raney Ni	Raney nickel
dioxane	dioxacyclohexane
NaH	sodium hydride
H_2O	water
Pd/C	palladium/charcoal
H_2	hydrogen gas
N_2	nitrogen gas
HATU	O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
DMF	N,N-dimethylformamide
THF	tetrahydrofuran
Boc_2O	di- <i>t</i> -butyl dicarbonate
Boc	<i>t</i> -butoxycarbonyl
NBS	N-bromosuccinimide
NCS	N-chlorosuccinimide
NIS	N-iodosuccinimide
MeCN or CH_3CN	acetonitrile
DIPEA or DIEA	N,N-diisopropylethylamine
NaBH_4	sodium borohydride

AcOH	acetic acid
Ac ₂ O	acetic anhydride
AcCl	acetyl chloride
NaBH ₃ CN or NaBH ₃ (CN)	sodium cyanoborohydride
K ₂ CO ₃	potassium carbonate
Cs ₂ CO ₃	cesium carbonate
NaHCO ₃	sodium bicarbonate
<i>n</i> BuLi	<i>n</i> -butyllithium
LiAlH ₄	lithium aluminum hydride
Pd(dppf)Cl ₂ or PdCl ₂ (dppf)	1,1'-bis(diphenylphospho)ferrocene]palladium (II) dichloride
PdCl ₂ (PPh ₃) ₂	bis(triphenylphosphine)palladium(II) dichloride
KOAc	potassium acetate
Fumaronitrile	fumaronitrile
P(<i>n</i> Bu) ₃	tri- <i>n</i> -butylphosphine
LDA	lithium diisopropylamide
LiOH	lithium hydroxide
MeI	iodomethane
EtI	iodoethane
(CH ₂ O) _n	paraform
HCO ₂ H or FA	formic acid
CH ₃ COCl	acetyl chloride
HPLC	high performance liquid chromatography
CH ₃ COOK or AcOK	potassium acetate
<i>t</i> -BuONa	sodium <i>t</i> -butoxide
DMSO	dimethyl sulfoxide
h	hour(s)
min	minute(s)
DMAP	4-dimethylamipryidine
r.t.或 RT	room temperature
T ₃ P	1-propylphosphonic anhydride
DMEA	N,N-dimethylethanolamine
POCl ₃	phosphorus oxychloride
°C	degrees centigrade
EA	ethyl acetate
Bu ₄ NBr ₃	tetra- <i>n</i> -butylammonium tribromide
CuI	cuprous iodide
Mg	magnesium
Py	pyridine
TLC	thin-layer chromatography
LCMS	liquid chromatography-mass spectrometry
TBS	<i>t</i> -butyldimethylsilane
TBSCl	<i>t</i> -butyldimethylsilyl chloride


BPin ₂	bis(pinacolato)diboron
PE	petroleum ether
MW	microwave
DEA	diethylamine
HEP	n-heptane
IPA	isopropanol
HEX	n-hexane

Synthesis of Intermediates

Intermediate 4: Synthesis of 7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline (4)




Step 1. Synthesis of 7-fluoroindoline (2)



Into a dry 50 mL round bottom flask, Compound **1** (5000 mg, 37 mmol) and AcOH (30 mL) were added at room temperature, and NaBH₃CN (5813 mg, 92.49 mmol) was added in portions at 0°C. The mixture was stirred at room temperature for 3 h. After the reaction was completed as detected by TLC plate, the reaction was concentrated under reduced pressure, added with 100 mL water, and adjusted to pH = 9 with 2 mol/L aqueous sodium hydroxide solution at 0°C. The mixture was stirred for 1 hour, then warmed to 25°C, and stirred for 1 hour. The mixture was extracted with ethyl acetate, dried, and filtered. The filtrate was evaporated to dryness. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate/petroleum ether = 1/50 to 1/10) to give Intermediate **2** 7-fluoroindoline (4.0g, off white solid). Yield: 78.4%. LCMS: m/z 138.1 (M + H).

Step 2. Synthesis of 5-bromo-7-fluoroindoline (3)



Method I:


NBS (5.2 g, 29.19 mmol) was slowly added into the solution of Intermediate **2** (4.0 g, 29.19 mmol) in acetonitrile (100 mL) in a dry 50 mL round bottom flask at 0°C. The mixture was then warmed to room temperature, and stirred for 2 h. After the reaction was completed, the reaction was

concentrated under reduced pressure, added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phase washed with saturated aqueous sodium bicarbonate solution and saturated brine (100 mL×1), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:8) to give Intermediate **3** (5.0 g, light purple solid). Yield: 80.6%. LCMS: m/z 215.9 (M+H).

Method II:


Into a 100 mL flask in ice-water bath, Compound **2** (9.8 g, 0.072 mol) and dichromethane (100 mL) were added, and tetra-*n*-butylammonium tribromide (34.5 g, 0.072 mol) was added in portions. The mixture was naturally warmed to room temperature, and stirred at room temperature for 4 h. After the reaction was completed, the reaction was concentrated under reduced pressure, slowly added with saturated aqueous sodium bicarbonate solution to adjust the pH to 6-7, and was extracted with ethyl acetate (50 mL×4). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:15) to give 5-bromo-7-fluoroindoline **3** (9.5 g, off-white solid). LCMS: m/z 215.9 (M+H).

Step 3. Synthesis of 7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indoline (**4**)



Into a dry 50 mL single-necked flask, Intermediate **3** (600 mg, 2.777 mmol), bis(pinacolato)diboron (1410 mg, 5.554 mmol), Pd(dppf)Cl₂ (243 mg, 0.333 mmol), potassium acetate (545mg, 5.554mmol) and 1,4-dioxane (4 mL) were added at room temperature. The mixture was purged with nitrogen gas three times, and heated to 110°C with stirring under nitrogen gas for 3 h. After the reaction was completed as detected by LCMS, the reaction was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (EA/PE = 2%-10%) to give Intermediate **4**, 7-fluoro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-1H-indole (600 mg, yellow solid). Yield: 82.1%. Purity: about 90%. LCMS: m/z 264.1 (M+H).


Intermediate 7: Synthesis of 4-bromo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine (**7**)



Into a dry 250 mL round bottom flask, Compound **6** (4.2 g, 23.86 mmol), Compound **5** (2.8 g, 28.83 mmol), sodium *t*-butoxide (4.6 g, 47.8 mmol) and DMSO (60 mL) were added at room


temperature. The mixture was purged with nitrogen gas three times, and stirred under reflux at 125°C for 24 h. After the reaction was completed as detected by LC/MS, the reaction was extracted with EA (50 mL×3), washed with saturated saline (30 mL), and then was dried and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (PE:EA = 3:7) to give Intermediate **7** (2.1g, light yellow solid). Yield: 40%. LCMS: m/z 253.0/255.0 (M+H).

**Intermediate 8: Synthesis of t-butyl
(4-bromopyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate (8)**




Into a dry 100 mL round bottom flask, Intermediate **7** (500 mg, 1.976 mmol), DMAP (67 mg, 0.593 mmol), DIPEA (766 mg, 5.928 mmol) and DMF (5 mL) were added at room temperature. After dissolution with stirring at room temperature, Boc₂O (1299 mg, 5.928 mmol) was slowly added, and reacted at room temperature for 3 h. After the reaction was completed, the reaction was extracted with EA. The combined organic phase washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate/petroleum ether = 15/85 to 70/30) to give Intermediate **8** (626 mg, light yellow solid). Yield: 88%. LCMS: m/z 352.9 (M+H).

**Intermediate 13: Synthesis of
1-(5-(2-bromopyrimidin-4-yl)-7-fluoroindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (13)**




Step 1. Synthesis of 1-(5-bromo-7-fluoroindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (10)



Into a dry 250 mL round bottom flask, N,N-dimethylformamide (10 mL), Intermediate **3** (1.7 g, 0.0079 mol), Compound **9** (1.23 g, 0.007 mol) and N,N-diisopropylethylamine (3.69 g, 0.028 mol) at room temperature. The mixture was purged with nitrogen gas three times, and was gradually warmed to 50°C. 1-Propylphosphonic anhydride (56 mL, 50% solution in ethyl acetate) was added and reacted for 0.5 h. After the reaction was completed as detected by TLC, the reaction was concentrated under reduced pressure. The resulting residue was poured into ice-water to precipitate. The solid was filtered to give Intermediate **10** (2.7 g, pale yellow solid). Yield: 93%. LCMS: m/z 368.8/370.8 (M+H).

Step 2. Synthesis of


2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**11**)



Into a dry 100 mL round bottom flask, Intermediate **10** (2 g, 0.0054 mol), bis(pinacolato)diboron (2.0 g, 0.0079 mol), potassium acetate (1.59 g, 0.016 mol) and 1,4-dioxane (36 mL) were added. The mixture was purged with nitrogen gas once, and was added with Pd(dppf)Cl₂ (442 mg, 0.0005 mol). The reaction was purged with nitrogen gas three times, heated to 90°C, and stirred for 4 h. After the reaction was completed as detected by LCMS, the reaction was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:3) to give Intermediate **11** (1.5 g, pale yellow solid). Yield: 68%. LCMS: m/z 417.1 (M+H).

Step 3. Synthesis of


1-(5-(2-bromopyrimidin-4-yl)-7-fluoroindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (**13**)




Into a dry 100 mL round bottom flask, Intermediate **11** (200 mg, 0.48 mmol), 2,4-dibromopyrimidine (126 mg, 0.53 mmol), potassium carbonate (200 mg, 1.44 mmol), (1,1-bis(diphenylphosphino)ferrocene)palladium (II) dichloride (70 mg, 0.096 mmol) and the

mixed solvent of 1,4-dioxane and water (4:1, 10.0 mL) were added at room temperature. The reaction was purged with nitrogen gas three times, warmed to 60°C, and stirred for 2 h. After the reaction was completed, the reaction was concentrated under reduced pressure, added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:1) to give the product **13** (140 mg, light yellow solid). Yield: 65.0%. LCMS: m/z 446.8 (M+H).

Intermediate 17: Synthesis of 4-chloro-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (17)




Step 1. Synthesis of 2-(1-methyl-1H-pyrazol-5-yl)amino-pyrimidin-4(3H)-one (16)



Into a dry 50 mL round bottom flask, Compound **14** (7.8 g, 80 mmol), Compound **15** (5.72 g, 40 mmol) and trimethylacetic acid (28.6 g) were added. The mixture was slowly heated to 150°C with stirring, and reacted for 40 h. After the reaction was completed as detected by LCMS, the reaction was reduced to room temperature, and added with 30 mL dichloromethane and 5 mL methanol to fully dissolve the reaction mixture, followed by the addition of silica gel. The purification by silica gel column chromatography with eluent system (dichloromethane:methanol = 3:2) gave Intermediate **16** (5 g, yellow solid). Yield: 65.8%. LCMS: m/z 191.9 (M+H).

Step 2. Synthesis of 4-chloro-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (17)




Into a dry 250 mL round bottom flask, Intermediate **16** (5 g, 26.1 mmol), phosphorus oxychloride (10 mL, 109.2 mmol) and acetonitrile (100.0 mL) were added at room temperature. The reaction was warmed to 100°C, and stirred for 2 h. After the reaction was completed, the reaction was concentrated under reduced pressure, quenched by addition of 100 mL water, and extracted with ethyl acetate (60 mL×3). The combined organic phase was washed with saturated brine (40 mL×2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under

reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 3:2) to give Intermediate **17** (2.9 g, pale yellow solid). Yield: 53.7%. LCMS: m/z 209.9 (M+H).


$^1\text{H-NMR}$ (CDCl_3 , 400 MHz): 8.27 (d, $J = 5.2\text{Hz}$, 1H), 7.53 (br, 1H), 7.48 (d, $J = 5.2\text{Hz}$, 1H), 6.80 (d, $J = 5.6\text{Hz}$, 1H), 6.28 (d, $J = 5.6\text{Hz}$, 1H), 3.77 (s, 3H).

Intermediate 23: Synthesis of

1-(7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (23)




Step 1. Synthesis of 1-(5-bromo-indolin-1-yl)ethan-1-one (19)




Into a dry 50 mL round bottom flask, Compound **18** (1500 mg, 7.57 mmol), DCM (20 mL), Et_3N (1915 mg, 18.93 mmol) and DMAP (30 mg) were added at room temperature, and acetyl chloride (1188 mg, 15.14 mmol) was added in portions at 0°C . After the addition, the reaction was stirred at room temperature for 3 h, and was poured into water at 0°C and stirred for 1 h. The reaction was extracted with DCM, dried and filtered. The filtrate was evaporated to dryness to give Intermediate **19** (1.75 g, yellow solid). Yield: 96.3%. LCMS: m/z 240.0/242.0 (M+H).

Step 2. 1-(5-bromo-7-chloro-indolin-1-yl)ethan-1-one (20)




Into a dry 50 mL round bottom flask, Intermediate **19** (1600 mg, 14.58 mmol), acetonitrile (30 mL) and NCS (979 mg, 7.33 mmol) were added at room temperature. After the addition, the reaction was then stirred at 70°C for 18 h, poured into water (20 mL), extracted with EA, dried, and filtered. The filtrate was evaporated to dryness. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate/petroleum ether = 1/50 to 1/10) to give Intermediate **20** (1.2 g, yellow liquid). Yield: 65.6%. LCMS: m/z 274.0/276.0 (M+H).

Step 3. Synthesis of 5-bromo-7-chloro-indoline (21)



Into a dry 50 mL single-necked flask, Intermediate **20** (1200 mg, 4.37 mmol), lithium hydroxide monohydrate (550 mg, 13.11 mmol), as well as methanol (15 mL) and water (8 mL) were added at room temperature. The mixture was heated to 70°C with stirring and reacted for 18 h. After the reaction was completed as detected by LCMS, the reaction was extracted with EA, washed, dried, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (EA/PE = 2%-10%) to give Intermediate **21** (700 mg, yellow solid). Yield: 68.9%. Purity: about 80%. LCMS: m/z 232.0 (M+H).


Step 4. Synthesis of 7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline (22)



Into a dry 50 mL single-necked flask, Intermediate **21** (600 mg, 2.581 mmol), bis(pinacolato)diboron (852 mg, 3.354 mmol), Pd(dppf)Cl₂ (188 mg, 0.2581 mmol), potassium acetate (329 mg, 3.354 mmol) and 1,4-dioxane (5 mL) were added at room temperature. The mixture was purged with nitrogen gas three times, heated to 100°C with stirring, and reacted for 3 h. After the reaction was completed as detected by LCMS, the reaction was filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (EA/PE = 2%-10%) to give Intermediate **22** (480 mg, yellow solid). Yield: 66.67%. Purity: about 80%. LCMS: m/z 280.1 (M+H).

Step 5. Synthesis of Intermediate

1-(7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (23)




Into a dry 25 mL single-necked flask, Intermediate **22** (440 mg, 1.574 mmol), Compound **9** (540 mg, 3.147 mmol), Et₃N (318 mg, 3.147 mmol), HATU (1193 mg, 3.147 mmol) and THF (8 mL) were added at room temperature, and stirred under nitrogen gas at 32°C for 18 h. After the reaction was completed as detected by LCMS, the reaction was extracted with EA, washed with


water, dried, and evaporated to dryness. The crude product was purified by silica gel column chromatography with eluent system (EA/PE 10-40%) to give Intermediate **23** (290 mg, yellow solid). Yield: 42.58%. LCMS: m/z 434.1 (M+H).

Intermediate 31: Synthesis of

2-(2-chloropyridin-3-yl)-1-(7-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (31)




Step 1. Synthesis of 7-methylindoline (28)



Into a dry 250 mL round bottom flask, Compound **27** 7-methyl-1H-indole (2.0g, 15.27 mmol), sodium cyanoborohydride (2.9 g, 45.81 mmol) and glacial acetic acid (40 mL) were added at 0°C. The reaction was warmed to room temperature, and stirred for 3 h. After the reaction was completed as detected by TLC plate, the reaction was concentrated under reduced pressure, added with 100 mL water, adjusted with 2 mol/L aqueous sodium hydroxide solution to pH 9, was extracted with ethyl acetate (100 mL×3). The combined organic phase washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified with flash column chromatography with eluent system (ethyl acetate : petroleum ether = 1:5) to give Intermediate **28** 7-methylindoline (1.5 g, off white solid). Yield: 75.3%. LCMS: m/z 134.1 (M+H).


Step 2. Synthesis of 5-bromo-7-methylindoline (29)



Into a dry 100 mL round bottom flask, Intermediate **28** 7-methylindoline (120 mg, 0.902 mmol), tetra-n-butylammonium tribromide (464 mg, 0.902 mmol) and dichloromethane (10.0 mL)


were added at room temperature. The reaction was stirred for 30 min. After the reaction was completed as detected by LCMS, the reaction was concentrated under reduced pressure, added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phase washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:5) to give Intermediate **29** 5-bromo-7-methylindoline (200 mg, light purple solid). Yield: 80.6%. LCMS: m/z 211.9 (M+H).

Step 3. Synthesis of 1-(5-bromo-7-methylindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (**30**)



Into a dry 100 mL round bottom flask, Intermediate **29** (80 mg, 0.38 mmol), Compound **9** 2-(2-chloropyridin-3-yl)acetic acid (67 mg, 0.38 mmol), N,N-diisopropylethylamine (0.25 mL, 1.52 mmol), T₃P (1.208g, 50% (wt%) solution in ethyl acetate (1.9 mmol)) and N,N-dimethylformamide (5.0 mL) were added. The reaction was stirred at room temperature for 30 min. After the reaction was completed, the reaction was added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phase washed with saturated brine (100 mL×6), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:5) to give Intermediate **30** 1-(5-bromo-7-methylindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (50 mg, off white solid). Yield: 36.3%. LCMS: m/z 364.8 (M+H).

Step 4. Synthesis of 2-(2-chloropyridin-3-yl)-1-(7-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**31**)




Into a dry 100 mL round bottom flask, Intermediate **30** 1-(5-bromo-7-methylindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (400 mg, 1.09 mmol), bis(pinacolato)diboron (1.38 g, 5.43 mmol), potassium acetate (233 mg, 3.27 mmol), (1,1-bis(diphenylphosphino)ferrocene)palladium (II) dichloride (70 mg, 0.11 mmol) and 1,4-dioxane (20.0 mL) were added at room temperature, purged with nitrogen gas five times,


warmed to 90°C, and stirred overnight. After the reaction was completed as detected by LCMS, the reaction was concentrated under reduced pressure, added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:10) to give Intermediate **31** 2-(2-chloropyridin-3-yl)-1-(7-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (200 mg, white solid). Yield: 44.0%. LCMS: *m/z* 413.0 (M+H).

Intermediate 53: Synthesis of

2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one




Step 1. Synthesis of ethyl 2-(3-fluoro-2-nitrophenyl)-3-oxobutanoate (47)



Into a dry 100 mL round bottom flask, ethyl acetoacetate (**46**) (6.1 g, 0.047 mol), potassium carbonate (8.7 g, 0.063 mol), 1,3-difluoro-2-nitrobenzene (5 g, 0.031 mol), N,N-dimethylformamide (20 mL) were sequentially added at room temperature, warmed to 50°C, and stirred for 2 h. After the reaction was completed as monitored by TLC, the reaction was diluted by addition of water (100 mL), and extracted with ethyl acetate (80 mL×3). The combined organic phase washed with saturated brine (300 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica


gel column chromatography (ethyl acetate : petroleum ether = 1:100) to give ethyl 2-(3-fluoro-2-nitrophenyl)-3-oxobutyrates **47** (2.8 g, pale yellow oil). Yield: 33%. ¹H NMR (CDCl₃, 300 MHz): 13.07 (s, 1H), 7.58-7.40 (m, 1H), 7.30-7.19 (m, 1H), 7.16-7.01 (m, 1H), 4.31-4.00 (m, 2H), 1.87 (s, 3H), 1.18 (t, *J* = 7.2 Hz, 3H).

Step 2. Synthesis of 1-(3-fluoro-2-nitrophenyl)propan-2-one (**48**)




Into a dry 100 mL round bottom flask, ethyl 2-(3-fluoro-2-nitrophenyl)-3-oxobutyrates (2.8 g, 0.01 mol), acetic acid (20 mL), 50% sulfuric acid (20 mL) were added at room temperature, warmed to 100 °C, and stirred for 4 h. After the reaction was completed as monitored by TLC, the reaction was diluted by addition of water (100 mL), and extracted with ethyl acetate (80 mL×3). The combined organic phase washed with saturated aqueous sodium bicarbonate solution (200 mL×2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. Purification by silica gel column chromatography (ethyl acetate : petroleum ether = 1:5) to give 1-(3-fluoro-2-nitrophenyl)propan-2-one **48** (1.86 g, pale yellow oil). Yield: 91%. ¹H NMR (DMSO-*d*₆, 300 MHz): 7.73-7.63 (m, 1H), 7.57-7.48 (m, 1H), 7.31 (d, *J* = 7.5 Hz, 1H), 4.13 (s, 3H), 2.51 (s, 2H).

Step 3. Synthesis of 7-fluoro-2-methyl-1H-indole (**49**)




Into a dry 100 mL round bottom flask, distilled water (32 mL) and sodium hydrosulfite (13.2 g, 0.076 mol) were sequentially added, and then the solution of 1-(3-fluoro-2-nitrophenyl)propan-2-one (1.5 g, 0.0076 mmol) in 1,4-dioxane (3.4 mL) was added dropwise. The reaction was stirred at room temperature for 2 h. After the reaction was completed as monitored by TLC, the reaction was diluted by addition of water (80 mL), and extracted with ethyl acetate (60 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. Purification by silica gel column chromatography (pure petroleum ether) gave 7-fluoro-2-methyl-1H-indole **49** (250 mg, white solid). Yield: 22%. ¹H NMR (DMSO-*d*₆, 300 MHz): 11.34 (s, 1H), 7.21 (d, *J* = 6.9 Hz, 1H), 6.93-6.72 (m, 2H), 6.19 (s, 1H), 2.39 (s, 3H).

Step 4. Synthesis of 7-fluoro-2-methylindoline (**50**)



Into a dry 100 mL round bottom flask in ice bath, 7-fluoro-2-methyl-1H-indole **49** (1.8 g, 12.08 mmol), acetic acid (20 mL), sodium cyanoborohydride (2.28 g, 36.19 mmol) were sequentially added. The reaction was warmed to room temperature, and stirred for 2 h. After the reaction was completed as monitored by TLC, the reaction was concentrated under reduced pressure. Ethyl acetate (100 mL) was added to the residue to dissolve it. The solution washed with saturated aqueous sodium bicarbonate solution (80 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate : petroleum ether = 1:70) to give 7-fluoro-2-methylindoline **50** (1.4 g, colorless oil). Yield: 77%. LCMS: *m/z* 152.1 (M+H).


Step 5. Synthesis of 5-bromo-7-fluoro-2-methylindoline (51)



Into a dry 100 mL round bottom flask in ice bath, 7-fluoro-2-methylindoline **50** (1.4 g, 9.27 mmol), acetonitrile (20 mL), N-bromosuccinimide (1.65 g, 9.27 mmol) were sequentially added. The reaction was gradually warmed to room temperature, and stirred for 2 h. After the reaction was completed as monitored by TLC, the reaction was concentrated under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate : petroleum ether = 1:70) to give the product 5-bromo-7-fluoro-2-methylindoline **51** (1.5 g, pale yellow oil). Yield: 71%. LCMS: *m/z* 229.9/231.9 (M+H).

Step 6. Synthesis of

1-(5-bromo-7-fluoro-2-methylindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (52)




Into a dry 100 mL round bottom flask, 5-bromo-7-fluoro-2-methylindoline **7** (1.0 g, 4.35 mmol), 2-(2-chloropyridin-3-yl)acetic acid (748 mg, 4.35 mmol), N,N-dimethylformamide (10 mL), N,N-diisopropylethylamine (2.24 g, 17.36 mmol) were sequentially added at room temperature, purged with nitrogen gas three times, warmed to 50°C, added with 1-propylphosphonic anhydride (26 mL, 50% solution in ethyl acetate), and stirred for 0.5 h. After the reaction was completed as monitored by TLC, the reaction was concentrated under reduced pressure. The residue was poured into ice-water. The solid precipitated and was filtered. The filter cake was dried to give

1-(5-bromo-7-fluoro-2-methylindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one **52** (1.5 g, pale brown solid). Yield: 90%. LCMS: m/z 382.8/384.8(M+H).

Step 7. Synthesis of


2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**53**)




Into a dry 100 mL round bottom flask, 1-(5-bromo-7-fluoro-2-methylindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (**52**) (500 mg, 1.3 mmol), bis(pinacolato)diboron (496 mg, 1.95 mmol), potassium acetate (383 mg, 3.9 mmol) and 1,4-dioxane (20 mL) were sequentially added at room temperature, purged with nitrogen gas once, added with [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride dichloromethane complex (10.6 mg, 0.013 mol), purged with nitrogen gas three times, heated to 90°C, and stirred for 3 h. After the reaction was completed as monitored by LCMS, the reaction was concentrated under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate : petroleum ether = 1:3) to give 2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one **53** (450 mg, colorless oil). Yield: 80%. LCMS: m/z 430.9 (M+H).

Intermediate 70: Synthesis of

2-(2-chloropyridin-3-yl)-1-(4,7-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**70**)




Step 1. Synthesis of 5-bromo-4,7-difluoro-1H-indole (**67**)



Vinylmagnesium bromide (45.6 mL, 45.6 mmol) was added into tetrahydrofuran (50 mL). The mixture was cooled to -78°C under nitrogen gas, and was dropwise added with Compound **66** (3.9 g, 15.2 mmol, dissolved in 50 mL tetrahydrofuran). After completion of the addition, the reaction was stirred for 2 h. After the reaction was completed, the reaction was slowly added with saturated aqueous ammonium chloride solution (20 mL), and was extracted with ethyl acetate (20 mL $\times$ 3). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:8) to give 5-bromo-4,7-difluoro-1H-indole **67** (1.47 g, light yellow oil). Yield: 38.7%.


^1H NMR (CD_3OD , 300 MHz): 7.29 (d, $J = 3.0$ Hz, 1H), 7.01-6.97(m, 1H), 6.60-6.54 (m, 1H).

Step 2. Synthesis of 5-bromo-4,7-difluoro-indoline (68)



Into a 50 mL round bottom flask in ice-water bath, Compound **67** (1.45 g, 6.28 mmol) and glacial acetic acid (20 mL) were sequentially added, and sodium cyanoborohydride (0.87 g, 12.6 mol) was added in portions over about 30 min. The reaction was stirred at room temperature for 16 h. After the reaction was completed, the reaction was cooled in ice-water bath, was slowly added with saturated aqueous sodium bicarbonate solution to adjust the pH to 6-7, and was extracted with ethyl acetate (10 mL $\times$ 3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:6) to give 5-bromo-4,7-difluoro-indoline **68** (0.43 g, light yellow oil). Yield: 30.0%. LCMS: m/z 234.0/236.0 (M+H).

Step 3. Synthesis of 1-(5-bromo-4,7-difluoro-indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (69)




Into a 100 mL flask, Compound **68** (0.43 mg, 0.185 mol), ethyl acetate (10 mL), Compound **9**

(0.35 g, 2.04 mmol), T₃P (50% solution in ethyl acetate, W/W, 2.83 g, 3.71 mmol), diisopropylethylamine (0.48 g, 3.71 mmol) were sequentially added at room temperature. The reaction was stirred at room temperature for 3 h. After the reaction was completed, the reaction was slowly added with saturated aqueous sodium bicarbonate solution to adjust the pH to 6-7, and was extracted with ethyl acetate (10 mL×4). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:3) to give 1-(5-bromo-4,7-difluoro-indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one **69** (0.56 g, light yellow oil). Yield: 78.2%. LCMS: *m/z* 386.9/388.9 (M+H).

Step 4. Synthesis of


2-(2-chloropyridin-3-yl)-1-(4,7-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**70**)




Compound **69** (0.27 g, 0.69 mmol), bis(pinacolato)diboron (0.23 g, 0.89 mol), potassium acetate (0.10 g, 1.02 mmol), (1,1'-bis(diphenyl phosphino)ferrocene)palladium (II) dichloride (0.028 g, 0.89 mmol) were sequentially added into 1,4-dioxane (10 mL) in a dry 100 mL round bottom flask. The reaction was purged with nitrogen gas three times, warmed to 90°C, and stirred for 16 h. After the reaction was completed, the reaction was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:3) to give the crude product 2-(2-chloropyridin-3-yl)-1-(4,7-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one **70** (0.18 g, light yellow solid). LCMS: *m/z* 434.7/436.8 (M+H).

Intermediate 77: Synthesis of

2-(2-chloropyridin-3-yl)-1-(6,7-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**77**)




Step 1. Synthesis of 4-bromo-2,3-difluoro-6-iodophenylamine (**72**)




Into a 100 mL round bottom flask, Compound **71** (0.85 g, 4.1 mmol), glacial acetic acid (15 mL), N-iodosuccinimide (0.97 g, 4.31 mmol) were sequentially added. After completion of the addition, the reaction was stirred at room temperature for 3 h. After the reaction was completed, the reaction was concentrated under reduced pressure. The resulting residue was added with saturated aqueous sodium bicarbonate solution to adjust the pH to 6-7, and extracted with ethyl acetate (20 mL×3). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1: 10) to give 4-bromo-2,3-difluoro-6-iodophenylamine **72** (1.30 g, light yellow solid). Yield: 95%. LCMS: m/z 333.9/335.8 (M+H).

Step 2. Synthesis of 4-bromo-2,3-difluoro-6-((trimethylsilyl)ethynyl)phenylamine (**73**)




Into a 100 mL round bottom flask, Compound **72** (1.30 g, 3.91 mmol), triethylamine (20 mL), cuprous iodide (37.2 mg, 0.20 mol), ethynyltrimethylsilane (460 mg, 4.69 mmol), bis(triphenylphosphine)palladium(II) dichloride (137 mg, 0.20 mmol) were sequentially added. The reaction was stirred at room temperature for 16 h. After the reaction was completed, the reaction was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:10) to give 4-bromo-2,3-difluoro-6-((trimethylsilyl)ethynyl)phenylamine **73** (1.02 g, pale yellow oil). Yield: 86.2%. ^1H NMR (DMSO- d_6 , 400 MHz): δ 7.32 (d, J = 7.2, 1H), 5.86 (s, 2H), 0.25 (s, 9H).

Step 3. Synthesis of 5-bromo-6,7-difluoro-1H-indole (74)




Into a 50 mL eggplant shape flask, Compound **73** (0.85 g, 2.80 mmol), N,N-dimethylformamide (2 mL), cuprous iodide (1.07 g, 5.61 mmol) were added. The reaction was heated to 100°C under nitrogen gas, and stirred for 4 h. After the reaction was completed, the reaction was cooled to room temperature, added with water (20 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:6) to give 5-bromo-6,7-difluoro-1H-indole **74** (560 mg, light yellow oil). Yield: 86%. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 12.46 (s, 1H), 7.74-7.70 (m, 1H), 7.51 (s, 1H), 3.36(d, *J* = 5.6 Hz, 1H).

Step 4. Synthesis of 5-bromo-6,7-difluoro-indoline (75)



Into a 50 mL round bottom flask in ice-water bath, Compound **74** (0.56 g, 2.42 mmol) and glacial acetic acid (10 mL) were sequentially added, and sodium cyanoborohydride (0.35 g, 4.85 mmol) was added in portions over about 30 min. The reaction was stirred at room temperature for 16 h. After the reaction was completed, the reaction was placed in ice-water bath, slowly added with saturated sodium bicarbonate solution to adjust the pH to 6-7, and then extracted with ethyl acetate (10 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:6) to give the crude product 5-bromo-6,7-difluoro-indoline **75** (0.23 g) as light yellow oil. LCMS: *m/z* 233.9/235.9 (M+H); RT = 1.470 min (2.5 min).


Step 5. Synthesis of 1-(5-bromo-6,7-difluoro-indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (76)



Into a 100 mL flask, Compound **75** (0.23 mg, 0.99 mmol), ethyl acetate (10 mL), Compound **9** (0.20 g, 1.18 mmol), T₃P (50% solution in ethyl acetate, W/W, 1.26 g, 1.98 mmol), diisopropylethylamine (0.38 g, 2.96 mmol) were sequentially added at room temperature. The reaction was stirred at room temperature for 3 h. After the reaction was completed, the reaction was slowly added with saturated aqueous sodium bicarbonate solution to adjust the pH to 6-7, and extracted with ethyl acetate (10 mL×4). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:3) to give 1-(5-bromo-6,7-difluoro-indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one **76** (0.10 g, light yellow oil). Yield: 26.2%. LCMS: *m/z* 386.9/388.9 (M+H); RT = 1.427 min (2.5 min).

Step 6. Synthesis of


2-(2-chloropyridin-3-yl)-1-(6,7-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**77**)




Compound **76** (0.10 g, 0.26 mmol), bis(pinacolato)diboron (0.079 g, 0.31 mmol), potassium acetate (0.038 g, 0.39 mmol), (1,1-bis(diphenylphosphino)ferrocene)palladium (II) dichloride (0.011 g, 0.013 mmol) were sequentially added into 1,4-dioxane (10 ml) in a dry 50 mL round bottom flask. The reaction was purged with nitrogen gas three times, warmed to 90°C, and stirred for 5 h. After the reaction was completed, the reaction was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:3) to give the crude product 2-(2-chloropyridin-3-yl)-1-(6,7-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one **77** (0.065 g, light yellow solid). LCMS: *m/z* 435.1/437.1 (M+H).

Intermediate 89: Synthesis of

2-(2-chloropyridin-3-yl)-1-(7-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (**89**)




Step 1. Synthesis of 7-fluoro-3-methyl-1H-indole (85)



Compound **84** (200.0 mg, 1.23 mmol) was added into tetrahydrofuran (15 mL). The mixture was purged with nitrogen gas three times, cooled to 0°C, and added with lithium aluminum hydride (140.0 mg, 3.69 mmol). After completion of the addition, the reaction was naturally warmed to room temperature, and stirred for 2 h. After the reaction was completed, the reaction was dropwise added with water (20 mL), and extracted with ethyl acetate (20 mL ×3). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:8) to give 7-fluoro-3-methyl-1H-indole **85** (130.0 mg, light yellow oil). Yield: 71.0%.


¹H NMR (DMSO-*d*₆, 400 MHz): δ 11.21 (s, 1H), 7.29 (d, *J* = 7.6 Hz, 1H), 7.17 (s, 1H), 6.97-6.87 (m, 2H).

Step 2. Synthesis of 7-fluoro-3-methyl-indoline (86)




Into a 50 mL round bottom flask in ice-water bath, Compound **85** (819.0 mg, 5.49 mmol) and glacial acetic acid (20 mL) were sequentially added, and added in portions with sodium cyanoborohydride (691.0 mg, 10.99 mol) over about 30 min. The reaction was warmed to room temperature, and stirred for 16 h. After the reaction was completed, the reaction was cooled in ice-water bath, slowly added with saturated sodium bicarbonate solution to adjust the pH to 6-7, and extracted with ethyl acetate (10 mL ×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:6) to give 7-fluoro-3-methyl-indoline **86** (49.0 mg, light yellow oil). LCMS: *m/z* 152.0 (M+H).

Step 3. Synthesis of 5-bromo-7-fluoro-3-methyl-indoline (87)




Into a 50 mL flask in ice-water bath, Compound **86** (49.0 mg, 0.324 mmol) and dichloromethane (5 mL) were added, and N-bromosuccinimide (63 mg, 0.356 mmol) was added in portions. The reaction was stirred at room temperature for 4 h. After the reaction was completed, the reaction was concentrated at room temperature under reduced pressure, slowly added with saturated aqueous sodium bicarbonate solution to adjust the pH to 6-7, and extracted with ethyl acetate (10 mL×4). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:5) to give 5-bromo-7-fluoro-3-methyl-indoline **87** (61.0 mg, light yellow solid). Yield: 82.0%. LCMS: m/z 229.8/231.8 (M+H).

Step 4. Synthesis of 1-(5-bromo-7-fluoro-3-methyl-indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (88)




Into a 50 mL flask, Compound **87** (61.0 mg, 0.266 mol), ethyl acetate (5 mL), T_3P (50% solution in ethyl acetate, W/W, 406.0 mg, 0.53 mmol), diisopropylethylamine (103.0 mg, 0.80 mmol) were sequentially added at room temperature. The reaction was stirred for 3 h. After the reaction was completed, the reaction was slowly added with saturated aqueous sodium bicarbonate solution to adjust the pH to 6-7, and was extracted with ethyl acetate (10 mL×4). The solvents were removed from the combined organic phase under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:3) to give 1-(5-bromo-7-fluoro-3-methyl-indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one **88** (79.0 mg, light yellow oil). Yield: 78.0%. LCMS: m/z 382.5/384.6 (M+H).

Step 5. Synthesis of 2-(2-chloropyridin-3-yl)-1-(7-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)ethan-1-one (89)




Compound **88** (45.0 mg, 0.12 mmol), bis(pinacolato)diboron (36.0 mg, 0.14 mmol), potassium acetate (17.3 mg, 0.18 mmol), (1,1-bis(diphenylphosphine)ferrocene)palladium (II) dichloride (4.8 mg, 0.0058 mmol) were sequentially added into 1,4-dioxane (10 ml) in a dry 50 mL round bottom flask. The reaction was purged with nitrogen gas three times, warmed to 90°C, and stirred for 3 h. After the reaction was completed, the reaction was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:3) to give 2-(2-chloropyridin-3-yl)-1-(7-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indol-1-yl)ethan-1-one **89** (36.0 mg, pale brown solid). Yield: 76.0%. LCMS: m/z 430.8/432.8 (M+H).

Intermediate 57: Synthesis of 2-(2-chloro-4-fluoropyridin-3-yl)acetic acid (57)




Step 1. Synthesis of ethyl 2-(2-chloro-4-fluoropyridin-3-yl)acetate (56)



Into a 50 mL round bottom flask, Compound **54** (1.0 g, 5.71 mmol), dichloromethane (25 mL), N,N-dimethylformamide (1 mL) were sequentially added at room temperature, and then the solution of oxalyl chloride (0.90 g, 7.14 mmol) in dichloromethane (10 mL) was added dropwise. After completion of the addition, the reaction was stirred at room temperature for 1 h, and was concentrated under reduced pressure. 15 mL anhydrous tetrahydrofuran was added into the residue. The mixture was added dropwise into the solution of Compound **55** (2M solution in n-hexane, 5.2 mL, 10.3 mmol) and triethylamine (1.04 g, 10.3 mmol) in acetonitrile and tetrahydrofuran (20 mL:20 mL) in ice-water bath. Next, the reaction was stirred at 0°C for 1 h, then placed into freezing compartment of refrigerator for 16 h, diluted by addition of ethyl acetate (100 mL), and washed with water. The organic phase was adjusted with 0.5 mmol/L hydrochloric acid to pH 4-5, stirred at room temperature for 5 min, then adjusted with 1 mol/L aqueous sodium hydroxide solution to pH 8-9, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was dissolved in 20 mL ethanol, added with triethylamine (692 mg, 6.85 mmol), added in portions with silver benzoate (197 mg, 0.86

mmol) at room temperature, stirred for 10 min, heated to 80°C, stirred for 10 min, and cooled to room temperature. After suction filtration, the filtrate was concentrated. The resulting residue was purified by column chromatography with eluent system (ethyl acetate : petroleum ether = 1:7) to give ethyl 2-(2-chloro-4-fluoropyridin-3-yl)acetate **56** (250 mg, colorless oil). Yield: 20.0%. LCMS: m/z 217.8/219.8 (M+H).

Step 2. Synthesis of 2-(2-chloro-4-fluoro-pyridin-3-yl)acetic acid (**57**)




At room temperature, Compound **56** (250 mg, 1.15 mmol) was dissolved in tetrahydrofuran (10 mL), and added with aqueous lithium hydroxide solution (10 mL, 0.5 mol/L). The reaction was stirred at room temperature for 1 h. After the reaction was completed as detected by LCMS, ethyl acetate (10 mL) was added. The aqueous phase was adjusted with 0.5 mol/L diluted hydrochloric acid to pH 3-4. After suction filtration, the filter cake washed with water, and dried to give 2-(2-chloro-4-fluoro-pyridin-3-yl)acetic acid **57** (220 mg, crude, light yellow oil). LCMS: m/z 189.9/191.9 (M+H).


Intermediates **65** and **83** were obtained analogously to the preparation of Intermediate **57** from the corresponding starting materials listed in the table below:

Intermediate No.	Starting material	Structure of the Intermediate	Analytical data
65			LCMS: m/z 152.1 (M+H)
83			LCMS: m/z 171.9 (M+H)

Intermediate 82: Synthesis of 3-(2-chloropyridin-3-yl)propionic acid (**82**)




Step 1. Synthesis of ethyl (E)-3-(2-chloropyridin-3-yl)acrylate (**80**)




Into a dry 100 mL round bottom flask in ice bath, Compound **79** (634 mg, 4.46 mmol), tetrahydrofuran (50 mL), sodium hydride (357 mg, 8.93 mmol) were added. The reaction was stirred in ice bath for 0.5 h, added with Compound **78** (1000 mg, 4.46 mmol), gradually warmed to room temperature, and stirred for 1 h. The reaction was carried out under monitoring by LCMS, quenched with saturated aqueous ammonium chloride solution, and extracted with ethyl acetate (50 mL×3). The organic phase was dried and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to give ethyl (E)-3-(2-chloropyridin-3-yl)acrylate **80** (300 mg, white solid). Yield: 20%. LCMS: m/z 212.0(M+H).

Step 2. Synthesis of ethyl 3-(2-chloropyridin-3-yl)propionate (**81**)



Into a dry 100 mL round bottom flask, Compound **80** (300 mg, 1.4 mmol), methanol (12 mL), water (3 mL), cuprous chloride (140 mg, 1.4 mmol), sodium borohydride (54 mg, 1.4 mmol) were added at room temperature. After the reaction was stirred at 0°C for 1 h, additional sodium borohydride (54 mg, 1.4 mmol) was added. The reaction was gradually warmed to room temperature and stirred for 1 h. The reaction was completed as monitored by LCMS. The reaction was quenched with ice-water, and extracted with ethyl acetate (50 mL×3). The organic phase was dried and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to give ethyl 3-(2-chloropyridin-3-yl)propionate **81** (260 mg, white solid). Yield: 86%. LCMS: m/z 214.0(M+H).

Step 3. Synthesis of 3-(2-chloropyridin-3-yl)propionic acid (**82**)




Into a dry 100 mL round bottom flask, Compound **81** (260 mg, 1.21 mmol), lithium hydroxide monohydrate (153 mg, 3.64 mmol), tetrahydrofuran (20 mL), methanol (4 mL), water (4 mL) were added at room temperature. The reaction was stirred for 2 h. After the reaction was completed as monitored by TLC, the reaction was concentrated and lyophilized to give 3-(2-chloropyridin-3-yl)propionic acid **82** (300mg, white solid), which was used directly in the next step without purification. LCMS: m/z 185.9(M+H).

Example:

Example P1:

Synthesis of Compound



2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-hydroxyprop-2-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one (P1)







Into a dry 100 mL round bottom flask, Intermediate **13** (100 mg, 0.22 mmol), DL-aminopropanol (84 mg, 1.10 mmol) and DMSO (0.5 mL) were added at room temperature. The reaction was warmed to 90°C and stirred for 1 h. After the reaction was completed, the reaction was concentrated under reduced pressure, added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate) to give the product **P1** (10 mg, white solid). Yield: 10.0%. LCMS: m/z 441.9 (M+H).

$^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.334 (s, 1H), 8.333 (d, $J = 10.4$ Hz, 1H), 7.91 (s, 1H), 7.76 (m, 3H), 7.84 (m, 1H), 7.83 (d, $J = 10.4$ Hz, 1H), 7.43 (dd, $J = 7.6$ Hz, 5.2 Hz, 1H), 7.14 (d, $J = 5.2$ Hz, 1H), 6.85 (d, $J = 8.0$ Hz, 1H), 4.71 (t, $J = 5.6$ Hz, 1H), 4.29 (t, $J = 8.0$ Hz, 2H), 4.08 (s, 2H), 3.50 (m, 1H), 3.31 (m, 2H), 3.23 (t, $J = 8.4$ Hz, 2H), 1.16 (d, $J = 6.4$ Hz, 2H).

Examples **P2-P7** were obtained analogously to the preparation of Example **P1** in accordance with the general scheme A as shown in Figure 1 from Intermediate **13** and the corresponding amines.

Ex.	Structure	Name	Analytical data
P2		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((2-hydroxyethyl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	$^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.34 (d, $J = 2.8$ Hz, 2H), 7.98 – 7.75 (m, 3H), 7.43 (dd, $J = 7.4$, 4.8 Hz, 1H), 7.16 (d, $J = 5.2$ Hz, 1H), 7.07 (t, $J = 5.6$ Hz, 1H), 4.70 (s, 0H), 4.29 (t, $J = 7.9$ Hz, 2H), 4.08 (s, 2H), 3.55 (s, 2H), 3.42 (s, 1H), 3.23 (t, $J = 7.9$ Hz, 2H). LCMS: m/z 427.9 (M+H).
P3		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((4-hydroxycyclohexyl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	$^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.36-8.31 (m, 2H), 7.92-7.87 (m, 2H), 7.81 (d, $J = 12.3$ Hz, 1H), 7.43 (dd, $J = 7.5$, 4.8 Hz, 1H), 7.12 (d, $J = 5.2$ Hz, 1H), 7.05 (d, $J = 8.0$ Hz, 1H), 4.56 (s, 1H), 4.29 (t, $J = 7.9$ Hz, 2H), 4.08 (s, 2H), 3.73 (s, 1H), 3.41 (s, 1H), 3.23 (t, $J = 7.9$ Hz, 2H), 1.95-1.81 (m, 4H), 1.35-1.20 (m, 4H). LCMS: m/z 481.6.


P4		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((3-hydroxycyclopentyl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H-NMR (DMSO- <i>d</i> ₆ , 400 MHz): δ 8.34 (d, <i>J</i> = 4.7 Hz, 2H), 7.93 – 7.79 (m, 3H), 7.43 (dd, <i>J</i> = 7.4, 4.7 Hz, 1H), 7.14 (t, <i>J</i> = 5.3 Hz, 3H), 4.44 (s, 1H), 4.28 (t, <i>J</i> = 7.8 Hz, 2H), 4.22 (s, 1H), 4.13 (s, 1H), 4.07 (s, 2H), 3.58 (s, 0H), 3.25 – 3.20 (m, 1H), 1.91 (s, 2H), 1.68 (s, 4H), 1.48 (d, <i>J</i> = 6.0 Hz, 2H). LCMS: <i>m/z</i> 467.9 (M+H).
P5		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.33 (br, 2H), 7.77-7.68 (m, 3H), 7.24 (s, 1H), 6.94 (d, <i>J</i> = 4.76 Hz, 1H), 4.33 (t, <i>J</i> = 7.8 Hz, 2H), 4.15 (br, 1H), 4.07-3.95 (m, 4H), 3.61 (t, <i>J</i> = 11.0 Hz, 2H), 3.20 (t, <i>J</i> = 7.8 Hz, 2H), 2.13-2.04 (m, 2H), 1.67-1.57 (m, 2H). LCMS: <i>m/z</i> 454.0 (M+H).
P6		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.33 (br, 2H), 7.79-7.68 (m, 3H), 7.24 (s, 1H), 6.97 (d, <i>J</i> = 4.68 Hz, 1H), 4.69 (br, 1H), 4.34 (t, <i>J</i> = 7.72 Hz, 2H), 4.08-4.02 (m, 2H), 3.99 (s, 2H), 3.94-3.86 (m, 1H), 3.79 (dd, <i>J</i> = 3.0 Hz, 9.1 Hz, 1H), 3.20 (t, <i>J</i> = 7.70 Hz, 2H), 2.43-2.32 (m, 1H), 2.00-1.91 (m, 1H). LCMS: <i>m/z</i> 454.0 (M+H).
P7		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((4-hydroxybutan-2-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H-NMR (DMSO- <i>d</i> ₆ , 400 MHz): δ 8.36-8.30 (m, 2H), 7.93-7.86 (m, 2H), 7.84 (d, <i>J</i> = 12.7 Hz, 1H), 7.45 (dd, <i>J</i> = 7.5 Hz, 4.8 Hz, 1H), 7.12 (d, <i>J</i> = 5.1 Hz, 1H), 7.02 (d, <i>J</i> = 8.1 Hz, 1H), 4.42 (br, 1H), 4.30 (t, <i>J</i> = 7.92 Hz, 2H), 4.16 (br, 1H), 4.07 (s, 2H), 3.53-3.49 (m, 2H), 3.24 (t, <i>J</i> = 7.84 Hz, 2H), 1.79-1.68 (m, 1H), 1.68-1.57 (m, 1H), 1.17 (d, <i>J</i> = 6.3 Hz, 3H). LCMS: <i>m/z</i> 456.0 (M+H).

Example P8:


Synthesis of

2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-hydroxyprop-2-yl)amino)pyrimidin-4-yl)indolin-1-

yl)ethan-1-one (P8)




Step 1. Synthesis of 2-((4-bromopyridin-2-yl)amino)propan-1-ol (**24**)



Into a dry 20 mL microwave vial, dimethyl sulfoxide (8 mL), Compound 4-bromo-2-fluoropyridine (1 g, 0.0057mol), Compound 2-aminopropanol (0.65g, 0.0085mol) and N,N-diisopropylethylamine (1.1 g, 0.0085mol) were added. The reaction was warmed to 140°C, and stirred for 0.5 h. After the reaction was completed as monitored by LCMS, the reaction was poured into water (10 mL), and extracted with ethyl acetate (10 mL×3). The combined organic phase was washed with saturated brine (10 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography with eluent system (ethyl acetate : petroleum ether = 1:1) to give Compound **24** 2-((4-bromopyridin-2-yl)amino)propan-1-ol (0.8g, yellow solid). Yield: 61%. LCMS: *m/z* 230.8/232.8 (M+H).

Step 2. Synthesis of 2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-hydroxyprop-2-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one (**P8**)










Into a dry 100 mL round bottom flask, Intermediate **24** (0.05 g, 0.00021mol), K₂CO₃ (0.058 g, 0.00042 mol), Intermediate **11** (0.108 g, 0.00026 mol), Pd(dppf)Cl₂ (15 mg, 0.000021 mol), 1,4-dioxane (20 mL) and distilled water (2 mL) were added at room temperature. The mixture was purged with nitrogen gas three times, warmed to 80°C and stirred for 5 h under nitrogen gas. After the reaction was completed, the reaction was concentrated under reduced pressure. The crude product was purified by thin-layer chromatography (ethyl acetate) to give Compound **P8** (0.04 g, white solid). Yield: 43%. LCMS: *m/z* 440.7 (M+H).




¹H-NMR (DMSO-*d*₆, 400 MHz): δ 8.34 (d, *J* = 3.6 Hz, 1H), 7.98 (d, *J* = 5.8 Hz, 1H), 7.89 (d, *J* = 6.8 Hz, 1H), 7.51 (s, 1H), 7.45 - 7.40 (m, 2H), 6.96 (br s, 1H), 6.88 (br s, 1H), 4.91 (br s, 1H), 4.28 (t, *J* = 7.8 Hz, 2H), 4.08 (s, 2H), 4.05-3.96 (m, 1H), 3.52-3.44 (m, 1H), 3.37 (s, 1H), 3.22 (t, *J* = 7.8




Hz, 2H), 1.15 (d, $J = 6.5$ Hz, 3H).





Examples **P10-P16**, **P32**, **P34**, **P36**, **P44**, **P47-51**, **P53** and **P58-59** were obtained analogously to the preparation of Example **P8** in accordance with the general scheme B as shown in Figure 2 from Intermediate **11**, **53** or a borate intermediate analogous to Intermediate **11**.

Ex.	Structure	Name	Analytical data
P10		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-ylethan-1-one	$^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 9.43 (s, 1H), 8.47 (d, $J = 5.2$ Hz, 1H), 8.31 (dd, $J = 4.8, 1.8$ Hz, 1H), 7.89 (s, 1H), 7.87 – 7.71 (m, 2H), 7.46 – 7.36 (m, 2H), 7.34 (d, $J = 1.8$ Hz, 1H), 6.24 (d, $J = 1.7$ Hz, 1H), 4.26 (t, $J = 7.9$ Hz, 2H), 4.04 (s, 2H), 3.66 (s, 3H), 3.20 (t, $J = 7.8$ Hz, 2H). LCMS: m/z 464.1(M+H).
P11		1-(7-chloro-5-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one	$^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 9.44 (s, 1H), 8.47 (d, $J = 5.2$ Hz, 1H), 8.31 (dd, $J = 4.6, 1.5$ Hz, 1H), 8.00 (d, $J = 2.3$ Hz, 2H), 7.88 – 7.80 (m, 1H), 7.50 – 7.37 (m, 2H), 7.33 (d, $J = 1.5$ Hz, 1H), 6.23 (d, $J = 1.3$ Hz, 1H), 4.26 (t, $J = 7.6$ Hz, 2H), 4.07 (s, 2H), 3.66 (s, 3H), 3.17 (t, $J = 7.5$ Hz, 2H). LCMS: m/z 482.0 (M+H).
P12		2-(2,4-difluorophenyl)-1-(7-fluoro-5-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-ylethan-1-one	$^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ 9.44 (s, 1H), 8.47 (d, $J = 5.2$ Hz, 1H), 8.31 (dd, $J = 4.6, 1.5$ Hz, 1H), 8.00 (d, $J = 2.3$ Hz, 2H), 7.88 – 7.80 (m, 1H), 7.50 – 7.37 (m, 2H), 7.33 (d, $J = 1.5$ Hz, 1H), 6.23 (d, $J = 1.3$ Hz, 1H), 4.26 (t, $J = 7.6$ Hz, 2H), 4.07 (s, 2H), 3.66 (s, 3H), 3.17 (t, $J = 7.5$ Hz, 2H). LCMS: m/z 482.0 (M+H).

P13	 P13	2-(2-chloropyridin-3-yl)-1-(7-methyl-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H NMR (DMSO- <i>d</i> ₆ , 400 MHz): δ 9.41 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 8.35 (d, <i>J</i> = 4.5 Hz, 1H), 7.94 – 7.75 (m, 3H), 7.51 – 7.32 (m, 3H), 6.28 (s, 1H), 4.25 (t, <i>J</i> = 7.7 Hz, 2H), 4.11 (s, 3H), 3.70 (s, 3H), 3.15 (s, 2H), 2.20 (s, 3H). LCMS: <i>m/z</i> 460.2 (M+H).
P14	 P14	1-(7-chloro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one	¹ H NMR (600 MHz, DMSO- <i>d</i> ₆) δ 8.83 (s, 1H), 8.35 (d, <i>J</i> = 4.5 Hz, 1H), 8.16 (d, <i>J</i> = 5.1 Hz, 1H), 7.88 (d, <i>J</i> = 7.4 Hz, 1H), 7.62 (s, 1H), 7.55 (s, 1H), 7.48 – 7.41 (m, 1H), 7.34 (s, 1H), 7.09 (d, <i>J</i> = 5.2 Hz, 1H), 7.02 (s, 1H), 6.28 (s, 1H), 4.28 (t, <i>J</i> = 7.3 Hz, 2H), 4.11 (s, 2H), 3.68 (s, 3H), 3.20 (t, <i>J</i> = 7.3 Hz, 2H). LCMS: <i>m/z</i> 479.1 (M+H).
P15		2-(2-chloro-5-fluoropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H-NMR (CD ₃ OD, 400 MHz) δ 8.47 (d, <i>J</i> = 5.2, 1H), 8.28 (d, <i>J</i> = 2.8 Hz, 1H), 7.93 (s, 1H), 7.86 (d, <i>J</i> = 12.8 Hz, 1H), 7.77 (dd, <i>J</i> = 8.4 Hz, 2.8 Hz, 1H), 7.49 (s, 1H), 7.39 (d, <i>J</i> = 5.2 Hz, 1H), 6.36 (s, 1H), 4.37 (t, <i>J</i> = 8.0 Hz, 2H), 4.15 (s, 2H), 3.78 (s, 3H), 3.28 (t, <i>J</i> = 7.6 Hz, 2H). LCMS: <i>m/z</i> 481.9/483.9 (M+H).
P16	 (racemate)	2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-methyl-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one	¹ H-NMR (DMSO- <i>d</i> ₆ , 400 MHz) δ 8.85 (s, 1H), 8.35 (d, <i>J</i> = 4.0 Hz, 1H), 8.17 (d, <i>J</i> = 5.2 Hz, 1H), 7.90 (d, <i>J</i> = 7.2 Hz, 1H), 7.53 (s, 1H), 7.48-7.41 (m, 2H), 7.36 (s, 1H), 7.10 (d, <i>J</i> = 5.2 Hz, 1H), 7.02 (s, 1H), 6.28 (s, 1H), 4.97-4.89 (m, 1H), 4.19 (d, <i>J</i> = 16.8 Hz, 1H), 3.98 (d, <i>J</i> = 17.2 Hz, 1H), 3.69 (s, 3H), 3.55 (dd, <i>J</i> = 9.2 Hz, 16.8 Hz, 1H), 2.73 (d, <i>J</i> = 16.4 Hz, 1H), 1.28 (d, <i>J</i> = 6.0 Hz, 3H). LCMS: <i>m/z</i> 476.9 (M+H)

P32		2-((2-chloropyridin-3-yl)-1-(7-fluoro-2-methyl-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (DMSO, 400 MHz): 9.46 (s, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.35 (d, J = 4.4 Hz, 1H), 7.96 (s, 1H), 7.93-7.83 (m, 2H), 7.49-7.35 (m, 3H), 6.28 (s, 1H), 4.99-4.90 (m, 1H), 4.20 (d, J = 16.4 Hz, 1H), 3.98 (d, J = 16.8 Hz, 1H), 3.70 (s, 3H), 3.57 (dd, J = 8.8 Hz, 16.8 Hz, 1H), 2.74 (d, J = 16.4 Hz, 1H), 1.29 (d, J = 6.4 Hz, 3H). LCMS: m/z 478.0 (M+H).
P34		2-((5-chloro-2-fluorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (CD₃OD, 400 MHz): 8.46 (d, J = 5.2, 1H), 7.90 (s, 1H), 7.84 (d, J = 13.2, 1H), 7.48 (d, J = 2.4 Hz, 1H), 7.39 (dd, J = 10.4 Hz, 6.4 Hz, 1H), 7.38 (d, J = 5.6 Hz, 1H), 7.33 (m, 1H), 6.36 (d, J = 2.0 Hz, 1H), 4.33 (t, J = 8.0 Hz, 2H), 4.02 (s, 2H), 3.78 (s, 3H), 3.27 (t, J = 8.0 Hz, 2H). LCMS: m/z 480.5/482.6 (M+H).
P36		2-((2-chloro-4-fluorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (CD₃OD, 400 MHz): 8.47 (d, J = 5.2, 1H), 7.91 (s, 1H), 7.86 (d, J = 12.4 Hz, 1H), 7.48 (s, 1H), 7.44 (t, J = 8.4 Hz, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.27 (dd, J = 11.2 Hz, 2.8 Hz, 1H), 7.10 (t, J = 5.6 Hz, 1H), 6.35 (s, 1H), 4.34 (t, J = 8 Hz, 2H), 4.08 (s, 2H), 3.78 (s, 3H), 3.26 (t, J = 8 Hz, 2H). LCMS: m/z 480.8/482.8 (M+H).


P53	 (racemate)	2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((3-hydroxycyclobutyl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (CD₃OD, 400 MHz): 8.34 (d, <i>J</i> = 4.4 Hz, 1H), 7.97(d, <i>J</i> = 6 Hz, 1H), 7.90 (d, <i>J</i> = 7.6 Hz, 1H), 7.52 (s, 1H), 7.44-7.39 (m, 2H), 6.96-6.93(m, 1H), 6.82 (s, 1H), 4.50-4.49 (m, 0.5 H), 4.37 (t, <i>J</i> = 8 Hz, 2H), 4.33-4.27 (m, 0.5 H), 4.14 (s, 2H), 4.09-4.05 (m, 1H), 3.84-3.79 (m, 1H), 3.29 (t, <i>J</i> = 8 Hz, 2H), 2.88-2.87 (m, 2H), 2.42-2.34 (m, 2H), 1.89-1.87 (m, 2H). LCMS: m/z 452.8/454.9 (M+H).
P44		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(6-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (DMSO-<i>d</i>₆, 300 MHz): 9.51 (s, 1H), 8.65 (s, 1H), 8.34 (s, 1H), 7.87(d, <i>J</i> = 6.6 Hz, 1H), 7.80 (s, 1H), 7.73(d, <i>J</i> = 12.3 Hz, 1H), 7.41(s, 2H), 7.14(s, 1H), 6.33(s, 1H), 4.28(t, <i>J</i> = 7.2 Hz, 2H), 4.07(s, 2H), 3.68(s, 3H), 3.23(t, <i>J</i> = 7.2 Hz, 2H) LCMS: m/z 463.8/465.9 (M+H).
P47		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (DMSO-<i>d</i>₆, 400 MHz): 9.36 (s, 1H), 8.39 (s, 1H), 8.35 (d, <i>J</i> = 4.4 Hz, 1H), 7.89 (d, <i>J</i> = 7.6 Hz, 1H), 7.46-7.37 (m, 3H), 7.32 (s, 1H), 6.24 (s, 1H), 4.29 (t, <i>J</i> = 7.6 Hz, 2H), 4.09 (s, 2H), 3.68 (s, 3H), 3.22 (t, <i>J</i> = 8.4 Hz, 2H), 2.25(s, 3H). LCMS: m/z 478.0/480.0 (M+H)

P48		2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-methyl-5-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (DMSO-<i>d</i>₆, 400 MHz): 9.34 (s, 1H), 8.39 (s, 1H), 8.35 (d, <i>J</i> = 4.8 Hz, 1H), 7.90 (d, <i>J</i> = 7.2 Hz, 1H), 7.49 (s, 1H), 7.44-7.39 (m, 2H), 7.33 (s, 1H), 6.25 (s, 1H), 4.94 (t, <i>J</i> = 7.2 Hz, 1H), 4.20 (d, <i>J</i> = 16.8 Hz, 1H), 3.98 (d, <i>J</i> = 16.8 Hz, 1H), 3.69 (s, 3H), 3.59-3.53 (m, 1H), 2.71 (d, <i>J</i> = 16.4 Hz, 1H), 2.26 (s, 3H), 1.29 (d, <i>J</i> = 6.0 Hz, 3H). LCMS: <i>m/z</i> 492.1/494.1 (M+H).
P49		2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-(methoxymethyl)-5-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (DMSO-<i>d</i>₆, 400 MHz): 9.34 (s, 1H), 8.39 (s, 1H), 8.35 (d, <i>J</i> = 4.4 Hz, 1H), 7.87 (d, <i>J</i> = 7.2 Hz, 1H), 7.46-7.40 (m, 3H), 7.33 (s, 1H), 6.24 (s, 1H), 5.01 (m, 1H), 4.20 (t, <i>J</i> = 16.8 Hz, 2H), 3.69 (s, 3H), 3.54-3.48 (m, 1H), 3.35 (d, <i>J</i> = 6.0 Hz, 2H), 3.31 (s, 3H), 2.86 (d, <i>J</i> = 16.0 Hz, 1H), 2.25 (s, 3H). LCMS: <i>m/z</i> 522.1/524.1 (M+H).
P50		2-(2-chloropyridin-3-yl)-1-(4,7-difluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (CD₃OD, 400 MHz): δ 8.49 (d, <i>J</i> = 5.6 Hz, 1H), 8.33 (d, <i>J</i> = 4.8 Hz, 1H), 7.89-7.83 (m, 2H), 7.46-7.38 (m, 3H), 7.35 (s, 1H), 4.43 (t, <i>J</i> = 8.0 Hz, 2H), 4.14 (s, 2H), 3.78 (s, 3H), 3.29 (t, <i>J</i> = 8.0, 2H). LCMS: <i>m/z</i> 482.0/484.0 (M+H).
P51		2-(2-chloropyridin-3-yl)-1-(6,7-difluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (CD₃OD, 400 MHz): δ 8.52 (s, 1H), 8.35 (s, 1H), 7.90 (d, <i>J</i> = 8.0 Hz, 1H), 7.81 (s, 1H), 7.54 (s, 1H), 7.45 (s, 1H), 7.35 (s, 1H), 6.44 (s, 1H), 4.40 (t, <i>J</i> = 8.0 Hz, 2H), 4.17 (s, 2H), 3.81 (s, 3H), 3.26 (t, <i>J</i> = 8.0 Hz, 2H). LCMS: <i>m/z</i> 481.6/483.6 (M+H).

P58		2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-(methoxymethyl)-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one	¹ H NMR (400 MHz, CDCl ₃) δ 8.35(d, <i>J</i> = 4.0 Hz, 1H), 8.20 (s, 1H), 7.75 (d, <i>J</i> = 7.4 Hz, 1H), 7.56 (s, 1H), 7.27 – 7.20 (m, 4H), 7.03 (d, <i>J</i> = 5.3 Hz, 1H), 6.72 (s, 1H), 6.24 (s, 1H), 5.05 (d, <i>J</i> = 7.6 Hz, 1H), 4.05 (s, 2H), 3.84 (s, 3H), 3.58 – 3.51 (m, 1H), 3.47-3.41 (m, 2H), 3.37 (s, 3H), 2.93 (d, <i>J</i> = 16.3 Hz, 1H). LCMS: <i>m/z</i> 507.1/509.1 (M+H).
P59		2-(2-chloropyridin-3-yl)-1-(7-fluoro-3-methyl-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one	¹ H NMR (CD ₃ OD, 400 MHz): δ 8.33 (d, <i>J</i> = 3.6 Hz, 1H), 8.14 (d, <i>J</i> = 5.6 Hz, 1H), 7.88 (d, <i>J</i> = 6.4 Hz, 1H), 7.48 (s, 2H), 7.44-7.39 (m, 2H), 7.11 (d, <i>J</i> = 5.6 Hz, 1H), 6.99 (s, 1H), 6.28 (s, 1H), 4.53 (t, <i>J</i> = 8.4 Hz, 1H), 4.14 (s, 2H), 3.91-3.87 (m, 1H), 3.76 (s, 3H), 3.61-3.59 (m, 1H), 1.42 (d, <i>J</i> = 6.8 Hz, 3H). LCMS: <i>m/z</i> 477.0/479.0 (M+H).


Example P9:

Synthesis of 2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one (P9)



Step 1. Synthesis of t-butyl

(4-(7-fluoroindolin-5-yl)pyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate (25)



Method I: Into a dry 50 mL round bottom flask, Intermediate **4** (600 mg, 2.279 mmol),


1,4-dioxane (4 mL) and water (0.8 mL), Intermediate **8** (563 mg, 1.595 mmol), Pd(dppf)Cl₂ (167 mg, 0.2279 mmol) and sodium bicarbonate (383 mg, 4.56 mmol) were added at room temperature. The mixture was purged with nitrogen gas three times, warmed to 75°C, and stirred for 2 h. After the reaction was completed, the reaction was filtered hot. The filtrate was evaporated under reduced pressure to give the crude product, which was purified by silica gel column chromatography with eluent system (ethyl acetate/petroleum ether = 1/5 to 3/1) to give Intermediate **25** t-butyl (4-(7-fluoroindolin-5-yl)pyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate (620 mg, solid). Yield: 60.45%. ¹H NMR (400 MHz, DMSO) δ 8.27 (d, *J* = 5.2 Hz, 1H), 7.85 (d, *J* = 1.2 Hz, 1H), 7.49 (dd, *J* = 5.2, 1.6 Hz, 1H), 7.43 (s, 1H), 7.41 – 7.36 (m, 2H), 6.18 (d, *J* = 2.0 Hz, 1H), 6.14 (s, 1H), 3.70 (s, 3H), 3.57 (t, *J* = 8.8 Hz, 2H), 3.08 (t, *J* = 8.8 Hz, 2H), 1.41 (s, 9H). LCMS: *m/z* 410.2 (M+H).

Method II: At room temperature, into a dry 250 mL round bottom flask, Intermediate **8** (0.984 g, 2.80 mmol), Intermediate **4** (0.88 g, 2.90 mol), triethylamine (1.19g, 12 mmol), 1,4-dioxane (15 mL), distilled water (3 mL) were sequentially added, and then Pd(dppf)Cl₂ (240 mg, 0.3 mol) was added. The reaction was purged with nitrogen gas three times, warmed to 70°C, and stirred for 16 h. After the reaction was completed as monitored by LCMS, the reaction was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate: petroleum ether = 1:3 ~ 1:5) to give Intermediate **25** t-butyl (4-(7-fluoroindolin-5-yl)pyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate (1.0 g, solid). Yield 88%. LCMS: *m/z* 410.1 (M+H).

Method III: In to a round bottom flask (50 mL), Intermediate **8** (1.80 g), Intermediate **4** (2.15 g), methyltetrahydrofuran (15 mL), triethylamine (2.06 g), pure water (3.6 g) and Pd(dppf)Cl₂ (1.25g) were sequentially added. The mixture was purged with nitrogen gas three times, and reacted for about 15 h, maintaining the temperature at 65~75°C. After the reaction was completed as detected by HPLC, the reaction was concentrated under reduced pressure. The residue was added with MTBE and tap water to dissolve with stirring. The solution was filtered with suction on diatomite. The filter cake washed. The combined filtrate stratified. The organic layer was washed with tap water twice. The combined organic layer was concentrated under reduced pressure. The residue was added dropwise with n-heptane, and stirred at reduced temperature. After suction filtration under reduced pressure, the filter cake was washed with methyl t-butyl ester, and oven-dried under reduced pressure to give Intermediate **25** t-butyl (4-(7-fluoroindolin-5-yl)pyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate 1.72 g. LCMS: *m/z* 410.1 (M+H).

Step 2: Synthesis of t-butyl


(4-(1-(2-(2-chloropyridin-3-yl)acetyl)-7-fluoroindolin-5-yl)pyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate (26)



Method I: Into a dry 25 mL round bottom flask, Compound **9** 2-chloropyridin-3-acetic acid (493 mg, 2.876 mmol), Ac₂O (285 mg, 2.80 mmol) and THF (3 mL) were added at room temperature. The reaction was carried out at 75°C for 1 h, and added with additional Intermediate **25** (620 mg, 1.514 mmol), THF (2 mL), DMF (1 mL) and pyridine (240 mg, 3.028 mmol). The reaction was purged with nitrogen gas three times, warmed to 70°C, and stirred for 3 h. After the reaction was completed, the reaction was added with methanol (2 mL), and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate/petroleum ether = 1/4 to DCM:MeOH = 30/1) to give Intermediate **26** (400 mg, light yellow solid). Yield: 46.9%. LCMS: *m/z* 564.2(M+H).

Method II: Into a 1000 mL round bottom flask, Compound **25** (1.682 g, 4.1 mmol), diisopropylethylamine (2.121 g, 16.4 mmol), Compound **9** (0.843 g, 4.9 mol), ethyl acetate (20 mL), 1-propylphosphonic anhydride (50% solution in ethyl acetate, 6.54 g, 10 mmol) were sequentially added at room temperature. After completion of the addition, the reaction was stirred at room temperature for 5 h. After the reaction was completed as monitored by LCMS, the reaction was neutralized to pH 7-8 by addition of saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate (50 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered with suction. The filtrate was concentrated under reduced pressure to give t-butyl (4-(1-(2-(2-chloropyridin-3-yl)acetyl)-7-fluoroindolin-5-yl)pyridin-2-yl) (1-methyl-1H-pyrazol-5-yl)carbamate (**26**) (2.033 g, pale yellow oil, crude product). LCMS: *m/z* 562.5/564.5(M+H).

Step 3. Synthesis of 2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one (P9)





Method I: Into a dry 25 mL single-necked flask, Intermediate **26** (350 mg, 0.622 mmol), TFA (709 mg, 6.22 mmol), acetonitrile (5 mL) and H₂O (0.5 mL) were added at room temperature. The reaction was stirred at 40°C under nitrogen gas for 8 h. After the reaction was completed as detected by LCMS, the crude product was purified by preparative liquid chromatography to give the product **P9** 2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1


-yl)ethan-1-one (135 mg, yellow solid). Yield: 46.9%. LCMS: m/z 463.1(M+H).

$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 8.82 (s, 1H), 8.35 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.17 (d, $J = 5.6$ Hz, 1H), 7.88 (dd, $J = 7.2, 1.2$ Hz, 1H), 7.50 (s, 1H), 7.45 – 7.41 (m, 2H), 7.34 (d, $J = 1.2$ Hz, 1H), 7.10 (d, $J = 5.2$ Hz, 1H), 7.02 (s, 1H), 6.28 (d, $J = 1.2$ Hz, 1H), 4.28 (t, $J = 8.0$ Hz, 2H), 4.08 (s, 2H), 3.69 (s, 3H), 3.21 (t, $J = 8.0$ Hz, 2H)..

Method II: Into a dry 50 mL round bottom flask, dichloromethane (15 mL) and Intermediate **26** (2.033 g, 3.6 mmol) were sequentially added, and then trifluoroacetic acid (4 mL) was slowly added. The reaction was stirred at room temperature overnight. After the reaction was completed as monitored by LCMS, saturated aqueous sodium carbonate solution was added dropwise to adjust the pH to 7-8. The reaction stratified, and was extracted with dichloromethane (50 mL $\times$ 3). The combined organic phase was concentrated under reduced pressure. The resulting suspension was added with water (20 mL) under stirring, and stirred in ice bath for 1-2 h. After suction filtration, the filter cake washed with water (10 mL) once, and oven-dried under reduced pressure to give **P9** (2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one) 1.63g. LCMS: m/z 463.1(M+H).


Examples **P45-46** and **P61** were obtained analogously to the preparation of Example **P9** in accordance with the general scheme C as shown in Figure 3 using Intermediate **25** or similar intermediates.

Ex.	Structure	Name	Analytical data
P45		1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-(2-methylpyridin-3-yl)ethan-1-one	$^1\text{H NMR}$ ($\text{DMSO-}d_6$, 400 MHz): δ 8.81 (s, 1H), 8.38 (d, $J = 4.8$ Hz, 1H), 8.17 – 8.12 (m, 2H), 7.67 (s, 1H), 7.48 (s, 1H), 7.41 (d, $J = 12.2$ Hz, 1H), 7.34 (d, $J = 2.0$ Hz, 1H), 7.26 (s, 1H), 7.09 (dd, $J = 5.4, 1.5$ Hz, 1H), 7.01 (s, 1H), 6.27 (d, $J = 1.8$ Hz, 1H), 4.26 (t, $J = 8.0$ Hz, 2H), 4.01 (s, 2H), 3.68 (s, 3H), 3.22 (t, $J = 7.8$ Hz, 2H), 2.44 (s, 3H). LCMS: m/z 443.0 (M+H).
P46		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-deuteriomethyl)-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one	$^1\text{H-NMR}$ ($\text{DMSO-}d_6$, 400 MHz): δ 8.83 (s, 1H), 8.35 (d, $J = 4.8$ Hz, 1H), 8.17 (d, $J = 5.2$ Hz, 1H), 7.88 (d, $J = 7.2$ Hz, 1H), 7.51 (s, 1H), 7.46–7.43 (m, 2H), 7.35 (s, 1H), 7.10 (d, $J = 5.6$ Hz, 1H), 7.02 (s, 1H), 6.28 (s, 1H), 4.29 (t, $J = 8.0$ Hz, 2H), 4.08 (s, 2H), 3.23 (t, $J = 7.6$ Hz, 2H). LCMS: m/z 466.0/468.0 (M+H).

P61		2-(2-chloropyridin-3-yl)-1-(5-(2-(cyclopropylamino)pyridin-4-yl)-7-fluoroindolin-1-yl)ethan-1-one	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.34 (d, <i>J</i> = 4.6 Hz, 1H), 8.04 (d, <i>J</i> = 5.2 Hz, 1H), 7.88 (d, <i>J</i> = 7.4 Hz, 1H), 7.51 (s, 1H), 7.45-7.40 (m, 2H), 6.93-6.78 (m, 3H), 4.27 (t, <i>J</i> = 7.6 Hz, 2H), 4.07 (s, 2H), 3.22 (t, <i>J</i> = 7.6 Hz, 2H), 2.59-2.55 (m, 1H), 0.73-0.71 (m, 2H), 0.47-0.42 (m, 2H). LCMS: <i>m/z</i> 422.9(M+H).
------------	---	---	--


Example P17:

Synthesis of 1-(7-fluoro-5-(2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)-2-(2-fluorophenyl)ethan-1-one (P17)



Step 1. Synthesis of

N-4-(7-fluoroindolin-5-yl)-N-(1-methyl-1*H*-pyrazol-5-yl)pyrimidin-2-ylamine (32)




Into a dry 100 mL round bottom flask, Compound **4** 7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline (900 mg, 3.80 mmol), Compound **17** 4-chloro-N-(1-methyl-1*H*-pyrazol-5-yl)pyrimidin-2-amine (800 mg, 3.80 mmol), potassium carbonate (1.1 g, 7.60 mmol), (1,1-bis(diphenylphosphino)ferrocene)palladium (II) dichloride (278 mg, 0.38 mmol) and 1,4-dioxane (20.0 mL) were added at room temperature, The reaction was purged with nitrogen gas five teimes, warmed to 80°C, and stirred overnihgt. After the reaction was completed, the reaction was concentrated under reduced pressure, added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:10) to give Intermediate **32** N-4-(7-fluoroindolin-5-yl)-N-(1-methyl-1*H*-pyrazol-5-yl)pyrimidin-2-ylamine (150 mg, white solid). Yield: 12.0%.

LCMS: *m/z* 311.0 (M+H).

Step 2. Synthesis of

1-(7-fluoro-5-(2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)-2-(2-fluorophenyl)ethan-1-one (P17)










Into a dry 100 mL round bottom flask, Compound **32** N-4-(7-fluoroindolin-5-yl)-N-(1-methyl-1*H*-pyrazol-5-yl)pyrimidin-2-ylamine (50 mg, 0.16 mmol), Compound **33** 2-(2-fluorophenyl)acetic acid (25 mg, 0.16 mmol), *N,N*-diisopropylethylamine (0.1 mL, 0.64 mmol), 1-propylphosphonic anhydride (407 mg, 50% (wt%) solution in ethyl acetate (0.64 mmol) and *N,N*-dimethylformamide (1.0 mL) were added at room temperature. The reaction was stirred for 30 min. After the reaction was completed, the reaction was concentrated under reduced pressure, added with 100 mL water, and extracted with ethyl acetate (150 mL×3). The combined organic phase washed with saturated brine (50 mL×5), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:1) to give the product **P17** 1-(7-fluoro-5-(2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)-2-(2-fluorophenyl)ethan-1-one (16.7 mg, light yellow solid). Yield: 20.0%. LCMS: *m/z* 447.0 (M+H).





¹H NMR (DMSO-*d*₆, 400 MHz): δ 9.48 (s, 1H), 8.51 (d, *J* = 5.2 Hz, 1H), 7.91 (s, 1H), 7.83 (d, *J* = 12.4 Hz, 1H), 7.46 (d, *J* = 5.2 Hz, 1H), 7.41-7.31 (m, 3H), 7.19 (q, *J* = 7.6 Hz, 2H), 6.29 (s, 1H), 4.26 (t, *J* = 8.0 Hz, 2H), 3.98 (s, 2H), 3.70 (s, 3H), 3.23 (t, *J* = 8.0 Hz, 2H).





Examples **P18-P20**, **P23-P25**, **P28-31**, **P33**, **P37-39** and **P54-57** were obtained in accordance with the general scheme C as shown in Figure 3 using Intermediate **32** or similar intermediates.



Ex.	Structure	Name	Analytical data
P18		2-(2-chlorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1 <i>H</i> -pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H NMR (DMSO- <i>d</i> ₆ , 400 MHz): δ 9.46 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 7.92 (s, 1H), 7.83 (d, <i>J</i> = 12 Hz, 1H), 7.46-7.41 (m, 3H), 7.37 (s, 1H), 7.33-7.30 (m, 2H), 6.28 (s, 1H), 4.27 (t, <i>J</i> = 8.0 Hz, 2H), 4.04 (s, 2H), 3.70 (s, 4H), 3.21 (d, <i>J</i> = 7.6 Hz, 3H). LCMS: <i>m/z</i> 462.9 (M+H).

P19	 P19	2-(4-chlorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (DMSO-<i>d</i>₆, 400 MHz): δ 9.46 (s, 1H), 8.50 (d, <i>J</i> = 5.6 Hz, 1H), 7.90 (s, 1H), 7.82 (d, <i>J</i> = 12.8 Hz, 1H), 7.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (s, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 6.28 (s, 1H), 4.23 (t, <i>J</i> = 8.0 Hz, 2H), 3.95 (s, 2H), 3.70 (s, 3H), 3.20 (t, <i>J</i> = 8.0 Hz, 3H). LCMS: <i>m/z</i> 462.9 (M+H).
P20		2-(2-chloro-5-methylpyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (DMSO-<i>d</i>₆, 400 MHz) δ 9.48 (s, 1H), 8.52 (d, <i>J</i> = 5.2 Hz, 1H), 8.18 (s, 1H), 7.94 (s, 1H), 7.85 (d, <i>J</i> = 12.8 Hz, 1H), 7.71 (s, 1H), 7.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.38 (d, <i>J</i> = 2.0 Hz, 1H), 6.29 (s, 1H), 4.30 (t, <i>J</i> = 7.6 Hz, 2H), 4.03 (s, 2H), 3.71 (s, 3H), 3.24 (t, <i>J</i> = 7.6 Hz, 2H), 2.31 (s, 3H). LCMS: <i>m/z</i> 477.9/479.9 (M+H).
P23		2-(3-chlorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (DMSO-<i>d</i>₆, 400 MHz) δ 9.49 (s, 1H), 8.52 (d, <i>J</i> = 5.2 Hz, 1H), 7.91 (s, 1H), 7.83 (d, <i>J</i> = 12.4 Hz, 1H), 7.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.41–7.32 (m, 4H), 7.27 (d, <i>J</i> = 6.8 Hz, 1H), 6.30 (s, 1H), 4.24 (t, <i>J</i> = 8.0 Hz, 2H), 3.97 (s, 2H), 3.71 (s, 3H), 3.21 (t, <i>J</i> = 8.0 Hz, 2H). LCMS: <i>m/z</i> 462.9 (M+H).
P24		2-(2-bromophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (400 MHz, DMSO-<i>d</i>₆) δ 9.46 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 7.92 (s, 1H), 7.84 (d, <i>J</i> = 12.6 Hz, 1H), 7.65 – 7.60 (m, 1H), 7.46 (d, <i>J</i> = 5.3 Hz, 1H), 7.44 – 7.34 (m, 2H), 7.23 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 6.27 (d, <i>J</i> = 1.8 Hz, 1H), 4.28 (t, <i>J</i> = 7.9 Hz, 2H), 4.03 (s, 2H), 3.70 (s, 3H), 3.23 (t, <i>J</i> = 7.9 Hz, 2H). LCMS: <i>m/z</i> 507.0/509.0 (M+H).


P25		1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)-2-(2-iodophenyl)ethan-1-one	¹H-NMR (400 MHz, DMSO-<i>d</i>₆) δ 9.46 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 7.93 (s, 1H), 7.85 (d, <i>J</i> = 8.2 Hz, 1H), 7.47 (d, <i>J</i> = 5.3 Hz, 1H), 7.42 – 7.32 (m, 3H), 7.17 – 6.92 (m, 1H), 6.28 (d, <i>J</i> = 1.8 Hz, 1H), 4.28 (t, <i>J</i> = 8.0 Hz, 2H), 4.01 (s, 2H), 3.70 (s, 3H), 3.23 (t, <i>J</i> = 8.0 Hz, 2H). LCMS: <i>m/z</i> 555.0 (M+H).
P28		2-(3-chloropyridin-2-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (400 MHz, DMSO-<i>d</i>₆) δ 8.81 (s, 1H), 8.48 (dd, <i>J</i> = 4.8, 1.4 Hz, 1H), 8.16 (d, <i>J</i> = 5.2 Hz, 1H), 7.94 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 7.48 (s, 1H), 7.45 – 7.36 (m, 2H), 7.34 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 (dd, <i>J</i> = 5.4, 1.6 Hz, 1H), 7.01 (s, 1H), 6.27 (d, <i>J</i> = 2.0 Hz, 1H), 4.25 (t, <i>J</i> = 8.0 Hz, 2H), 4.22 (s, 2H), 3.68 (s, 3H), 3.20 (t, <i>J</i> = 8.0 Hz, 2H). LCMS: <i>m/z</i> 463.0 (M+H).
P29		2-(6-chloropyridin-2-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H-NMR (400 MHz, DMSO-<i>d</i>₆) δ 8.83 (s, 1H), 8.16 (d, <i>J</i> = 5.2 Hz, 1H), 7.85 (t, <i>J</i> = 8.0 Hz, 1H), 7.48 (s, 1H), 7.41 (dd, <i>J</i> = 7.6, 5.2 Hz, 1H), (m, 2H), 7.34 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 (dd, <i>J</i> = 5.4, 1.6 Hz, 1H), 7.01 (s, 1H), 6.27 (d, <i>J</i> = 2.0 Hz, 1H), 4.25 (t, <i>J</i> = 8.0 Hz, 2H), 4.11 (s, 2H), 3.69 (s, 3H), 3.20 (t, <i>J</i> = 8.0 Hz, 2H). LCMS: <i>m/z</i> 463.0 (M+H).

P30		2-(2-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)-2-oxoethyl)benzonitrile	¹ H NMR (DMSO- <i>d</i> ₆ , 400 MHz): δ 9.46 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 7.93 (s, 1H), 7.84 (d, <i>J</i> = 12 Hz, 1H), 7.69 (td, <i>J</i> = 7.6, 1.6 Hz, 1H), 7.54 (d, <i>J</i> = 7.2 Hz, 1H), 7.51-7.44 (m, 2H), 7.37 (d, <i>J</i> = 2.0 Hz, 1H), 6.28 (d, <i>J</i> = 2.0 Hz, 1H), 4.31 (t, <i>J</i> = 8.0 Hz, 2H), 4.18 (s, 2H), 3.70 (s, 4H), 3.24 (t, <i>J</i> = 8.0 Hz, 2H). LCMS: <i>m/z</i> 454 (M+H).
P31		2-(2-chlorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one	¹ H NMR (DMSO- <i>d</i> ₆ , 400 MHz): δ 8.81 (s, 1H), 8.16 (d, <i>J</i> = 5.6 Hz, 1H), 7.49 (s, 1H), 7.47-7.39 (m, 3H), 7.35-7.27 (m, 3H), 7.09 (d, <i>J</i> = 5.2 Hz, 1H), 7.01 (s, 1H), 6.27 (s, 1H), 4.25 (t, <i>J</i> = 8.0 Hz, 2H), 4.03 (s, 2H), 3.68 (s, 3H), 3.21 (t, <i>J</i> = 7.8 Hz, 2H). LCMS: <i>m/z</i> 462.0 (M+H)
P33		2-(2-chloro-4-fluoropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H NMR (CD ₃ OD, 400 MHz): δ 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 8.37 (t, <i>J</i> = 5.6 Hz, 1H), 7.93 (s, 1H), 7.86 (d, <i>J</i> = 12.8 Hz, 1H), 7.51 (s, 1H), 7.40 (d, <i>J</i> = 5.2 Hz, 1H), 7.31 (t, <i>J</i> = 5.6 Hz, 1H), 6.39 (s, 1H), 4.40 (t, <i>J</i> = 7.6 Hz, 2H), 4.19 (s, 2H), 3.79 (s, 3H), 3.30 (t, <i>J</i> = 7.6 Hz, 2H). LCMS: <i>m/z</i> 481.9/483.9 (M+H).
P37		2-(3-chloropyridin-4-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹ H NMR (CD ₃ OD, 400 MHz): δ 8.58 (s, 1H), 8.47 (d, <i>J</i> = 4.8 Hz, 2H), 7.92 (s, 1H), 7.87 (d, <i>J</i> = 13.2 Hz, 1H), 7.51-7.48 (m, 2H), 7.39 (d, <i>J</i> = 5.2 Hz, 1H), 6.39 (d, <i>J</i> = 2.0 Hz, 1H), 4.36 (t, <i>J</i> = 8 Hz, 2H), 4.19 (s, 2H), 3.78 (s, 3H), 3.28 (t, <i>J</i> = 8 Hz, 2H). LCMS: <i>m/z</i> 463.9/466.0 (M+H).


P38		2-(2-chloro-5-fluorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (CD₃OD, 400 MHz): 8.47 (d, <i>J</i> = 5.6 Hz, 1H), 7.92 (s, 1H), 7.87 (d, <i>J</i> = 12.4 Hz, 1H), 7.49 (d, <i>J</i> = 2.0 Hz, 1H), 7.44 (dd, <i>J</i> = 8.8 Hz, 3.6 Hz, 1H), 7.39 (d, <i>J</i> = 5.2 Hz, 1H), 7.24 (dd, <i>J</i> = 8.8 Hz, 2.8 Hz, 1H), 7.08 (t, <i>J</i> = 8 Hz, 1H), 6.35 (d, <i>J</i> = 2 Hz, 2H), 4.35 (t, <i>J</i> = 8 Hz, 2H), 4.10 (s, 2H), 3.78 (s, 3H), 3.26 (t, <i>J</i> = 7.2 Hz, 2H). LCMS: <i>m/z</i> 481.0/482.9 (M+H)
P39		2-(2,5-difluorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (CD₃OD, 400 MHz): 8.46 (d, <i>J</i> = 4.0 Hz, 1H), 7.90 (s, 1H), 7.87 (d, <i>J</i> = 12.4 Hz, 1H), 7.48 (d, <i>J</i> = 2.0 Hz, 1H), 7.39 (d, <i>J</i> = 5.6 Hz, 1H), 7.16-7.10 (m, 1H), 7.08-7.04 (m, 1H), 6.35 (d, <i>J</i> = 2.0 Hz, 1H), 4.33 (t, <i>J</i> = 8.0 Hz, 2H), 4.02 (s, 2H), 3.78 (s, 3H), 3.26 (t, <i>J</i> = 8.0 Hz, 2H). LCMS: <i>m/z</i> 465.0 (M+H)
P54		2-(2-chloro-3-fluorophenyl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (400 MHz, DMSO) δ 9.47 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 7.92 (s, 1H), 7.84 (d, <i>J</i> = 12.6 Hz, 1H), 7.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.40-7.33 (m, 3H), 7.31-7.26 (m, 1H), 6.28 (d, <i>J</i> = 1.5 Hz, 1H), 4.28 (t, <i>J</i> = 7.8 Hz, 2H), 4.11 (s, 2H), 3.70 (s, 3H), 3.23 (t, <i>J</i> = 7.8 Hz, 2H). LCMS: <i>m/z</i> 480.9 (M+H).
P55		3-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)propan-1-one	¹H NMR (400 MHz, DMSO) δ 8.82 (s, 1H), 8.28 (d, <i>J</i> = 3.2 Hz, 1H), 8.16 (d, <i>J</i> = 5.6 Hz, 1H), 7.87 (d, <i>J</i> = 7.0 Hz, 1H), 7.46 (s, 1H), 7.44-7.37 (m, 2H), 7.34 (s, 1H), 7.08 (d, <i>J</i> = 5.6 Hz, 1H), 7.00 (s, 1H), 6.27 (s, 1H), 4.16 (t, <i>J</i> = 7.8 Hz, 2H), 3.68 (s, 3H), 3.14 (t, <i>J</i> = 7.8 Hz, 2H), 3.06-2.98 (m, 2H), 2.92-2.85 (m, 2H). LCMS: <i>m/z</i> 476.9 (M+H)

P56		2-(4-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one	¹H NMR (400 MHz, DMSO) δ9.47 (s, 1H), 8.57 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 8.47 (d, <i>J</i> = 4.8 Hz, 1H), 7.93 (s, 1H), 7.84 (d, <i>J</i> = 12.4 Hz, 1H), 7.57 (d, <i>J</i> = 5.2 Hz, 1H), 7.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.37 (d, <i>J</i> = 1.6 Hz, 1H), 6.27 (d, <i>J</i> = 1.2 Hz, 1H), 4.31 (t, <i>J</i> = 8.0 Hz, 2H), 4.11 (s, 2H), 3.70 (s, 3H), 3.25 (t, <i>J</i> = 7.6 Hz, 2H). LCMS: <i>m/z</i> 463.9 (M+H).
P57		1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)pyridin-3-yl)ethan-1-one	¹H NMR (400 MHz, DMSO) δ8.83 (s, 1H), 8.46 (d, <i>J</i> = 4.4 Hz, 1H), 8.17 (d, <i>J</i> = 7.2 Hz, 1H), 7.61 (d, <i>J</i> = 7.4 Hz, 1H), 7.50 (s, 1H), 7.42 (d, <i>J</i> = 12.01 Hz, 1H), 7.35 (s, 1H), 7.20-7.17 (m, 1H), 7.09 (d, <i>J</i> = 5.2 Hz, 1H), 7.01 (s, 1H), 6.27 (s, 1H), 4.27 (t, <i>J</i> = 7.8 Hz, 2H), 4.05 (s, 2H), 3.93-3.89 (m, 2H), 3.69 (s, 3H), 3.23 (t, <i>J</i> = 7.6 Hz, 2H), 3.04-2.98 (m, 1H), 1.94-1.84 (m, 2H), 1.58-1.55 (m, 2H). LCMS: <i>m/z</i> 513.0 (M+H).

Example P35:




Step 1. Synthesis of methyl 1-methyl-5-nitro-1H-pyrazol-3-carboxylate (59)



Into a 100 mL round bottom flask in ice-water bath, Compound **58** (5.0 g, 12.74 mmol), potassium carbonate (1.94 g, 14.0 mmol), N,N-dimethylformamide (50 mL) were sequentially added, and solution of iodomethane (3.80 g, 26.75 mmol) in N,N-dimethylformamide (10 mL) was added dropwise. After completion of the dropwise addition, the reaction was stirred for 16 h. After the reaction was completed, the reaction was added with water (150 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phase washed with saturated brine (30 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography with eluent system (ethyl acetate : petroleum ether = 1:20) to give methyl 1-methyl-5-nitro-1H-pyrazol-3-carboxylate **59** (1.0 g, white solid). Yield: 17.0%. LCMS: m/z 185.9 (M+H)


Step 2. Synthesis of methyl 5-amino-1-methyl-1H-pyrazol-3-carboxylate (**60**)



At room temperature, Compound **59** (200 mg, 1.081 mmol) was dissolved in methanol (10 mL) and added with Pd/C (10%, 90 mg). The reaction was stirred for 4 h under 1 atm of hydrogen gas. After the reaction was completed as monitored by LCMS, the reaction was filtered with suction. The filtrate was concentrated under reduced pressure to give methyl 5-amino-1-methyl-1H-pyrazol-3-carboxylate **60** (145 mg, light yellow oil). Yield: 87.0%. LCMS: m/z 156 (M+H).

Step 3. Synthesis of methyl


5-((4-bromopyridin-2-yl)amino)-1-methyl-1H-pyrazol-3-carboxylate (**61**)



At room temperature, into a 50 mL round bottom flask, Compound **60** (650 mg, 4.19 mmol) and N,N-dimethylformamide (10 mL) were sequentially added, and sodium hydride (335 mg, 8.38 mmol) was added in portions. The reaction was stirred for 0.5 h, added with 2-bromo-4-fluoropyridine (1.47 g, 8.387 mmol), and stirred for 16 h. After the reaction was completed as monitored by LCMS, the reaction was added with water (30 mL), and extracted with ethyl acetate (10 mL×5). The combined organic phase washed with saturated brine (20 mL×3),

dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography with eluent system (ethyl acetate : petroleum ether = 1:4) to give methyl 5-((4-bromopyridin-2-yl)amino)-1-methyl-1H-pyrazol-3-carboxylate **61** (130 mg, pale yellow solid). Yield: 10%. LCMS: m/z 310.9/312.9 (M+H).


Step 4. Synthesis of (5-((4-bromopyridin-2-yl)amino)-1-methyl-1H-pyrazol-3-yl)methanol (**62**)



At room temperature, Compound **61** (130 mg, 0.418 mmol) was dissolved in anhydrous methanol (25 mL), and added in portions with sodium borohydride (156 mg, 4.18 mmol). After completion of the addition, the reaction was stirred at room temperature for 2 h, and was concentrated under reduced pressure. The resulting residue was purified by column chromatography with eluent system (ethyl acetate : petroleum ether = 4:1) to give (5-((4-bromopyridin-2-yl)amino)-1-methyl-1H-pyrazol-3-yl)methanol **62** (100 mg, white gum). Yield: 85%. LCMS: m/z 282.9/284.9 (M+H).

Step 5. Synthesis of


N-(3-(((t-butyldimethylsilyl)oxy)methyl)-1-methyl-1H-pyrazol-5-yl)-N-(4-bromopyridin-2-yl)-amine (63**)**



Into a 50 mL round bottom flask, Compound **62** (100 mg, 0.355 mmol), t-butyldimethylsilyl chloride (532 mg, 3.55 mmol), triethylamine (358 mg, 3.55 mmol), 4-dimethylaminopyridine (4.33 mg, 0.036 mmol), dichloromethane (10 mL) were sequentially added at room temperature. The reaction was purged with nitrogen gas three times, and stirred at room temperature for 16 h. After the reaction was completed, the reaction was added with water (30 mL), and extracted with ethyl acetate (10 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 1:5) to give N-(3-(((t-butyldimethylsilyl)oxy)methyl)-1-methyl-1H-pyrazol-5-yl)-N-(4-bromopyridin-2-yl)-amine **63** (50 mg, light yellow oil). Yield: 33.0%. LCMS: m/z 396.9/398.9 (M+H).

Step 6. Synthesis of


1-(5-(2-((3-(((t-butyltrimethylsilyl)oxy)methyl)-1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-7-fluoroindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one (**64**)



Into a 50 mL round bottom flask, Compound **63** (50 mg, 0.126 mmol), 1,4-dioxane (10 mL), $PdCl_2(dppf)$ (9.2 mg, 0.0126 mmol), potassium carbonate (26.1 mg, 0.189 mmol), Compound **11** (52.5 mg, 0.126 mmol) were sequentially added at room temperature. The reaction was purged with nitrogen gas three times, warmed to $80\text{ }^\circ\text{C}$, and stirred for 3 h. After the reaction was completed, the reaction was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with eluent system (ethyl acetate : petroleum ether = 5:1) to give 1-(5-(2-((3-(((t-butyltrimethylsilyl)oxy)methyl)-1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-7-fluoroindolin-1-yl)-2-(2-chloropyridin-3-yl)ethan-1-one **64** (60 mg, pale yellow oil). Yield: 78.5%. LCMS: m/z 606.5/608.5, (M+H)

Step 7. Synthesis of

2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((3-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one (**P35**)




Into a 50 mL flask, Compound **64** (60 mg, 0.099 mmol), trifluoroacetic acid (2 mL), dichloromethane (10 mL) were sequentially added at room temperature. The reaction was stirred at room temperature for 1 h. After the reaction was completed, the reaction was concentrated under reduced pressure, slowly added with saturated aqueous sodium bicarbonate solution (15 mL), and extracted with ethyl acetate (10 mL $\times$ 5). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified by preparative liquid chromatography (column: -Gemini-C18 150 x 21.2 mm, 5 μ m; mobile phase: ACN - H_2O (0.1%FA), gradient:10-60) to give 2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((3-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one **P35** (12 mg, pale yellow solid). Yield: 25%.

^1H -NMR (CD_3OD , 400 MHz): 8.33 (d, J = 3.2 Hz, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.51 (s, 1H), 7.44-7.38 (m, 2H), 7.12 (d, J = 5.6 Hz, 1H), 6.99 (s, 1H), 6.31 (s, 1H),


4.56 (s, 2H), 4.37 (t, $J = 7.6$ Hz, 2H), 4.14 (s, 2H), 3.73 (s, 3H), 3.28 (t, $J = 7.2$ Hz, 2H). LCMS: m/z 492.9/494.9 (M+H)

Example P60: Synthesis of

2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-hydroxyethan-1-one (P60)




Step 1. Synthesis of ethyl 2-(2-chloropyridin-3-yl)-2-hydroxyacetate (91)



Into a dry 250 mL round bottom flask in ice bath, Compound **90** (6.0 g, 0.031 mol), tetrahydrofuran (100 mL), isopropylmagnesium chloride - lithium chloride complex (31 mL, 40.3 mol) were added. The reaction was purged with nitrogen gas three times, naturally warmed to room temperature, and stirred for 3 h. The reaction was cooled in ice-water bath, added with Compound **2** (3.2 g, 0.031 mol), gradually warmed to room temperature, stirred for 2 h, quenched with saturated ammonium chloride (100 mL), and extracted with ethyl acetate (80 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate : petroleum ether = 1:10) to give ethyl 2-(2-chloropyridin-3-yl)-2-hydroxyacetate **91** (1.4 g, pale yellow oil). Yield: 21%. LCMS: m/z 216.0 (M+H).


Step 2. Synthesis of ethyl 2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)acetate (92)



Into a dry 100 mL round bottom flask, Compound **91** (800 mg, 3.7 mmol), dichloromethane (50 mL), t-butyldimethylsilyl chloride (2796 mg, 18.5 mmol), 4-dimethylamio-pyridine (452 mg, 3.7 mmol), triethylamine (3740 mg, 37.0 mmol) were added at room temperature. The reaction was purged with nitrogen gas three times, and stirred at room temperature for 18 h. After the reaction

was completed, the reaction was quenched by addition of ice-water (100 mL), and extracted with dichloromethane (60 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate : petroleum ether = 1:20) to give ethyl 2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)acetate **92** (640 mg, colorless oil). Yield: 52%. LCMS: m/z 330.0 (M+H).


Step 3. Synthesis of 2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)acetic acid (**93**)



Into a dry 100 mL round bottom flask, Compound **92** (640 mg, 1.94 mmol), lithium hydroxide monohydrate (244 mg, 5.81 mmol), tetrahydrofuran (20 mL), water (4 mL) were added at room temperature. The reaction was stirred for 2 h and filtered. The filtrate was concentrated under reduced pressure, and adjusted with 1 N aqueous hydrochloric acid solution to pH 7. The solid precipitated, was filtered, and dried to give 2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)acetic acid **93** (180 mg, white solid). Yield: 31%. LCMS: m/z 302.0 (M+H).

Step 4. Synthesis of t-butyl

N-(4-(1-(2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)acetyl)-7-fluoroindol-5-yl)pyridin-2-yl)-N-(1-methyl-1H-pyrazol-5-yl)carbamate (94**)**




In a dry 100 mL round bottom flask in ice bath, Compound **93** (243 mg, 0.6 mmol), Compound **25** (180 mg, 0.6 mmol), phosphorus oxychloride (273 mg, 1.8 mmol) and pyridine (20 mL) were added. The reaction was gradually warmed to room temperature, stirred for 3 h, diluted by addition of ice-water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phase was concentrated under reduced pressure. The resulting residue was purified with preparative TLC (ethyl acetate : petroleum ether = 1:3) to give t-butyl N-(4-(1-(2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)acetyl)-7-fluoroindol-5-yl)pyridin-2-yl)-N-(1-methyl-1H-pyrazol-5-yl)carbamate **94** (250 mg). Yield: 61%. LCMS: m/z 692.5 (M+H).

Step 5. Synthesis of

2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-


5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one (95)



Into a dry 100 mL round bottom flask, Compound **94** (250 mg, 0.36 mmol), dichloromethane (20 mL) and trifluoroacetic acid (5 mL) were added at room temperature. The reaction was stirred at room temperature for 2 h, cooled in ice bath, neutralized with saturated aqueous sodium bicarbonate solution (50 mL), and extracted with dichloromethane (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 2-((t-butyldimethylsilyl)oxy)-2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)ethan-1-one **95** (200 mg, colorless oil). Yield: 93%. LCMS: m/z 593.1 (M+H)

Step 6. Synthesis of

2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-hydroxyethan-1-one (P60)




Into a dry 100 mL round bottom flask, Compound **95** (200 mg, 0.34 mmol), tetrahydrofuran (4 mL), tetrabutylammonium fluoride (1N solution in THF, 4 mL) were added at room temperature. The reaction was stirred at room temperature for 1 h, diluted with water (50 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate : petroleum ether = 1:20) to give 2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-hydroxyethan-1-one **P60** (120 mg, white solid), which was recrystallized from ethyl acetate : n-hexane = 1:2 to give 2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-hydroxyethan-1-one **P60** (55 mg, white solid). Yield: 34%.



^1H NMR (400 MHz, DMSO- d_6) δ 8.82 (s, 1H), 8.38 (dd, J = 2.0, 4.8 Hz, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.02 (dd, J = 2.0, 7.6 Hz, 1H), 7.55-7.47 (m, 2H), 7.41 (d, J = 12 Hz, 1H), 7.34 (d, J = 1.6 Hz, 1H), 7.09 (dd, J = 1.2, 5.2 Hz, 1H), 7.01 (s, 1H), 6.63 (d, J = 6.8 Hz, 1H), 6.27 (d, J = 2.0 Hz, 1H), 5.77 (d, J = 6.4 Hz, 1H), 4.42-4.33 (m, 1H), 4.24-4.14 (m, 1H), 3.68 (s, 3H), 3.27-3.20 (m, 1H).

LCMS: m/z 479.0 (M+H).

Example **P64** was obtained analogously to the preparation of Example **60** using intermediates similar to Intermediate **25**.

Ex.	Structure	Name	Analytical data
P64		2-(2-chloropyridin-3-yl)-1-(7-fluoro-5-(2-((1-deuteriomethyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)indolin-1-yl)-2-hydroxyethan-1-one	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.82 (s, 1H), 8.38 (dd, <i>J</i> = 1.6, 4.8 Hz, 1H), 8.16 (d, <i>J</i> = 5.2 Hz, 1H), 8.02 (dd, <i>J</i> = 1.6, 7.6 Hz, 1H), 7.53 (dd, <i>J</i> = 4.8, 7.6 Hz, 1H), 7.49 (s, 1H), 7.41 (d, <i>J</i> = 12 Hz, 1H), 7.34 (d, <i>J</i> = 1.2 Hz, 1H), 7.09 (dd, <i>J</i> = 1.2, 5.2 Hz, 1H), 7.01 (s, 1H), 6.63 (d, <i>J</i> = 6.4 Hz, 1H), 6.27 (d, <i>J</i> = 1.2 Hz, 1H), 5.77 (d, <i>J</i> = 6.4 Hz, 1H), 4.39-4.35 (m, 1H), 4.24-4.17 (m, 1H), 3.27-3.20 (m, 1H). LCMS: m/z 482.0 (M+H).

Step 7: Preparation of Compounds **P62** and **P63** by resolution of Compound **P60**



Resolution conditions:

Chiral column: AD-H, 0.46cm I.D.X15cm L

Mobile phase: HEP:IPA (0.1%DEA) = 60:40

Flow rate: 0.5 mL

Detection wavelength: UV 254nm

Column temperature: 25°C

The compound that was eluted first (Peak 1) was numbered **P62**


¹H NMR (400 MHz, DMSO) δ 8.81 (s, 1H), 8.38 (dd, *J* = 4.8, 1.8 Hz, 1H), 8.16 (d, *J* = 5.4 Hz, 1H), 8.02 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.52 (dd, *J* = 7.6, 4.8 Hz, 1H), 7.48 (s, 1H), 7.40 (d, *J* = 12.0 Hz, 1H), 7.34 (d, *J* = 1.8 Hz, 1H), 7.09 (d, *J* = 4.2 Hz, 1H), 7.00 (s, 1H), 6.61 (s, 1H), 6.27 (d, *J* = 1.6 Hz, 1H), 5.77 (d, *J* = 6.6 Hz, 1H), 4.37-4.41 (m, 1H), 4.26 – 4.14 (m, 1H), 3.68 (s, 3H), 3.22 (dd, *J* = 13.4, 7.2 Hz, 2H).

.LCMS: m/z 479.0 (M+H).

The compound that was eluted second (Peak 2) was numbered **P63**

^1H NMR (400 MHz, DMSO) δ 8.81 (s, 1H), 8.38 (dd, $J = 4.8, 1.8$ Hz, 1H), 8.16 (d, $J = 5.4$ Hz, 1H), 8.02 (dd, $J = 7.6, 1.8$ Hz, 1H), 7.52 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.48 (s, 1H), 7.40 (d, $J = 12.0$ Hz, 1H), 7.34 (d, $J = 1.8$ Hz, 1H), 7.09 (dd, $J = 5.4, 1.6$ Hz, 1H), 7.00 (s, 1H), 6.61 (d, $J = 6.8$ Hz, 1H), 6.27 (d, $J = 1.8$ Hz, 1H), 5.77 (d, $J = 6.8$ Hz, 1H), 4.43 – 4.35 (m, 1H), 4.25-4.15 (m, 1H), 3.68 (s, 3H), 3.22 (dd, $J = 13.4, 7.2$ Hz, 2H).
LCMS: m/z 479.0 (M+H).

Examples P40 and P41. Preparation of Compounds P40 and P41 by resolution of Compound P53



Resolution conditions:

Chiral column: chiralpak-OJ, 0.46 cm I.D. $\times$ 25 cm L

Mobile phase: HEX-EtOH (0.2% DEA) = 50: 50

Flow rate: 0.8 mL

Detection wavelength: UV 214/254nm

Column temperature: 40°C

The compound that was eluted first (Peak 1) was numbered **P40**

^1H NMR (CD_3OD , 400 MHz): 8.34 (d, $J = 4.8$ Hz, 1H), 7.98 (d, $J = 5.6$ Hz, 1H), 7.90 (d, $J = 7.6$ Hz, 1H), 7.51 (s, 1H), 7.44-7.38 (m, 2H), 6.94-6.92 (m, 1H), 6.79 (s, 1H), 4.51-4.48 (m, 1H), 4.37 (t, $J = 8$ Hz, 2H), 4.30-4.27 (m, 1H), 4.14 (s, 2H), 3.28 (t, $J = 7.6$ Hz, 2H), 2.41-2.38 (m, 2H), 2.35-2.31 (m, 2H).


LCMS: m/z 452.8/454.9 (M+H)

The compound that was eluted second (Peak 2) was numbered **P41**

^1H NMR (CD_3OD , 400 MHz): 8.33 (d, $J = 4.8$ Hz, 1H), 7.97 (d, $J = 6$ Hz, 1H), 7.90 (d, $J = 7.6$ Hz, 1H), 7.53 (s, 1H), 7.43-7.40 (m, 2H), 6.96 (d, $J = 5.6$ Hz, 1H), 6.84 (s, 1H), 4.37 (t, $J = 7.6$ Hz, 2H), 4.14 (s, 2H), 4.10-4.03 (m, 1H), 3.85-3.77 (m, 1H), 3.29 (t, $J = 8$ Hz, 2H), 2.91-2.85 (m, 2H), 1.92-1.85 (m, 2H).

LCMS: m/z 452.8/454.9 (M+H)

Examples P42 and P43. Preparation of Compounds P42 and P43 by resolution of Compound P16



Resolution conditions:

Chiral column: OJ, 0.46cm I.D. *25 cm L

Mobile phase: n-hexane:ethanol(0.2%diethylamine) = 50:50

Flow rate: 0.8 mL

Detection wavelength: UV 214/254nm

Column temperature: 40°C

The compound that was eluted first (Peak 1) was numbered **P42**

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.82 (s, 1H), 8.34 (d, *J* = 3.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.89 (d, *J* = 7.6 Hz, 1H), 7.52 (s, 1H), 7.49-7.41 (m, 2H), 7.34 (d, *J* = 1.4 Hz, 1H), 7.10 (d, *J* = 5.4 Hz, 1H), 7.01 (s, 1H), 6.28 (s, 1H), 4.97-4.89 (m, 1H), 4.18 (d, *J* = 16.8 Hz, 1H), 3.96 (d, *J* = 16.8 Hz, 1H), 3.68 (s, 3H), 3.57-3.51 (m, 1H), 2.72 (d, *J* = 16.0 Hz, 1H), 1.27 (d, *J* = 6.4 Hz, 3H).
LCMS: *m/z* 476.9 (M+H).

The compound that was eluted second (Peak 2) was numbered **P43**

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.82 (s, 1H), 8.34 (d, *J* = 3.6 Hz, 1H), 8.16 (d, *J* = 5.4 Hz, 1H), 7.89 (d, *J* = 6.8 Hz, 1H), 7.52 (s, 1H), 7.48-7.41 (m, 2H), 7.34 (s, 1H), 7.10 (d, *J* = 5.4 Hz, 1H), 7.01 (s, 1H), 6.27 (s, 1H), 4.98-4.89 (m, 1H), 4.18 (d, *J* = 16.8 Hz, 1H), 3.96 (d, *J* = 16.8 Hz, 1H), 3.68 (s, 3H), 3.57-3.51 (m, 1H), 2.72 (d, *J* = 16.0 Hz, 1H), 1.27 (d, *J* = 6.4 Hz, 3H).

LCMS: *m/z* 476.9 (M+H).

Effect Example I: Chemical Stability Assay

1. Detection means and conditions used in the chemical stability assay

Detection method: Ultra-high performance liquid chromatography (UPLC)

Chromatographic conditions:

System: Ultra-high performance liquid chromatography system including pump, automatic sample injector, detector, and column oven

Column: Waters Acquity UPLC BEH C18 (2.1*50mm,1.7μm)

Detector: PDA detector

Detection wavelength: 225nm

Mobile phase: A: 0.05% trifluoroacetic acid in water
B: acetonitrile

Gradient:

Time (min)	A%	B%
0	95	5

15	50	50
16	20	80
19	20	80
20	95	5
24	95	5

Flow rate: 0.4 ml/min

Column temperature: 40°C

Injection volume: 2µl

2. Study on the chemical stability of the compounds of the invention

(1). Formulation of solutions of test Compound **P9**

Compound **P9** was formulated as solutions in different buffer systems at a concentration of 0.2mg/ml using PEG400 as cosolvent. These solutions were used for chemical stability study. The solutions with various pH values were formulated as follows:

Type of solutions	Solvent system	Found pH
Solution, pH 7.4	10% PEG400 + 90% phosphate buffer pH7.4, adjusted with diluted phosphoric acid to pH 7.4	7.43
Solution, pH 6.8	10% PEG400 + 90% phosphate buffer pH6.8, adjusted with diluted phosphoric acid to pH 6.8	6.81
Solution, pH 2.0	10% PEG400 + 90% HCl solution pH2.0	1.99

Conditions for the chemical stability assay: the solutions of Compound **P9** with various pH values were stored at 37°C for 24 h. The content of Compound **P9** was determined by HPLC at 0, 4, 8, 12, 14 and 24 h.

(2). Results obtained from the chemical stability assay of test Compound **P9** in solutions with various pH values

Solution of Compound P9 , pH 7.4						
Time	0h	4h	8h	12h	14h	24h
Percentage (%) relative to the peak area of the compound at the original point	100.0	100.3	101.4	100.9	101.3	101.1
Percentage (%) of the peak area of the total impurity	0.72	0.67	0.65	0.67	0.71	0.74
Solution of Compound P9 , pH 6.8						
Time	0h	4h	8h	12h	14h	24h

Percentage (%) relative to the peak area of the compound at the original point	100.0	101.0	101.4	101.6	100.8	101.7
Percentage (%) of the peak area of the total impurity	0.75	0.69	0.71	0.71	0.68	0.68
Solution of Compound P9 , pH 2.0						
Time	0h	4h	8h	12h	14h	24h
Percentage (%) relative to the peak area of the compound at the original point	100.0	100.1	101.0	100.6	100.6	101.0
Percentage (%) of the peak area of the total impurity	0.84	0.85	0.85	0.85	0.84	0.85

(3). Conclusion

The results of this study showed that impurities were not significantly increased after storage of Compound **P9** in the solutions with pH 2.0, pH 6.8, and pH 7.4 at 37°C for 24 h, and Compound **P9** had a good chemical stability.

3. Study on the chemical stability of the reference compound

Similarly, the chemical stability of Compound A107 of WO2017/114510A1 in solutions with pH 1.2, pH 6.8, pH 7.4 was studied using the method above.

(1). Formulation of solutions of Compound A107

(1.1). Formulation of Compound A107 solution (pH 1.2):

Solution composition: 10% PEG400 + 5% Solutol HS-15 + 85% pH 1.2 diluted hydrochloric acid

Concentration: 0.2mg/ml

Formulation method: Compound A107 was weighed, added with PEG400 and Solutol HS-15 in the specified amount above, and vortexed to afford a clear solution. Said solution was added with the diluted hydrochloric acid pH 1.2 in the specified amount above and mixed uniformly.

(1.2). Formulation of Compound A107 solution (pH6.8):

Solution composition: 10%PEG400 + 5% Solutol HS-15 + 85% pH6.8 phosphate buffer

Concentration: 0.2mg/ml

Formulation method: Compound A107 was weighed, added with PEG400 and Solutol HS-15 in the specified amount above, and vortexed to afford a clear solution. Said solution was added with

phosphate buffer pH 6.8 in the specified amount above and mixed uniformly.

(1.3). Formulation of Compound A107 solution (pH7.4):

Solution composition: 10%PEG400 + 5% Solutol HS-15 + 85% pH 7.4 phosphate buffer

Concentration: 0.2mg/ml

Formulation method: Compound A107 was weighed, added with PEG400 and Solutol HS-15 in the specified amount above, and vortexed to afford a clear solution. Said solution was added with phosphate buffer pH 7.4 in the specified amount above and mixed uniformly.

(2) Results obtained from the chemical stability assay of Compound A107 at various pH values:

Solution of Compound A107, pH 7.4						
Time	0h	2h	4h	6h	8h	24h
Percentage (%) relative to the peak area of the compound at the original point	100.00	98.32	97.42	95.86	94.98	84.39
Percentage (%) of the peak area of the total impurity	0.48	2.15	3.05	4.6	5.48	16.02
Solution of Compound A107, pH 6.8						
Time	0h	2h	4h	6h	8h	24h
Percentage (%) relative to the peak area of the compound at the original point	100.00	99.52	99.23	98.74	98.47	95.24
Percentage (%) of the peak area of the total impurity	0.39	0.87	1.16	1.65	1.91	5.13
Solution of Compound A107, pH 2.0						
Time	0h	2h	4h	6h	8h	24h
Percentage (%) relative to the peak area of the compound at the original point	100.00	99.94	99.90	99.83	99.79	99.27
Percentage (%) of the peak area of the total impurity	0.35	0.41	0.45	0.52	0.56	1.08

The results in the table above showed that impurities were significantly increased after storage of Compound A107 of WO2017/114510A1 in solutions with pH 1.2, pH 6.8 and pH 7.4 at 37°C for 24h, and Compound A107 had a poor chemical stability under acidic, neutral, and slightly alkaline conditions.

Effect Example II: *In vitro* Enzyme Activity Assay

Half inhibitory activity of the compounds of the invention against ERK2 kinase (IC₅₀ value) was determined in this Example.

(1). Materials and Instruments:

Enzyme: extracellular signal-regulated kinase ERK2 kinase (PV3595, Invitrogen)
Kit: Z'-LYTE® Protein Kinase Assay Kit - Ser/Thr 3 Peptide (PV3176, Invitrogen)
Kit components: The substrate Z'-LYTE™ Ser/Thr 3 Peptide (PV3200)
The phosphorylation substrate Z'-LYTE™ Ser/Thr 3 Phospho-peptide (PV3215)
5X kinase buffer: 250 mM HEPES (pH 7.5), 50 mM MgCl₂,
5 mM EGTA, 0.05% BRIJ-35 (PV3189, Invitrogen)
ATP (PV3227, Invitrogen)
Development Reagent A (PV3295, Invitrogen)
Development Buffer (P3127, Invitrogen)
Stop Reagent (P3094, Invitrogen)
Microplate reader: The multil-mode microplate reader PerkinElmer EnVision®
Microplate : black shallow 384-well microplate (6008269, PerkinElmer)

(2). Assay Protocol:

The substrate Z'-LYTE™ Ser/Thr 3 Peptide, the phosphorylation substrate Z'-LYTE™ Ser/Thr 3 Phospho-peptide, 1X kinase buffer (5X kinase buffer was diluted with ultra pure water by five times), ATP, Development Reagent A, Development Buffer, Stop Reagent were balanced to room temperature for use. The screening concentrations for detecting the effect of the compounds of the invention on the ERK kinase activity were seven 3-fold serial dilutions starting from 1 μM (from 0.2 μM for the positive drug control) using 4% DMSO as co-solvent. 5 μL enzyme system (50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl₂, 0.01% Brij-35, 4 μM substrate, 0.8 ng/μL enzyme), 2.5 μL Compound, 2.5 μL 400 μM ATP were added into 384 well microplate, followed by incubation at room temperature for 60 min in the dark. After the reaction was completed, 5 μL the developing agent (Development Reagent A) diluted with the developing buffer (Development Buffer) was added to all reaction wells, followed by incubation at the room temperature for 60 min in the dark. 5 μL the terminating agent was added to each well to terminate the reaction. The fluorescence was determined using the multil-mode microplate reader PerkinElmer EnVision® (excitation wavelength 400 nm, emission wavelength 460 nm and 528 nm).

The inhibition rate of each well was calculated from 100% phosphorylation substrate well and 0% phosphorylation substrate well using the data analysis method below:

$$\text{phosphorylation\%} = 1 - \frac{\{(\text{emission rate} \times F_{100\%} - C_{100\%}) / [C_{0\%} - C_{100\%} + \text{emission rate} \times (F_{100\%} - F_{0\%})]\} \times 100}{94}$$

$$\text{inhibition\%} = 100 \times (1 - \text{phosphorylation\% of the test compound well} / \text{phosphorylation\% of the 0\% inhibition control})$$

wherein :

emission rate = fluorescence emission of the sample at 445nm / fluorescence emission of the sample at 520nm

$F_{100\%}$ = the average fluorescence emission of the control well of 100% phosphorylation substrate at 520nm

$F_{0\%}$ = the average fluorescence emission of the control well of 0% phosphorylation substrate at 520nm

$C_{100\%}$ = the average fluorescence emission of the control well of 100% phosphorylation substrate at 445nm

$C_{0\%}$ = the average fluorescence emission of the control well of 0% phosphorylation substrate at 445nm

Tests were carried out in duplicate. IC_{50} values were calculated from the inhibition of the kinase by the test compounds at a range of different concentrations.

(3). Results

The inhibition activity data of the compounds of the invention on the ERK2 kinase activity (IC_{50}) were listed in the table below, wherein :

A: represented that the IC_{50} of the compound was less than or equal to 10 nM;

B: represented that the IC_{50} of the compound was more than 10 nM and less than 100 nM;

C: represented that the IC_{50} of the compound was more than or equal to 100 nM and less than 1 μ M.

The inhibition activity data of the compounds of the invention
on the ERK2 kinase activity

Compound No.	ERK2 IC_{50}
P1	C
P2	B
P3	B
P4	B
P5	A
P6	B
P7	B
P8	C
P9	A
P10	A
P11	B
P12	B
P13	C

P14	B
P17	B
P18	A
P19	C
P28	B
P29	B
P30	B
P31	A
P32	A
P33	B
P34	B
P35	B
P36	B
P37	B
P38	B
P39	C
P40	B
P41	B
P43	B
P44	B
P45	A
P46	A
P47	A
P48	A
P49	A
P50	C
P53	C
P54	B
P55	B
P56	B
P57	C
P58	A
P61	B

More specifically, the IC₅₀ values of Compounds **P5**, **P9**, **P10**, **P18**, **P42**, **P59** and **P60** in this Example were 8.2 nM, 3.3 nM, 6.1 nM , 3.0 nM, 2.7nM, 4.8nM and 10nM, respectively.

Effect Example III: *In vitro* Cell Study

The inhibitory activity of Compound **P9** of the invention and the representative compounds of WO2017/114510A1 on the proliferation of human melanoma cell line A375 (IC₅₀ value) was determined in this Example.

(1). Materials and Instruments:

Cell:	human melanoma cell line A375 (CRL-1619™, ATCC)
Detection reagent:	sulforhodamine B SRB (S9012, Sigma)
Microplate:	96 well microplate (3599, Corning)
Microplate reader:	full-wavelength microplate reader (SpectraMax 190, Molecular Devices)

(2). Assay Protocol:

Cells in logarithmic growth phase were seeded at appropriate density (3500/well) into 96-well microplates in the volume of 90 µL per well. After incubation in a CO₂ incubator at 37°C overnight, 10 µL of the compound at various concentrations or saline for medium control was added in triplicate and incubated for 72 h, and a blank well was set. After the end of the action, the culture liquid was removed from the cells, and 10% (w/v) trichloroacetic acid (100 µL/well) was added for fixation at 4°C for 1 h, followed by five washes with distilled water. After drying in an oven, 100 µL of SRB solution (4 mg/mL, dissolved in 1% glacial acid) was added into each well. After incubation for staining at room temperature for 15 min, the unbound SRB was removed by five washes with 1% glacial acid. The microplates were dried in an oven, and 150 µL of 10 mM Tris solution was added to each well. The optical density (OD value) at the wavelength of 560 nm was measured using a full-wavelength microplate reader SpectraMax 190. The inhibition rate of the drug on the growth of the tumor cells was calculated according to the following formula:

$$\text{Inhibition rate (\%)} = \left(1 - \frac{\text{OD value of the compound well}}{\text{OD value of the negative control}} \right) \times 100\%$$

The IC₅₀ values were obtained by regression with four-parameter method using the software attached to the microplate reader. The assay was repeated twice.

The assay results were listed in the table below.

Comparison of the cell-based activity data between the representative compounds of WO2017/114510A1 and Compound **P9** of the invention

Compound	IC ₅₀ against A375 cell (µM)
Compound A1 of WO2017/114510A1	6.10
Compound A179 of WO2017/114510A1	0.957
Compound A205 of WO2017/114510A1	2.70
Compound A200 of WO2017/114510A1	7.80
Compound A180 of WO2017/114510A1	>10.0
Compound P9 of the invention	0.363

The assay results showed that Compound **P9** of the invention had a significantly higher activity than the representative compounds of WO2017/114510A1.

Effect Example IV: Permeability Study

The permeability of Compound **P9** of the invention and Compound A107 of WO2017/114510A1 was determined using Caco-2 cell in vitro drug absorption model in this Example.

(1). Materials and Instruments:

Cell:	human intestinal cancer Caco2 (HTB-37, ATCC)
Petri dish:	10cm petri dish (430167, Corning)
	Millicell-24 microplate (PSHT010R5, Millipore)
Buffer:	PBS (14190, Invitrogen)
	HEPES (H0887, Sigma)
	HBSS (H8264, Sigma)
Substances related to cell culture:	high glucose DMEM medium (L0103-500, Biowest)
	fetal bovine serum (S1810-500, Biowest)
	trypsin (255200-056, Invitrogen)
	nonessential amino acid (M7145, Sigma)
	penicillin and streptomycin (B-13234, GIBCO)
	sodium pyruvate (11360-070, Invitrogen)
	L-glutamine (25030-081, Invitrogen)
Relevant reagents:	fluorescein (L0144, Sigma)
	propranolol (P831800, Sigma)
	colchicine (C9754, Sigma)
	atenolol (A7655, Sigma)
Instruments:	liquid chromatography (Waters Acquity UPLC I-class, Waters)
	mass spectrometry (Waters xevo TQ-S MS/MS, Waters)
	ohmmeter (Millicell-ERS, Thermo)
	microplate reader (Infinite Pro, Tecan)

(2). Assay Protocol:

Establishment of Caco-2 cell monolayer model

1) The Caco-2 cells were revived, and incubated in a 10 cm petri dish in a 5-6% CO₂ and 95% RH incubator at 37°C. The medium was high glucose DMEM medium supplemented with 10% fetal bovine serum, 1% glutamine, 1% non-essential amino acid, 100U/mL penicillin, and 100 µg/mL streptomycin.

2) When the cell grew to 80-90% confluency, the cells were digested with trypsin, and centrifuged. The supernatant was discarded. The cells were re-suspended in 6 ml complete medium, and counted three times.

3) The cells were harvested by centrifugation at 1000 rpm for 5 min, and diluted in suspension.

The cells were seeded in Millicell-24 well microplate at the concentration of $2 \times 10^5/\text{mL}$ in the volume of 400 μL per well. 800 μL of the culture liquid was added to the substrate side for incubation in a 5% CO_2 incubator at 37°C .

4) The medium was replaced 72 h after the seeding of the cells, and then every other day. The cells were incubated for 21 days.

Evaluation of Caco-2 monolayer cells

1) After 21 days of incubation, the integrity of the Caco-2 monolayer cells in each well was assessed by measuring the electric resistance across the membrane during the cell growth.

2) Marker leakage inspection

The integrity of the Caco-2 cell monolayer was verified by fluorescent marker Lucifer Yellow. On day 21 of the growth of the cell monolayer, 200 μL of Lucifer Yellow (100 $\mu\text{g}/\text{mL}$) was added to the top side (apical side, AP side) of the cell layer, and 800 μL of HBSS liquid was added to the basal side (basolateral side, BL side). After incubation in 5% CO_2 incubator at 37°C for 1.5 h, sample was collected, and the absorbance was measured at wavelength 485- 535 nm. The leakage amount was calculated and generally not more than 0.4%. The blank HBSS solution was used as blank control.

Bilateral transport experiment

Under the same conditions, drug transport from the top side (apical side, AP side) $\rightarrow$ the basal side (basolateral side, BL side) and from BL side $\rightarrow$ AP side of the Caco-2 cell layer was simultaneously determined.

1) The mother liquids of the compounds were prepared in DMSO at a concentration of 10 mM.

2) The mother liquor was diluted with HBSS solution to 20 μM working concentration.

3) The cells were washed three times with HBSS, and the TEER value was measured with a cell potentiometer.

4) Reference compound or test compound and HBSS were added to both sides of the cells at 400 $\mu\text{L}/\text{well}$ on the AP side and 800 $\mu\text{L}/\text{well}$ on the BL side, respectively.

5) Samples were respectively collected from the AP side and the BL side after incubation in 5% CO_2 incubator at 37°C for 1.5 h.

(3). Data analysis:

The apparent permeability coefficients P_{app} of the drugs across the Caco-2 cell model were calculated according to the following formula (1):

$$P_{app} = (V_A / (\text{Area} \times \text{Time})) \times ([\text{drug}]_{\text{acceptor}} / [\text{drug}]_{\text{initial donor}}) \quad (1)$$

wherein V_A is the volume at the acceptor side, Area is the film area (cm^2), Time is the reaction time, $[\text{drug}]_{\text{acceptor}}$ is the drug concentration at the acceptor side, and $[\text{drug}]_{\text{initial donor}}$ is the drug concentration at the donor side.

The assay results were listed in the table below.

	Compound A107 of WO2017/114510A1	Compound P9 of the invention
apparent permeability coefficient (Caco-2)	From A to B = 1.54×10^{-6} cm/s	From A to B = 23.69×10^{-6} cm/s
Efflux Ratio	26.2	1.3

From the assay results of the permeability parameters, it was seen that Compound **P9** of the invention had a significantly higher apparent permeability coefficient (Papp, Apical to Basal) than Compound A107 of WO2017/114510A1 in the Caco-2 permeability assay. It is known that a drug is believed to have good permeability if it has $P_{app} > 2 \times 10^{-6}$ (see, for example, Journal of Pharmacological and Toxicological Methods 44 (2000) 235 - 249). The apparent permeability coefficient of Compound **P9** was significantly higher than this index, but that of Compound A107 was lower than this index. Moreover, Compound A107 had a higher Efflux Ratio, while the Efflux Ratio of Compound P9 was lower. Thus, Compound **P9** has a better permeability and is expected to have a better intestinal absorption property and a better oral absorption degree in vivo.

Effect Example V: Solubility Assay

The thermodynamic solubility of the compounds of the invention was determined in this Example.

(1). Reagents and Materials:

Name	Supplier	Catalog No. / Batch No.
DPBS	Corning	R21-031-CV
HBSS	Sigma	RNBC5907
ACN	Merck	JA054630
NaOH	SinoPharm Group	20120515
HCl	SinoPharm Group	20160503
384 well microplate	Greiner	B16093FV
DMSO	Merck	K42958652 225

(2) Instruments and Equipments:

Name	Source
ThermoMixer	Eppendorf
Centrifuge	Eppendorf 5424R centrifuge, Eppendorf
Centrifuge	Eppendorf 5810R centrifuge, Eppendorf
Plate sealer	Plate Loc sealer, Agilent
Oscillator	IKA MS3 digital oscillator, IKA
Liquid chromatograph	Waters ACQUITY I-Class System, Waters
pH meter	Sartorius PB-10, Sartorius
Vortex generator	MS3 digital vortex generator, IKA
Analytical balance	Sartorius MSE125P-100-DA analytical balance
MS/MS system	Waters ACQUITY XEVO TQ-S (ESI source), Waters

(3) Assay Protocol:

Blank vehicle with different pH values:

PH7.4: DPBS

PH6.8: 9900 μ L HBSS +100 μ L HEPS +5 μ L 2N NaOH

PH7.4: DPBS adjusted with 2N HCl to pH 2.0

Incubation:

About 3mg of the compound was weighed, added with 500 μ L of blank vehicle, and shaken at 37°C for 24 h.

Sample treatment:

After incubation, the samples were centrifuged for 30min, and the supernatant was transferred to a new EP tube and further centrifuged for 30min.

After centrifugation, the samples were diluted by 100 times with ACN/H₂O (V/V, 1:1).

Linear concentration range from 12.5 nM to 1 mM was configured with ACN/H₂O (V/V, 1:1).

Biological analysis:

All samples were mixed with water at the 1:1 ratio by volume, centrifuged at 4000rpm for 5min, and analyzed by LC-MS/MS.

Analysis methods:

Chromatography conditions:

Analysis column: Acquity BEH C18 (1.7 μ m; 2.1 x 50 mm, Waters)

Mobile phase A: 0.1% FA in H₂O

Mobile phase B: 0.1% FA in CAN/MEOH (9:1,V/V)

Gradient: as shown in the table below.

Time (h)	Flow rate (mL/min)	A%	B%	Curve (h)
original	0.5	80	20	original
1.2	0.5	40	60	6
1.5	0.5	10	90	6
2.0	0.5	80	20	1

MS/MS system

Multiple Reaction Monitoring (MRM) mode was used:

Compound	Ionization mode	MRM
Compound P9 of the invention	ESI, positive	463.047>307.588

(4) Results:

Compound No.	Maximum solubility in pH 2.0 PBS (uM)	Maximum solubility in pH 6.8 HBSS/HEPES 10mM/BSA 0.1% (uM)	Maximum solubility in pH 7.4 PBS (uM)
Compound A65 of WO2017/114510A1	43.0 ± 2.33	31.7 ± 0.229	11.9 ± 1.36
Compound A107 of WO2017/114510A1	1011 ± 11.2	4.53 ± 1.13	2.53 ± 0.175
Compound P9 of the invention	2847± 62	267± 3	544± 5.3

The results above showed that at the three pH values examined, Compound **P9** of the invention had much higher solubility than the compounds of WO2017/114510A1, and was advantageous for formulation into a medicament.

Effect Example VI: Pharmacokinetic Study in Animal Model

The pharmacokinetic parameters of Compound **P9** of the invention and the representative compounds of WO2017/114510A1 in mice were determined in this Example.

(1) *In vivo* pharmacokinetics protocol for single intravenous (IV) and oral (PO) administration to ICR mice

(1.1) Formulation of test substances

The concentration during formulation of test substances was calculated on the basis of pure free base.

Intravenous injection (IV)

The test substance was accurately weighed, and added with the excipients (5% DMSO + 5% Solutol + 90% saline) in the specified amounts. After complete dissolution, the dosing solution for intravenous injection was obtained at the concentration of 0.2 mg/mL.

Oral administration by gavage (PO)

The test compound was accurately weighed, and added with the excipients (0.4% methylcellulose (viscosity: 400 cps)) in the specified amount. After sufficiently mixing, the dosing solution for oral administration was obtained at the concentration of 1 mg/mL.

(1.2) Animal reception and adaptation

Forty male SPF grade ICR mice were purchased from Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd., and 30 normal healthy ICR mice of them passed the physical examination and were used in this study. Animal weight: 20.12 - 25.56 g.

(1.3) Administration to animals

The experiments were conducted in the 30 male ICR mice as shown in the table below.

Group	Number of animals M	Administration dosage mg/kg	Administration concentration mg/mL	Administration volume mL/kg	Administration mode
1	15	1	0.2	5	Intravenous injection
2	15	10	1	10	Oral administration by gavage*

* All animals were fasted for 10-14 h prior to the administration, and fed 2 h after the administration.

(1.4) Collection and treatment of samples

Blood was collected through the orbit or through cardiac puncture after carbon dioxide (CO₂) euthanasia. About 0.20 milliliter (mL) of blood was collected for each sample with heparin sodium as anticoagulant agent. The samples were placed on ice after collection.

Blood collecting time points in the intravenous and oral administration groups: before administration as well as 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h after administration, as shown in the table below.

IV&PO	before administration	5 min	15 min	30 min	1 h	2 h	4 h	6 h	8 h	24 h
3 mice	X					X				
3 mice		X					X			
3 mice			X					X		
3 mice				X					X	
3 mice					X					X

Blood samples were placed on ice upon collection. The plasma was separated by centrifugation (centrifugation conditions: 8000 rpm, 6 minutes, 2-8°C). The collected plasma was stored at -80°C for analysis.

The biological samples of the test substances were analyzed by LC-MS/MS. The analysis method used was described under (1.7). The LLOQ for the detection of the samples was 1ng/mL. The sample analysis for standard curve and quality control was also conducted during the detection of test substances.

(1.5) Animal disposal

After the end of the experiment, all animals were euthanized according to the institutional SOP.

(1.6) Pharmacokinetic analysis

The pharmacokinetic parameters were calculated from the blood concentration data of the drug, using WinNonlin 7.0 to provide the parameters such as AUC_{0-t}, AUC_{0-∞}, MRT_{0-∞}, C_{max}, T_{max}, and T_{1/2}, and the average and standard deviation thereof.

For those samples with concentrations below the lower limit of quantitation, when calculating the pharmacokinetic parameters, samples collected before C_{max} should be calculated as zero, and

samples collected at the points after $C_{\max}$ should be calculated as being below the limit of qualification (BLQ).

(1.7) Analysis method

a. Instruments and Equipments

LC-MS/MS

Ultra high performance liquid chromatography system (Waters, ACQUITY UPLC), including binary solvent manager (ACQUITY UPLC Binary Solvent Manager), sample manager (ACQUITY UPLC Autosampler Mod.), high-throughput sample organizer (ACQUITY UPLC Sample Organizer), high temperature column oven (ACQUITY UPLC Column Heater HT).

Mass spectrometer (API 4000, Applied Biosystems), electrospray ionization source (ESI), tandem quadrupole mass analyzer.

The data processing system was Analyst software (Applied Biosystems, software version no. 1.5.1).

Micro-analytical balance (XP26, METTLER TOLEDO Instruments (Shanghai) Co., Ltd.); vortex oscillator (SI-A256, Scientific Industries, Inc.); small desktop high-speed refrigerated centrifuge (5417R, Eppendorf); ultra-pure water machine (Millipore); pipette (Eppendorf).

Reagents

Methanol (Burdick&Jackson, HPLC), acetonitrile (Burdick&Jackson, HPLC), formic acid (J&K), ultra pure water.

b. LC-MS/MS conditions

The liquid chromatography conditions are as follows:

column: ACQUITY UPLC HSS T3 1.8 μm (50 mm $\times$ 2.10 mm)

mobile phase:

Time (min)	A (%)	B (%)
0.00	80	20
0.40	10	90
0.80	10	90
0.81	80	20
1.20	80	20

A: 0.1% aqueous formic acid B: 0.1% formic acid in methanol

Column temperature: 40°C

Autosampler temperature: 4°C

Flow rate: 500 $\mu\text{L}/\text{min}$

Injection volume: 1 μL

The mass spectrometry conditions are as follows:

Scan mode: positive ion multiple reaction monitoring mode

Ion source: ESI source

Spray mode: electrospray

Q1 resolution: Unit

Q3 resolution: Unit

Spray gas (Gas 1): 65 psi

Heater gas (Gas2): 65 psi

Curtain gas (CUR): 35 psi

Collision gas (CAD): 10

Ion source voltage (IS): 5500 v

Ion source temperature (TEM): 550°C

c. Formulation of samples for standard curve and samples for quality control

An amount of test substance was weighed, added with methanol to completely dissolve it to prepare a stock solution with a concentration of 569,000 ng/mL. An amount of the stock solution was taken and diluted with methanol to a working solution with a concentration of 200,000 ng/mL. The 200,000 ng/mL standard solution was added to blank plasma at the ratio of 1:39 to prepare the sample for standard curve with a concentration of 5000 ng/mL. The 5000 ng/mL standard curve sample was diluted with blank plasma sequentially to obtain 1000, 500, 100, 50, 10, 5, 1 ng/mL standard curve samples, and 800, 200, 2.5 ng/mL quality control samples. The specific formulation process was shown in Table I.

Table I Formulation of samples for standard curve and QC

Standard sample	Sample taken	Concentration taken (ng/mL)	Volumn taken (μL)	Volumn of vehicle (μL)	Final volumn (μL)	Final concentration (ng/mL)
STD-PRE	NA	200,000	20	780	800	5000
STD-7	STD-PRE	5000	100	400	500	1000
STD-6	STD-7	1000	200	200	400	500
STD-5	STD-6	500	100	400	500	100
STD-4	STD-5	100	200	200	400	50
STD-3	STD-4	50	100	400	500	10
STD-2	STD-3	10	200	200	400	5
STD-1	STD-2	5	100	400	500	1
DQC	STD-PRE	5000	5	45	50	500
QCH	STD-PRE	5000	80	420	500	800
QCM	QCH	800	100	300	400	200
QCL	STD-2	5	100	100	200	2.5

Working solution of the internal standard: Pipette an amount of tolbutamide stock solution with a concentration of 767,000 ng/mL into a volumetric flask, make up to volume with methanol, and mix well to obtain the working solution of the internal standard.

d. Treatment of plasma sample

50 μL sample (samples for standard curve / samples for quality control / biological samples) was taken into a 1.5 mL centrifuge tube, added with 250 μL internal standard solution (added with the same volume of methanol, instead of the internal standard, for blank control), and mixed well by vortex. The mixture was centrifugated at 14000 rpm for 5 minutes. 200 μL of the supernatant was taken and added into the corresponding 96-well sample plate for LC-MS/MS analysis.

(2) Results

The pharmacokinetic data of the representative compounds of WO2017/114510A1 and Compound P9 of the invention were compared as follows.

Compound	Pharmacokinetic parameters
Compound A1 of WO2017/114510A1	nAUC _{0-t} /(ng·h/ mL, po): 145.0 CL _z /(L/hr/kg): 4.81 F/(%, po): 70.07
Compound A35 of WO2017/114510A1	nAUC _{0-t} /(ng·h/ mL, po): 66.97 CL _z /(L/hr/kg): 4.69 F/(%, po): 32.07
Compound A179 of WO2017/114510A1	nAUC _{0-t} /(ng·h/ mL, po): 0.00 CL _z /(L/hr/kg): 60.11 F/(%, po): 0.00
Compound A114 of WO2017/114510A1	nAUC _{0-t} /(ng·h/ mL, po): 180.44 CL _z /(L/hr/kg): 2.61 F/(%, po): 49.46
Compound P9 of the invention	nAUC _{0-t} /(ng·h/ mL, po): 1696.3 CL _z /(L/hr/kg): 0.36 F/(%, po): 60.55

From the measured results of *in vivo* pharmacokinetic parameters in these mice, it was seen that Compound P9 of the invention had a significantly greater area under curve (AUC), lower *in vivo* clearance (CL_z), and better bioavailability in mice, compared with the compounds of WO2017/114510A1. Thus, this compound is expected to have better absorption after oral administration and better druggability.

Formulation Example I

An amount of Compound P9 was accurately weighed, added with 5% DMSO + 5% Solutol + 90% saline or the like, to completely dissolve it to give the dosing solution with a concentration of 0.2 mg/mL, which was filtered sterile for intravenous injection administration.


Formulation Example II

An amount of Compound P9 was accurately weighed, added with 0.4% methylcellulose (viscosity: 400 cps) to the final volume. After sufficiently mixing, the dosing solution for oral administration was obtained at the concentration of 1 mg/mL.

All documents mentioned in the present disclosure are incorporated herein by reference in their entirety, as if they are individually listed. It is noted that based on the present disclosure, various changes or modifications to the invention are obvious to those skilled in the art, and these equivalent forms also fall within the scope defined by the claims appended to this application.

Claims

1. A compound of Formula (I), or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate or pharmaceutically acceptable salt thereof,



(I)

Wherein,

X₁ is selected from the group consisting of CR_{9a} and N;

X₂ is selected from the group consisting of CR_{9b} and N;

X₃ is selected from the group consisting of CR_{9c} and N; and at most one of X₁, X₂ and X₃ is N;

Y₁ and Y₂ are each independently selected from the group consisting of CR_{9'} and N;

R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylcarbonyl, optionally substituted alkoxyalkyl, optionally substituted cycloalkyl, amino, optionally substituted mono- or di-(alkyl)amino and -CONR_aR_b;

R_{9'} is selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylcarbonyl, optionally substituted alkoxyalkyl, optionally substituted cycloalkyl, amino, optionally substituted mono- or di-(alkyl)amino and CONR_aR_b;

R₁ is selected from the group consisting of H and D;

R₂ is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or R₂ together with X₁ forms optionally substituted heterocyclyl;

R₃ is selected from the group consisting of halo and optionally substituted alkyl;

R₄ is selected from the group consisting of H, D, optionally substituted alkyl, optionally substituted alkoxy, -CO(CR₁₀R₁₁)_mR₁₂, -SO₂(CR₁₀R₁₁)_mR₁₂, -CONR₁₃(CR₁₀R₁₁)_mR₁₂, -COO(CR₁₀R₁₁)_mR₁₂, -CR₁₃R_{13'}(CR₁₀R₁₁)_mR₁₂ and C₁₋₈alkylcarbonyl-; wherein m is 0, 1, 2 or 3, and wherein

R₁₀ and R₁₁ are each independently selected from the group consisting of H, D, halo, optionally substituted alkyl, and optionally substituted alkoxy; or R₁₀ and R₁₁ are joined together to form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and

R₁₂ is each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; and

R₁₃ and R_{13'} are each independently selected from the group consisting of H and optionally substituted alkyl; or R₁₃ and R_{13'} together with the adjacent carbon form optionally substituted cycloalkyl, cycloalkenyl and heterocyclyl;

R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of -H, -D, halo, -OH, amino, cyano, optionally substituted alkyl, optionally substituted alkoxy, -(CH₂)₀₋₃CONR_aR_b, -(CH₂)₀₋₃COOH, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; or any two of R₅, R₆, R₇ and R₈ together with the adjacent carbon form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and

R_a and R_b are each independently selected from the group consisting of H, D and optionally substituted alkyl;

wherein the optional substituent is independently selected from the group consisting of deuterium (D), halo, -OH, mercapto, cyano, -CD₃, -C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, 3-8 membered cycloalkyl, aryl, 3-8 membered heterocyclyl, heteroaryl, aryl-C₁-C₆alkyl-, heteroaryl-C₁-C₆alkyl-, C₁-C₆haloalkyl-, -OC₁-C₆alkyl, -OC₂-C₆alkenyl, -OC₁-C₆alkylphenyl, -C₁-C₆alkyl-OH, -C₁-C₆alkyl-SH, -C₁-C₆alkyl-O-C₁-C₆alkyl, -OC₁-C₆haloalkyl, -NH₂, -C₁-C₆alkyl-NH₂, -N(C₁-C₆alkyl)₂, -NH(C₁-C₆alkyl), -N(C₁-C₆alkyl)(C₁-C₆alkylphenyl), -NH(C₁-C₆alkylphenyl), nitro, -C(O)-OH, -C(O)OC₁-C₆alkyl, -CONR_iR_{ii} (wherein R_i and R_{ii} are each independently selected from H, D, and C₁₋₆alkyl), -NHC(O)(C₁-C₆alkyl), -NHC(O)(phenyl), -N(C₁-C₆alkyl)C(O)(C₁-C₆alkyl), -N(C₁-C₆alkyl)C(O)(phenyl), -C(O)C₁-C₆alkyl, -C(O)-5-7 membered heteroaryl, -C(O)C₁-C₆alkylphenyl, -C(O)C₁-C₆haloalkyl, -OC(O)C₁-C₆alkyl, -S(O)₂-C₁-C₆alkyl, -S(O)-C₁-C₆alkyl, -S(O)₂-phenyl, -S(O)₂-C₁-C₆haloalkyl, -S(O)₂NH₂, -S(O)₂NH(C₁-C₆alkyl), -S(O)₂NH(phenyl), -NHS(O)₂(C₁-C₆alkyl), -NHS(O)₂(phenyl), and -NHS(O)₂(C₁-C₆haloalkyl), wherein each of said alkyl, cycloalkyl, phenyl, aryl, heterocyclyl and heteroaryl is optionally further substituted with one or more substituents selected from the group consisting of halo, -OH, -NH₂, cycloalkyl, 3-8 membered heterocyclyl, C₁-C₄alkyl, C₁-C₄haloalkyl-, -OC₁-C₄alkyl, -C₁-C₄alkyl-OH, -C₁-C₄alkyl-O-C₁-C₄alkyl, -OC₁-C₄haloalkyl, cyano, nitro, -C(O)-OH, -C(O)OC₁-C₆alkyl, -CON(C₁-C₆alkyl)₂, -CONH(C₁-C₆alkyl), -CONH₂, -NHC(O)(C₁-C₆alkyl), -NH(C₁-C₆alkyl)C(O)(C₁-C₆alkyl), -SO₂(C₁-C₆alkyl), -SO₂(phenyl), -SO₂(C₁-C₆haloalkyl), -SO₂NH₂, -SO₂NH(C₁-C₆alkyl), -SO₂NH(phenyl), -NHSO₂(C₁-C₆alkyl), -NHSO₂(phenyl) and -NHSO₂(C₁-C₆haloalkyl),

provided that the compound is not 2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-(hydroxylmethyl)-5-(2-(isopropylamino)pyrimidin-4-yl)indolin-1-yl)ethan-1-one.

2. The compound according to claim 1, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

X₁ is selected from the group consisting of CR_{9a} and N;

X₂ is selected from the group consisting of CR_{9b} and N;

X₃ is selected from the group consisting of CR_{9c} and N; and at most one of X₁, X₂ and X₃ is N;

Y₁ and Y₂ are each independently selected from the group consisting of CR_{9'} and N;

R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted C₁₋₃alkyl, optionally substituted C₁₋₃alkoxy, optionally substituted C₁₋₃alkylcarbonyl, optionally substituted C₁₋₃alkoxycarbonyl, optionally substituted C₃₋₈cycloalkyl, amino, optionally substituted mono- or di-(C₁₋₃alkyl)amino, and -CONR_aR_b;

R_{9'} is selected from the group consisting of H, D, halo, -OH, cyano, optionally substituted C₁₋₃alkyl, optionally substituted C₁₋₃alkoxy, optionally substituted C₁₋₃alkylcarbonyl, optionally

substituted C₁₋₃alkoxycarbonyl, optionally substituted C₃₋₈cycloalkyl, amino, optionally substituted mono- or di-(C₁₋₃alkyl)amino, and CONR_aR_b;

R₁ is selected from the group consisting of H and D;

R₂ is selected from the group consisting of optionally substituted C₁₋₈alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl, or R₂ together with X₁ forms optionally substituted 3-8 membered heterocyclyl;

R₃ is selected from the group consisting of halo and C₁₋₈alkyl optionally substituted with one or more substituents independently selected from the group consisting of D and halo;

R₄ is selected from the group consisting of H, D, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxyl, -CO(CR₁₀R₁₁)_mR₁₂, -SO₂(CR₁₀R₁₁)_mR₁₂, -CONR₁₃(CR₁₀R₁₁)_mR₁₂, -COO(CR₁₀R₁₁)_mR₁₂, -CR₁₃R_{13'}(CR₁₀R₁₁)_mR₁₂, and C₁₋₈alkylcarbonyl-; wherein m is 0, 1, 2 or 3, and wherein

R₁₀ and R₁₁ are each independently selected from the group consisting of H, D, halo, optionally substituted C₁₋₈alkyl, and optionally substituted C₁₋₈alkoxyl, or R₁₀ and R₁₁ are joined together to form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and


R₁₂ is each independently selected from the group consisting of H, optionally substituted C₁₋₃alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl; and

R₁₃ and R_{13'} are each independently selected from the group consisting of H and optionally substituted C₁₋₃alkyl; or R₁₃ and R_{13'} together with the adjacent carbon form optionally substituted C₃₋₈cycloalkyl, C₄₋₈cycloalkenyl and C₅₋₈heterocyclyl;

R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of -H, -D, halo, -OH, amino, cyano, optionally substituted C₁₋₃alkyl, optionally substituted C₁₋₃alkoxyl, -(CH₂)₀₋₃CONR_aR_b, -(CH₂)₀₋₃COOH, optionally substituted C₃₋₈cycloalkyl, and optionally substituted 3-8 membered heterocyclyl; or any two of R₅, R₆, R₇ and R₈ together with the adjacent carbon form optionally substituted cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; and

R_a and R_b are each independently selected from the group consisting of H, D and optionally substituted C₁₋₃alkyl.

3. The compound according to any one of claims 1 to 2, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that the compound is represented by formula Ia, Ib, Ic or Id:



R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D, C₁₋₃alkyl, C₁₋₃haloalkyl, C₁₋₃alkoxyl, -OH, cyano, halo, amino, mono- or di-(C₁₋₃alkyl)amino,

C₁₋₃alkylcarbonyl, C₁₋₃alkoxycarbonyl and C₃₋₈cycloalkyl; preferably, R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H, D and C₁₋₃alkyl; more preferably, R_{9a}, R_{9b} and R_{9c} are each independently selected from the group consisting of H and D; and Other variables are as defined in claim 1 or 2.

4. The compound according to any one of claims 1 to 3, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

Y₁ is CR_{9'}, Y₂ is CR_{9'}, and wherein R_{9'} is selected from the group consisting of H, D, halo and C₁₋₃alkyl; more preferably, Y₁ is CR_{9'}, Y₂ is CR_{9'}, and wherein R_{9'} is H, D, F or methyl;

or

Y₁ is CR_{9'}, Y₂ is N, and wherein R_{9'} is selected from the group consisting of H, D, halo and C₁₋₃alkyl; more preferably, Y₁ is CR_{9'}, Y₂ is N, and wherein R_{9'} is H, D, F or methyl;


or

Y₁ is N, Y₂ is CR_{9'}, and wherein R_{9'} is selected from the group consisting of H, D, halo and C₁₋₃alkyl; more preferably, Y₁ is N, Y₂ is CR_{9'}, and wherein R_{9'} is H, D, F or methyl;

or

Y₁ is N, and Y₂ is N.

5. The compound according to claim 1, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: the compound is represented by formula Ie:



Ie

Wherein the variables are as defined in claim 1.

6. The compound according to any one of claims 1, 2 and 5, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: X₁ is selected from the group consisting of CR_{9a} and N, wherein R_{9a} is selected from the group consisting of H, D, halo, -OH, cyano, C₁₋₃alkyl, C₁₋₃haloalkyl, C₁₋₃alkoxyl, C₁₋₃alkylcarbonyl, C₁₋₃alkoxycarbonyl, C₃₋₈cycloalkyl, amino, and mono- or di-(C₁₋₃alkyl)amino; preferably, X₁ is selected from the group consisting of CR_{9a} and N, wherein R_{9a} is selected from the group consisting of H, D and C₁₋₃alkyl; more preferably, X₁ is selected from the group consisting of CH, CD and N.



7. The compound according to any one of claims 1 and 5, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

R₂ is selected from the group consisting of optionally substituted C₁₋₆alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted 3-8 membered heterocyclyl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, hydroxyl, -CD₃, C₁₋₆alkyl and hydroxylC₁₋₆alkyl, preferably is one or more substituents independently selected from the group consisting of D, halo, hydroxyl, -CD₃, -CH₃ and -CH₂OH;















or

R₂ is selected from the group consisting of C₁₋₆alkyl optionally substituted with one or more hydroxyl, C₃₋₈cycloalkyl optionally substituted with one or more hydroxyl, 3-8 membered heterocyclyl, and 5-12 membered heteroaryl such as 5-7 membered heteroaryl optionally substituted with one or more substituents selected from -CD₃, C₁₋₆alkyl and hydroxylC₁₋₆alkyl;



or

R₂ is selected from the group consisting of C₁₋₄alkyl, , , , , , , , and , which are optionally substituted with one or more substituents independently selected from the group consisting of D, halo, hydroxyl, C₁₋₄alkyl, -CD₃ and hydroxylC₁₋₄alkyl, preferably with one or more substituents independently selected from the group consisting of D, halo, hydroxyl, -CH₃, -CD₃ and -CH₂OH;



or

R₂ is selected from the group consisting of isopropyl, , , , , , , , , , , , , , , and ;

or

R₂ is selected from the group consisting of  and ;

or

R₂ is selected from the group consisting of  and .

8. The compound according to any one of claims 1 to 7, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R₃ is selected from the group consisting of halo and C₁₋₆alkyl optionally substituted with one or more substituents independently selected from the group consisting of D and halo; or R₃ is selected from the group consisting of halo and C₁₋₃alkyl optionally substituted with

one or more substituents independently selected from the group consisting of D and halo; or R_3 is selected from the group consisting of halo and C_{1-6} alkyl; or R_3 is selected from the group consisting of fluoro, chloro, bromo, iodo, $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH_2CH_3$, $-CF_3$, $-CHF_2$, CF_3CH_2- and CD_3- ; or R_3 is selected from the group consisting of fluoro, chloro and $-CH_3$; or R_3 is fluoro.

9. The compound according to any one of claims 1 to 8, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

R_4 is selected from the group consisting of $-CO(CR_{10}R_{11})_mR_{12}$ and $-CR_{13}R_{13}'(CR_{10}R_{11})_mR_{12}$; wherein m is 0, 1, 2 or 3, and wherein

R_{10} and R_{11} are each independently selected from the group consisting of H, D, and C_{1-4} alkyloptionally substituted with hydroxyl;


R_{12} is each independently selected from the group consisting of optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl;

R_{13} and R_{13}' are each independently selected from the group consisting of H, C_{1-3} alkyl and C_{1-3} haloalkyl.





10. The compound according to claim 9, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R_{12} is each independently selected from the group consisting of optionally substituted 6-12 membered aryl, and optionally substituted 5-12 membered heteroaryl such as 5-7 membered heteroaryl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, C_{1-4} alkyl, cyano, and C_{3-8} heterocyclyl- $(CH_2)_{0-4}-$ (for example, morpholinyl such as morpholino, piperazinyl, tetrahydropyranyl such as tetrahydropyran-4-yl, morpholinylmethyl such as morpholinomethyl, or piperazinylmethyl);


or R_{12} is selected from the group consisting of optionally substituted phenyl and optionally substituted pyridinyl such as pyridin-3-yl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, C_{1-4} alkyl (for example, methyl or ethyl), cyano, and C_{3-8} heterocyclyl- $(CH_2)_{0-4}-$ (for example, morpholinyl such as morpholino, piperazinyl, tetrahydropyranyl such as tetrahydropyran-4-yl, morpholinylmethyl such as morpholinomethyl, or piperazinylmethyl);

or R_{12} is selected from the group consisting of





, wherein R_c is selected from the group consisting of halo such as fluoro or chloro,


C_{1-4} alkyl such as methyl, , , , and  ;



, wherein R_d is selected from the group consisting of H, C_{1-4} alkyl such as methyl or




, wherein R_e is selected from the group consisting of halo such as fluoro and chloro, and p is 1 or 2; and



11. The compound according to any one of claims 1 to 8, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R_4 is selected from the group consisting of $-\text{CO}(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$, wherein m is 0, 1, 2 or 3, and wherein

R_{10} and R_{11} are each independently selected from the group consisting of H; and

R_{12} is selected from the group consisting of



12. The compound according to any one of claims 1 to 8, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that: R_4 is selected from the group consisting of $-\text{CO}(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$, wherein m is 0, 1, 2 or 3, and wherein R_{10} and R_{11} are each independently selected from the group consisting of H; R_{12} is selected from the group consisting of 2-cyanophenyl, 5-chloro-2-fluorophenyl, 2-chloro-3-fluorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-5-fluorophenyl, 2,5-difluorophenyl, 3-chloropyridin-2-yl, 6-chloropyridin-2-yl, 3-chloropyridin-4-yl, or 4-chloropyridin-3-yl.

13. The compound according to any one of claims 1 to 12, or a stereoisomer, racemate,

geometric isomer, tautomer, prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, characterized in that:

R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of -H, -D, halo, -OH, amino, cyano, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkoxyl, -(CH₂)₀₋₃CONR_aR_b, -(CH₂)₀₋₃COOH, optionally substituted C₃₋₈cycloalkyl, and optionally substituted 3-8 membered heterocyclyl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, -OH, -OC₁₋₆alkyl and NH₂, and wherein R_a and R_b are each independently selected from the group consisting of H, D and C₁₋₃alkyl;

or R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of H and C₁₋₆alkyl optionally substituted with hydroxyl or -OC₁₋₆alkyl;

or R₅ and R₆ are each independently selected from the group consisting of H and C₁₋₆alkyl; and R₇ and R₈ are each independently selected from the group consisting of H and C₁₋₆alkyl optionally substituted with hydroxyl or -OC₁₋₆alkyl;

or R₅, R₆, R₇ and R₈ are each independently selected from the group consisting of -H, -CH₃, and -CH₂OH;

or R₅, R₆ and R₇ are H, and R₈ is H, -CH₃ or -CH₂OH.

14. A compound selected from the group consisting of Examples P1-P20, P23-P25, P28-51, P53-P64, or a pharmaceutically acceptable salt thereof.


15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for use as a medicament.

16. A pharmaceutical composition, comprising the compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.

17. Use of the compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for prevention and/or treatment of a disease related to an ERK kinase, or use of the compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for use as a product as an ERK kinase inhibitor.


18. A non-therapeutic method of inhibiting ERK kinase activity, comprising contacting an effective amount of the compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, with an ERK kinase, thereby inhibiting the ERK kinase.

19. The compound t-butyl (4-(7-fluoroindolin-5-yl)pyridin-2-yl)(1-methyl-1H-pyrazol-5-yl)carbamate represented by the formula:



or a stereoisomer, racemate, geometric isomer, tautomer, hydrate, solvate, or pharmaceutically acceptable salt thereof.


20. A method for preparing the compound of formula (I) according to claim 1, or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate or pharmaceutically acceptable salt thereof, said compound of formula (I) is the compound of formula C3:



C3


wherein X_1 , R_2 , R_3 , R_{10} , R_{11} , R_{12} and m are as defined in claim 1, comprising the steps of:

(a) subjecting the compound of formula C1



C1


and the compound $\text{HO}-\text{C}(=\text{O})-(\text{CR}_{10}\text{R}_{11})_m\text{R}_{12}$ to amide coupling reaction, to give the compound of formula C2,



C2

; and

(b) When the compound of C2 is Boc-protected, deprotecting it, to give the compound of formula C3,



C3

21. The method according to claim 20, wherein the amide coupling reaction is carried out in the presence of a condensing agent and a base in an inert solvent.

22. The method according to claim 20, wherein the deprotection is carried out in the presence of an acid in an inert solvent.

23. The method according to claim 21 or 22, wherein the inert solvent is selected from the group consisting of ethyl acetate, tetrahydrofuran, methyltetrahydrofuran, acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, dichloromethane, 1,2-dichloroethane, N-methyl-2-pyrrolidone, or a combination thereof.

24. The method according to claim 21, wherein the condensing agent is one or more selected from the group consisting of 1-hydroxybenzotriazole (HOBT), 1-hydroxy-7-azobenzotriazole (HOAT), benzotriazol-1-yl-oxytripyrrolidino-phosphonium hexafluorophosphate (PyBOP), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), 1,1-carbonyldiimidazole (CDI), 1-propylphosphonic anhydride (T₃P), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl), N,N-dicyclohexylcarbodiimide (DCC), acetic anhydride, acetyl chloride, oxalyl chloride, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU).

25. The method according to claim 21, wherein the base is one or more selected from the group consisting of triethylamine, DIPEA, pyridine, 2,4-dimethylpyridine, NaOH, KOH, LiOH, Na₂CO₃, K₂CO₃, NaHCO₃, Cs₂CO₃, Na₃PO₄, or K₃PO₄.

26. The method according to claim 20, wherein the amide coupling reaction is carried out at a temperature from room temperature to reflux for 0.5 -24 h.

27. The method according to claim 22, wherein the acid is one or more selected from the group consisting of hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, formic acid, and phosphoric acid.

28. The method according to claim 20, wherein the deprotection is carried out at a temperature from -10°C to 80°C for 0.5 – 24 h.